Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry

ABSTRACT

The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application claims priority from Provisional Application U.S.Application 60/922,065, filed Apr. 5, 2007, incorporated herein byreference in its entirety.

FIELD OF THE INVENTION

The present invention relates to radioactively labeled high affinityCA-IX ligands that identify enzymatic activity of cell-surface expressedCA-IX, a protein over expressed in patients in with tumor growth. Thesecell impermeable tracers have high affinity for CA-IX, and are thusselective for CA-IX over CA-II, and exhibit favorable imagingproperties. In addition, these tracers bind to tumors expressing CA-IX.Because these tracers provide biochemical information related to CA-IXenzymatic activity, these tracers may provide valuable informationregarding a patient's potential response to therapy, outcome prognosisand treatment regimen.

BACKGROUND OF THE INVENTION

Positron Emission Tomography (PET), a molecular imaging technology,detects a myriad of diseases non-invasively. PET imaging systems createimages based on the distribution of positron-emitting isotopes in thetissue of the patient. The isotopes are typically administered to apatient by injection of probe molecules that are comprised of apositron-emitting isotope, such as F-18, C-11, N-13 or O-15, covalentlyattached to a molecule that metabolizes or localizes in the body, orthat binds to receptor sites within the body.

One of the most widely used positron-emitter labeled PET molecularimaging probes is 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG). [¹⁸F]FDG,which primarily targets glucose transporters, is an accurate clinicaltool for the early detection, staging, and restaging of cancer. PET-FDGimaging is increasingly used to monitor cancer chemo- and radio-therapybecause early changes in glucose utilization have been shown tocorrelate with outcome predictions. A characteristic feature of tumorcells is their accelerated glycolysis rate, which results from the highmetabolic demands of rapidly proliferating tumor tissue. Like glucose,FDG is taken up by cancer cells via glucose transporters and isphosphorylated by hexokinase to FDG-6 phosphate. The latter cannotproceed any further in the glycolysis chain or leave the cell, due toits charge, allowing cells with high glycolysis rates to be detected.

Although useful in many contexts, several limitations of FDG-PET imagingfor monitoring cancer exist as well. Accumulation of FDG in inflammatorytissue limits the specificity of FDG-PET. Conversely, nonspecific FDGuptake may also limit the sensitivity of PET for tumor responseprediction. Therapy-induced cellular stress reactions have been shown tocause a temporary increase in FDG-uptake in tumor cell lines treated byradiotherapy and chemotherapeutic drugs. Furthermore,physiologically-high normal background activity (e.g. FDG uptake in thebrain) can render the quantification of cancer-related FDG-uptakeimpossible in some areas of the body.

Due to these limitations, other PET imaging tracers are being developedto target a variety of enzyme-mediated transformations in cancer tissue,such as 6-[F-18]-fluoro-L-DOPA for dopamine synthesis,3′-[F-18]Fluoro-3′-deoxythymidine (FLT) for DNA replication, and[C-11](methyl)choline for choline kinase, as well as ultra-high specificactivity receptor-ligand binding (e.g., 16α. [F-18]fluoroestradiol).Molecularly targeted agents have demonstrated great potential value forthe non-invasive PET imaging of specific metabolic targets in cancers.Despite the clear clinical value of incorporating PET imaging intopatient management, limitations do exist. In certain instances, currentimaging probes lack specificity or have inadequate signal to backgroundcharacteristics. In addition, new biological targets that are beingtested for therapeutic intervention will require new imaging probes toevaluate their therapeutic potential. Additional biomarkers are neededthat show a very high affinity to, and specificity for, tumor targets tosupport cancer drug development and to provide health care providerswith a means to accurately diagnose disease and monitor treatment.

The carbonic anhydrases (CAs, EC 4.2.1.1) form a large family of genesencoding zinc metalloenzymes of great physiological importance. Ascatalysts for the reversible hydration of carbon dioxide, these enzymesparticipate in many diverse biological processes, including respiration,calcification, acid-base balance, bone resorption and in the formationof both cerebrospinal fluid and gastric acid. As a reflection of theimportance of these enzymes, the carbonic anhydrases are widelydistributed in many different living organisms. In higher vertebrates,including humans, 16 isozymes have been identified so far that differ intheir subcellular localization, catalytic activity and susceptibility todifferent classes of inhibitors. Some of these isozymes are cytosolic(CA-I, CA-II, CA-III, CA-VII and CA-XIII), others are membrane bound(CA-IV, CA-IX, CA-XII and CA-XIV), two are mitochondrial (CA-VA andCA-VB), and one is secreted in saliva (CA-VI). The CAs and CA-relatedproteins show extensive diversity in their tissue distribution, levelsof expression, and putative or established biological functions. SomeCAs are ubiquitously expressed in almost all tissues, such as CA-II,while the expression of other CAs appear to be restricted in theirtissue expression patterns.

Recently, it has been shown that two CA isozymes (CA-IX and CA-XII) areprominently associated with, and over expressed in, many tumors, wherethey are involved in crucial processes connected with cancerprogression. The first CA found to be associated with cancers was CA-IX,as reported in 1992 (Pastorekova S., et al., Virology, 1992, 187,620-626). The strong association between CA-IX expression andintratumorial hypoxia has been demonstrated in the cervical, breast,head and neck, bladder and non-small cell lung carcinomas. In addition,in breast carcinomas and non-small cell lung carcinomas, correlationbetween CA-IX and a constellation of proteins involved in angiogenesis,apoptosis inhibition and cell-cell adhesion disruption has beenobserved. Hypoxia is linked with acidification of the extracellularmilieu that facilitates tumor invasion and CA-IX is believed to play arole in this process via its catalytic activity. Thus, there are severalreasons that CA-IX is considered as one of the best targets for cancerdiagnosis and therapy. For instance, CA-IX is an integral plasmamembrane protein with an extracellularly exposed enzyme active site.Also, CA-IX has a very high catalytic activity with the highest protontransfer rate among the known CAs. In addition, CA-IX is present in fewnormal tissues such as the gall bladder and stomach, but its overexpression is strongly associated with many tumor tissues such as lung,head and neck, renal and cervical carcinomas. Finally, CA-IX levelsdramatically increase in response to hypoxia via a directtranscriptional activation of the CA-IX gene by HIF-1 (Giatromanolaki etal., Cancer Res., 2001, 61, 7992-7998; Dubois et al., Br. Cancer, 2004,91, 1947-1954), and the expression of CA-IX in certain tumors can be asign of poor prognosis. Consequently, discovery of specific inhibitorsfor CA-IX constitutes a novel approach to the diagnosis and treatment ofcancers in which CA-IX is expressed.

The enzymatic activity of carbonic anhydrases can be efficiently blockedby sulfonamide inhibitors, a fact that has been therapeuticallyexploited in diseases caused by excessive activities of certain CAisoforms (e.g. CA-II in glaucoma). There is also experimental evidencethat sulfonamides block both tumor cell proliferation and invasion invitro, and tumor growth in vivo, but the targets of those sulfonamideshave not yet been identified. Unfortunately, the sulfonamides availablethus far indiscriminately inhibit various CA isoenzymes and thesulfonamides' lack of selectivity compromises their clinical utilizationpresenting a major drawback for the application of sulfonamides inspecific CA-IX-targeted therapies.

Currently, there exists very few reported PET imaging agents that areboth selective for the CA-IX enzyme and which have provided useful invivo images. For example, the use of the radiolabeled monoclonalantibody ¹²⁴I-G250 for targeting CA-IX in hypoxic tumors and CA-IXexpression in xenografted human renal cell carcinoma animal models(Lawrentschuk, N., et al, British Journal of Urology, 2006, 97, Suppl.1, 10-10(1)) has been reported. However, it is well documented that theapplication of monoclonal antibodies has substantial limitations, suchas slow clearance.

SUMMARY OF THE INVENTION

We have identified a need for developing methods for identifyingmembrane-impermeable, high-affinity CA-IX inhibitors and for thedevelopment of inhibitors into useful candidates as PET tracers forimaging CA-IX expression in vivo. The present invention addresses theseneeds. In one aspect, the present invention provides novel sulfonamidecompounds that are particularly active in inhibiting carbonic anhydrase(CA), especially those selectively targeting the cancer-related,hypoxia-induced CA-IX isozyme. Such sulfonamide compounds and theirderivatives are useful for the development of in vivo positron emissiontomography (PET) imaging agents for the diagnosis of diseases such ascancer.

In one embodiment of the present application, there is provided acompound of the Formula I:Z—X-A-Y—B—SO₂NH₂  Formula Iwherein:

A is 3- to 7-membered saturated or unsaturated heterocycle,

B is aryl, heteroaryl, C₃-C₇cycloalkyl, C₃-C₇cycloalkenyl, C₃-C₇saturated heterocyclic, or C₃-C₇ unsaturated heterocyclic;

X is a linker, including alkyl, alkyloxyl, C₃-C₇ cycloalkyl, C₃-C₇cycloalkenyl, aryl, or 3- to 7-membered heterocycle, each of which maybe optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆alkenyl, (C₁-C₆ alkylene)-aryl, C₁-C₆ alkynyl, —N(R₁)₂, —CN, —OR₁, —SR₁,—S(O)—R₁, —SO₂—R₁, —SO₂NH—R₁, —SO₃H, —NH—SO₂—R₁, —C(O)R₂, P(O)(OR₁)₂, or—NHC(O)R₂ group;

Y is a linker, including a bond, alkyl, alkyloxy, C₃-C₇ cycloalkyl,C₃-C₇ cycloalkenyl, or 3- to 7-membered heterocycle, each of which maybe optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆alkenyl, (C₁-C₆ alkylene)-aryl, C₁-C₆ alkynyl, poly(alkoxy), —N(R₁)₂,—CN, —OR₁, —SR₁, —S(O)—R₁, —SO₂—R₁, —SO₂NH—R₁, —SO₃H, —NH—SO₂—R₁,—C(O)R₂, —P(O)(OR₁)₂, or —NHC(O)R₂ group;

each R₁ is independently H, C₁-C₆ alkyl, C₁-C₆ alkenyl, C₁-C₆ alkynyl,aryl, heteroaryl, (C₁-C₆ alkylene)-aryl, C₃-C₇ cycloaryl, C₃-C₇cycloalkenyl or 3- to 7-membered heterocycle;

each R₂ is independently —R₁, —N(R₁)₂ or —OR₁;

Z is optionally substituted aryl, optionally substituted heteroaryl,optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₃-C₇cycloalkenyl, or optionally substituted 3- to 7-membered heterocycle;

C is a charged component or species, which is optionally present in X,or Y, or Z;

W is a radionuclide, which is optionally present in X, or Y, or Z; and

including single stereoisomers and mixtures of stereoisomers and thepharmaceutically acceptable salts thereof.

In one embodiment, A is a triazole, B is an optionally substituted aryl,Y is a bond, X is independently a bond, optionally substituted alkyl,optionally substituted aryl, optionally substituted heterocycle,optionally substituted amino carbonyl, and Z is optionally substitutedaryl, optionally substituted heteroaryl, or optionally substitutedheterocycle. The substituted groups are selected from hydroxyl, amino orsubstituted amino, lower alkyl, lower alkenyl, alkoxy, aryl, alkoxyaryl,heteroaryl, halogen, carboxy, substituted amino carbonyl, cyano, nitro,sulfonyl, substituted amino acid, such as Ala, Asn, Cys, Glu, Gly, Gln,His, Lys, Ser, Tyr, Val or Phe, especially Cys, His and Phe.

In another embodiment, A is methyl triazole, B is an optionallysubstituted aryl, Y is an amino carbonyl, X is independently a covalentbond, optionally substituted alkyl, optionally substituted aryl,optionally substituted heterocycle, optionally substituted aminocarbonyl, and Z is optionally substituted aryl, optionally substitutedheteroaryl, or optionally substituted heterocycle. The substitutedgroups are selected from hydroxyl, amino or substituted amino, loweralkyl, lower alkenyl, alkoxy, aryl, alkoxyaryl, heterocycloalkyl,heteroaryl, halogen, optionally substituted carboxy, substituted aminocarbonyl, cyano, nitro, sulfonyl, substituted amino acid, such as Ala,Asn, Cys, Glu, Gly, Gln, His, Lys, Ser, Tyr, Val or Phe, especially Cys,His and Phe.

In yet another embodiment, A is a triazole, B is an optionallysubstituted heteroaryl, Y is an alkoxy, preferably methyleneoxy, X isindependently a covalent bond, optionally substituted alkyl, optionallysubstituted aryl, optionally substituted heterocycle, optionallysubstituted acyl, or optionally substituted amino carbonyl, and Z isoptionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycle, or optionally substituted aminoacid, preferably Ala, Val, Phe, Cys, Pro or Trp. The substituted groupsare selected from hydroxyl, amino or substituted amino, substitutedlower alkyl, substituted lower alkenyl, alkoxy, aryl, alkoxyaryl,heterocycloalkyl, heteroaryl, halogen, optionally substituted carboxy,substituted amino carbonyl, cyano, nitro, sulfonyl, substituted aminoacid, such as Ala, Asn, Cys, Glu, Gly, Gln, His, Lys, Ser, Tyr Val orPhe, especially Cys, His and Phe.

In all these embodiments, a charged moiety that is either a cation oranion, can be optionally incorporated into X, Y and Z. Without beingbound by any theory proposed herein, it is believed that the chargedmoiety is important for achieving cellular impermeability of the saidcompounds, and hence allows for selective binding to the extracellularlylocated CA-IX enzyme. The cation moiety can be selected from quaternaryammonium salts, imidate salts, thiolate salts, oxonium cations,lewis-acid base complexes such as boron-amine salts, or pyridiniumsalts, and the like. The anion moiety can be selected from such acidicgroups that become charged at physiological pH as carboxylic acid,sulfonic acid, phosphoric acid, phosphonic acid, N-oxides, sulfinates,or boronic acid.

In another embodiment, there is provided the compounds represented informula above, but the compounds have been converted into radiolabeledderivatives. In one embodiment, A is a triazole, B is an optionallysubstituted heteroaryl, Y is an alkoxy, preferably methyleneoxy, X isindependently a covalent bond, optionally substituted alkyl, optionallysubstituted aryl, optionally substituted heterocycle, optionallysubstituted acyl, or optionally substituted amino carbonyl, and Z isoptionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycle, or optionally substituted aminoacid, preferably Ala, Val, Phe, Cys, Pro or Trp. The substituted groupsare selected from hydroxyl, amino or substituted amino, substitutedlower alkyl, substituted lower alkenyl, alkoxy, aryl, alkoxyaryl,heterocycloalkyl, heteroaryl, halogen, optionally substituted carboxy,substituted amino carbonyl, cyano, nitro, sulfonyl, substituted aminoacid, such as Ala, Asn, Cys, Glu, Gly, Gln, His, Lys, Ser, Tyr or Phe,especially Cys, His and Phe. A charged moiety, either a cation or anion,is incorporated into either X, Y or Z. The cation moiety can be selectedfrom quaternary ammonium salts or pyridinium salts, and the like. Theanion moiety can be selected from such acidic groups that become chargedat physiological pH as carboxylic acid, sulfonic acid, phosphoric acid,phosphonic acid, or boronic acid. A radioactive element or nuclide maybe incorporated on either X, Y or Z. The radioactive elements may beselected from ¹⁸F, ¹¹C, ¹³N or ¹⁵O, preferably an ¹⁸F.

In another embodiment, there is provided a compound comprising theFormula Ia, Ib, IIa or IIb:

wherein for Ia and IIa:

each G is independently a bond or is independently selected from thegroup consisting of substituted or unsubstituted heterocyclyl, aryl andheteroaryl;

n is 0, 1, 2 or 3;

X is a bond, an amino acid residue, or is selected from the groupconsisting of —O—, —S—, —S(O)—, —S(O)₂—, —NR^(o)— where R^(o) is H orC₁₋₅alkyl, heterocyclyl, aryl, heteroaryl, C₁₋₆alkyl, C₁₋₆alkyl wherein1 or 2 carbon atoms of the C₁₋₆alkyl is replaced by a —O—, —C(O)—, —S—,—S(O)—, —S(O)₂— or —NR′″— where R′″ is H or C₁₋₅alkyl, and where theC₁₋₆alkyl is optionally substituted with 1 or 2 substituents selectedfrom the group consisting of —OH, —SH, NH₂, heterocyclyl, aryl andheteroaryl;

X′ is selected from the group consisting of a charged species, —OH,amino, halo, —CF₃, —CH₂F, —CHF₂, —COOH, —COC₁₋₅alkyl, —CO-aryl,—CO-heteroaryl, C₁₋₆alkyl, amino-C₁₋₅alkyl-, optionally substitutedaryl, optionally substituted heteroaryl, halo-C₁₋₅alkyl,halo-C₁₋₅alkoxy-; Z′—C₂₋₆alkyl-O—, Z′—C₂₋₆alkyl-S—, Z′—C₂₋₆alkyl-NH—,Z′—C₂₋₆alkyl-NH—C₁₋₃alkyl-, Z′—C₂₋₆alkyl-N(C₁₋₃alkyl)-C₁₋₃alkyl-,Z′—(CH₂CH₂—O)₁₋₅—, wherein Z′ is selected from the group consisting ofhalo, —CF₃, —CH₂F, —CHF₂, aryl and heteroaryl;

Y is H or is selected from the group consisting of a charged species,—COOR″, —SO₃R″, —P(O)₂OR″ and —OP(O)₂OR″ wherein R″ is H or C₁₋₃alkyl;

R is H or a side chain of an amino acid or a derivative thereof,—C₁₋₅alkyl-o, m, or p-aryl-(O—CH₂CH₂)₁₋₅-halo or —C₁₋₅alkyl-o, m, orp-aryl-(CH₂CH₂)-1-5-halo; and

Z is a bond or is selected from the group consisting of —O—, —C(O)—,—C(O)NR′—, —S—, —S(O)—, —S(O)₂—, —NR′— where R′ is H or C₁₋₅alkyl,C₁₋₃alkyl, C₁₋₃alkyl wherein 1 or 2 carbon atoms of the C₁₋₅alkyl isreplaced by a —O—, —S—, —C(O)—, —C(O)NR′″—, —S(O)—, —S(O)₂—, —S(O)₂NR′″—or —NR′″—, where R′″ is H or C₁₋₅alkyl; and

wherein for Ib and IIb:

each G is independently a bond or is independently selected from thegroup consisting of substituted or unsubstituted heterocyclyl, aryl andheteroaryl;

n is 0, 1, 2 or 3;

X is a bond, an amino acid residue, or is selected from the groupconsisting of —O—, —S—, —S(O)—, —S(O)₂—, —NR^(o)— where R^(o) is H orC₁₋₅alkyl, heterocyclyl, aryl, heteroaryl, C₁₋₆alkyl and C₁₋₆alkylwherein 1 or 2 carbon atoms of the C₁₋₆alkyl is replaced by a —O—,—C(O)—, —S—, —S(O)—, —S(O)₂— or —NR′″— where R′″ is H or C₁₋₅alkyl, andwhere the C₁₋₅alkyl is optionally substituted with 1 or 2 substituentsselected from the group consisting of —OH, —SH, NH₂, heterocyclyl, aryland heteroaryl;

X′ is selected from the group consisting of a charged species, —OH,amino, halo, —CF₃, —CH₂F, —CHF₂, —COOH, —COOC₁₋₅alkyl, —COC₁₋₅alkyl,—CO-aryl, —CO-heteroaryl, C₁₋₆alkyl, amino-C₁₋₅alkyl-, optionallysubstituted aryl, optionally substituted heteroaryl, halo-C₁₋₅alkyl,halo-C₁₋₅alkoxy-; Z′—C₂₋₆alkyl, Z′—C₂₋₆alkyl-O—,Z′—C₂₋₆alkyl-O—C₁₋₃alkyl-, Z′—C₂₋₆alkyl-S—, Z′—C₂₋₆alkyl-NH—,Z′—C₂₋₆alkyl-NH—C₁₋₃alkyl-, Z′—C₂₋₆alkyl-N(C₁₋₃alkyl)-C₁₋₃ alkyl-,Z′—(CH₂CH₂—O)₁₋₅—, wherein Z′ is selected from the group consisting ofhalo, —CF₃, —CH₂F, —CHF₂, aryl and heteroaryl;

Z is a bond or is selected from the group consisting of —O—, —C(O)—,—C(O)NR'-, —S—, —S(O)—, —S(O)₂—, —NR′— where R′ is H or C₁₋₅alkyl,C₁₋₃alkyl, C₁₋₃alkyl wherein 1 or 2 carbon atoms of the C₁₋₅alkyl isreplaced by a —O—, —S—, —C(O)—, —C(O)NR′″—, —S(O)—, —S(O)₂—, —S(O)₂NR′″—or —NR′″—, where R′″ is H or C₁₋₅alkyl; and

wherein at least one of the group X, X′, G, X and Y comprises aradionuclide or a non-radioactive element;

or a pharmaceutically acceptable salt thereof, optionally in the form ofa single stereoisomer or mixtures of stereoisomers thereof.

In one variation, the compound is of the Formula Ia, or apharmaceutically acceptable salt thereof, optionally in the form of asingle stereoisomer or mixtures of stereoisomers thereof. In anothervariation, the compound is of the Formula Ib, or a pharmaceuticallyacceptable salt thereof, optionally in the form of a single stereoisomeror mixtures of stereoisomers thereof. In another variation, the compoundis of the Formula IIa, or a pharmaceutically acceptable salt thereof,optionally in the form of a single stereoisomer or mixtures ofstereoisomers thereof. In another variation, the compound is of theFormula IIb, or a pharmaceutically acceptable salt thereof, optionallyin the form of a single stereoisomer or mixtures of stereoisomersthereof. In one aspect of the compound of Formula Ia, Ib, IIa or IIb,the radionuclide is selected from the group consisting of ¹¹C, ¹⁸F, ¹³Nand ¹⁵O.

In another aspect, Z is a bond or is selected from the group consistingof C₁₋₃alkyl and C₁₋₃alkyl wherein 1 or 2 carbon atoms of the C₁₋₅alkylis replaced by a —O—, —S—, —C(O)—, —C(O)NR′″—, —S(O)—, —S(O)₂—,—S(O)₂NR′″— or —NR′″—, where R′″ is H or C₁₋₅alkyl. In one variation ofthe above, the charged species is selected from the group consisting ofcarboxylic acids, sulfonic acids, phosphonic acid and ammonium ion andtheir respective salts. In another variation, the charged speciescomprises a group selected from —COOH, —SO₃H, —PO₃H, —N(C₁₋₆alkyl)₃ ⁺X⁻wherein X⁻ is a counter anion. In certain variations of the compound ofthe present application, the charged species exclude 1,2,3,5-substitutedpyrylium salts of 4-alkylenylbenzensulfonamides, 2-(1,2,3,5-substitutedpyrylium)-5-(sulfonamide)-1,3,4-thiadiazoles, and aryl and heteroarylsulfonamides of 2,4,6-trisubstituted-pyridinium-methylcarboxylic acidsand their derivatives.

In yet another variation of the above compound, Z is a bond or isselected form the group consisting of —CH₂—O—, —CH₂CH₂—O—, —CH₂O—CH₂—,—(CH₂)₂₋₃O—CH₂— and —CH₂—O—(CH₂)₂₋₃—. In a particular variation, X is abond, an amino acid residue, or is selected from the group consisting ofheterocyclyl, aryl, heteroaryl, C₁₋₆alkyl, C₁₋₅alkyl wherein 1 or 2carbon atoms of the C₁₋₆alkyl is replaced by a —O—, —C(O)—, —S—, —S(O)—,—S(O)₂— or —NR′″— where R′″ is H or C₁₋₅alkyl, and where the C₁₋₅alkylis optionally substituted with 1 or 2 substituents selected from thegroup consisting of —OH, —SH, NH₂, heterocyclyl, aryl and heteroaryl. Inanother variation of the above, each G is independently a bond or isindependently selected from the group consisting of substituted orunsubstituted heterocyclyl, aryl and heteroaryl; and Z is a bond or isselected from the group consisting of C₁₋₃alkyl and C₁₋₃alkyl wherein 1or 2 carbon atoms of the C₁₋₅alkyl is replaced by a —O—, —S—, —C(O)—,—C(O)NR′″—, —S(O)—, —S(O)₂—, —S(O)₂NR′″— or —NR′″— where R′″ is H orC₁₋₅alkyl.

In yet another aspect of the above compound, each G is independently abond or is independently selected from the group consisting ofsubstituted or unsubstituted heterocyclyl, aryl and heteroaryl; Z is abond or is selected from the group consisting of C₁₋₃alkyl wherein 1 or2 carbon atoms of the C₁₋₅alkyl is replaced by a —O—, —S—, —C(O)—,—C(O)NR′″—, —S(O)—, —S(O)₂—, —S(O)₂NR′″— or —NR′″—, where R′″ is H orC₁₋₅alkyl; and X′ is selected from the group consisting of a chargedspecies, halo, —CF₃, —CH₂F, —CHF₂, —COOH, halo-C₁₋₅alkyl,halo-C₁₋₅alkoxy-; Z′—C₂₋₆alkyl, Z′—C₂₋₆alkyl-O—,Z′—C₂₋₆alkyl-O—C₁₋₃alkyl-, Z′—C₂₋₆alkyl-S—, Z′—C₂₋₆alkyl-NH—,Z′—C₂₋₆alkyl-NH—C₁₋₃alkyl-, Z′—(CH₂CH₂—O)₁₋₅—, wherein Z′ is selectedfrom the group consisting of halo, —CF₃, —CH₂F, —CHF₂, aryl andheteroaryl.

In one aspect of the above for the compound of Formula Ia or Ha, Y is Hor is selected from the group consisting of a charged species, —COOR″,—SO₃R″, —P(O)₂OR″ and —OP(O)₂OR″ wherein R″ is H or C₁₋₃alkyl; R is H ora side chain of an amino acid or a derivative thereof, —C₁₋₅alkyl-o, m,or p-aryl-(O—CH₂CH₂)₁₋₅-halo or —C₁₋₅alkyl-o, m, orp-aryl-(CH₂CH₂)₁₋₅-halo; and Z is a bond or is selected from the groupconsisting of C₁₋₃alkyl and C₁₋₃alkyl wherein 1 or 2 carbon atoms of theC₁₋₅alkyl is replaced by a —O—, —S—, —C(O)—, —C(O)NR′″—, —S(O)—,—S(O)₂—, —S(O)₂NR′″— or —NR′″—, where R′″ is H or C₁₋₅alkyl.

In another embodiment of the compound of Formula Ia, Ib, IIa or IIb, X′is selected from the group consisting of a charged species, halo, —CF₃,—CH₂F, —CHF₂, halo-C₁₋₅alkyl, halo-C₁₋₅alkoxy-; Z′—C₂₋₆alkyl,Z′—C₂₋₆alkyl-O—, Z′—C₂₋₆alkyl-O—C₁₋₃alkyl-, Z′—C₂₋₆alkyl-S—,Z′—C₂₋₆alkyl-NH—, Z′—C₂₋₆alkyl-NH—C₁₋₃alkyl-,Z′—C₂₋₆alkyl-N(C₁₋₃alkyl)-C₁₋₃alkyl-, Z′—(CH₂CH₂—O)₁₋₅—, wherein Z′ isselected from the group consisting of halo, —CF₃, —CH₂F, —CHF₂, aryl andheteroaryl.

In another embodiment, there is provided a method for detecting hypoxictumors in a mammal, the method comprising: a) administering to themammal the compound of the above; and b) obtaining a diagnostic image ofthe hypoxic tumors. In one variation of the method, the diagnostic imageis obtained using positron emission tomography (PET). In anothervariation, the radionuclide is ¹¹C or ¹⁸F.

In yet another embodiment, there is provided a method for detectingcarbonic anhydrase IX (CA-IX) activity of a tissue, the methodcomprising: a) administering a compound as disclosed herein to thetissue; and b) detecting the CA-IX activity in the tissue. In onevariation of the above, the detection of the CA-IX activity is performedusing positron emission tomography (PET). In another embodiment, thereis provided a method for the diagnostic imaging of hypoxic tissue in amammal, the method comprising: a) administering to the mammalpharmaceutical formulation comprising a compound of the Formula Ia, Ib,IIa or IIb, or a pharmaceutically acceptable salt thereof, optionally inthe form of a single stereoisomer or mixtures of stereoisomers thereof;and b) obtaining a diagnostic image of the hypoxic tissue. In onevariation, the tissue is selected from a heart, a lung, a kidney, aliver and a brain tissue. In another variation of the method, the methodis employed for the diagnose of hypoxic tissue in tumors.

In another aspect, there is provided a method of using the radio-labeledcompounds of the present application as positron emission tomography(PET) imaging agents for the detection of CA IX over-expression in asubject, which allows monitoring the progress or regression of acancerous disease in the subject. The method comprises of the steps:

a) administering the radio-labeled compounds as described herein to asubject,

b) detecting the radioactive emission of the compound administered instep (a).

In the present method, the radioactive emission from a radioisotope,such as ¹⁸F, can be detected using positron emission tomography forimaging CA-IX expression in a subject. The radioactive emission can bedetected anywhere in the body of the subject. In one embodiment, thesubject can be known or suspected to have one or more of the followingconditions: a preneoplastic or neoplastic disease, including carcinomas,such as, colorectal, ovarian, uterine, cervical, endometrial, squamouscell and adenosquamous carcinomas; head and neck cancers; mesodermaltumors, such as, neuroblastomas and retinoblastomas; sarcomas, such asosteosarcomas; and melanomas. Of particular interest are cancers of thebreast, of the gastrointestinal tract, of the stomach includingesophagus, of the colon, of the kidney, of the prostate, of the liver,of the urinary tract including bladder, of the lung, and of the head andneck. Also of particular interest are gynecological cancers includingovarian, uterine, cervical, vaginal, vulval and endometrial cancers,particularly ovarian, uterine, cervical and endometrial cancers.

In another embodiment, there is provided a method of using clickchemistry to generate combinatorial compound libraries represented inFormula I, Ia, Ib, IIa and IIb, which are potent inhibitors for CA IXenzyme.

In one embodiment, ‘traditional’ combinatorial chemistry libraries weresynthesized through a click chemistry approach. The identificationprocess involved in using various azide reagents and a series ofalkyne-bearing moieties, as exemplified by benzenesulfonamide alkyne(Formula IIa), N-(prop-2-ynyl)-4-sulfamoylbenzamide (Formula IIb), and6-(prop-2-ynyloxy)benzo[d]-thiazole-2-sulfonamide (Formula IIc). Thesescaffolds generated a total of 109 compounds in these three exemplarycombinatorial libraries, which were then subjected to screening at 1 μMconcentration using a standard competitive fluorescence-based assay (A.Jain, S. G. Huang, G. M. Whitesides, J. Am. Chem. Soc. 1994, 116, 5057)against carbonic anhydrase enzymes. Sixteen of them were identified tobe active and with binding affinity Kd's from 5-20 nM for CA IX enzyme.

In another embodiment, ‘focused’ combinatorial chemistry libraries weresynthesized using click chemistry generated triazole building blocks.The identification process involved uses various amine reagents and anumber of triazole-bearing acid moieties (FIG. 2), as exemplified by(S)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanoicacid (Formula IIIa),(S)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanoicacid (Formula IIIb),(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanoicacid (Formula IIIc), and(S)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]-thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoicacid (Formula IIId). A total of 118 triazole-bearing amide compounds(Table 2) in four combinatorial libraries were made and screened at 1 μMconcentration using a standard competitive fluorescence-based assay (A.Jain, S. G. Huang, G. M. Whitesides, J. Am. Chem. Soc. 1994, 116, 5057)against carbonic anhydrase enzymes. Twenty two of them were identifiedto be active and with binding affinity Kds from 0.5-10 nM for CA-IX,with exemplary compounds with their binding affinities shown in FIGS.5A-5B. Inhibition assay results are shown in FIGS. 4A-1-4C and FIGS.6A-6D.

In another embodiment, a small subset of four compounds, derived fromlead CA-IX binders, were converted into either ammonium salts or freecarboxylic acids (FIG. 7). Three of the four compounds were shown tohave Kds ranging from 10-20 nM and displayed high cell impermeabilitycharacteristics in both the ethoxazolamide blocked and unblocked cellsuptake assays (FIG. 7).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows formulas IIa, IIb and IIc.

FIG. 2 shows formulas IIIa, IIIb, IIIc and IIId.

FIG. 3A is a table containing various compounds with the correspondingin vitro activity.

FIG. 3B is a continuation of the table shown in FIG. 3A.

FIG. 3C is a continuation of the tables shown in FIGS. 3A and 3B.

FIGS. 4A-1 is a graph showing the percent inhibition of variouscompounds.

FIGS. 4A-2 is a graph showing the percent inhibition of variouscompounds.

FIGS. 4B-1 is a graph showing the percent inhibition of variouscompounds.

FIGS. 4B-2 is a graph showing the percent inhibition of variouscompounds.

FIG. 4C is a graph showing the percent inhibition of various compounds.

FIG. 5A is a table showing various compounds with the corresponding invitro activity.

FIGS. 5B and 5C are continuations of the table shown in FIG. 5A.

FIG. 6A is a graph showing the percent inhibition of various compounds.

FIG. 6B is a graph showing the percent inhibition of various compounds.

FIG. 6C is a graph showing the percent inhibition of various compounds.

FIG. 6D is a graph showing the percent inhibition of various compounds.

FIG. 7 is a table showing various compounds with the corresponding invitro activity.

FIG. 8 is a graph showing the cell impermeability characteristics inboth the ethoxazolamide blocked and unblocked cells uptake assays forvarious compounds.

FIG. 9A is a “screen shot” showing PET images two CA-IX tracers inathymic mice bearing CA-IX expressing xenograph tumors.

FIG. 9B is the “screen shot” of FIG. 9A but with the colors inverted forfurther clarity.

FIG. 10A is a “screen shot” showing PET images two CA-IX tracers inathymic mice bearing CA-IX expressing xenograph tumors.

FIG. 10B is the “screen shot” of FIG. 10A but with the colors invertedfor further clarity.

FIG. 11A is a “screen shot” showing PET images two CA-IX tracers inathymic mice bearing CA-IX expressing xenograph tumors.

FIG. 11B is the “screen shot” of FIG. 11A but with the colors invertedfor further clarity.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention now will be described more fully hereinafter. Thisinvention may, however, be embodied in many different forms and shouldnot be construed as limited to the embodiments set forth herein; rather,these embodiments are provided so that this disclosure will be thoroughand complete, and will fully convey the scope of the invention to thoseskilled in the art.

Definitions

As used in the present specification, the following words and phrasesare generally intended to have the meanings as set forth below, exceptto the extent that the context in which they are used indicatesotherwise.

The term “optional” or “optionally” means that the subsequentlydescribed event or circumstance may or may not occur, and that thedescription includes instances where said event or circumstance occursand instances in which it does not. For example, “optionally substitutedalkyl” means either “alkyl” or “substituted alkyl,” as defined below. Itwill be understood by those skilled in the art with respect to any groupcontaining one or more substituents that such groups are not intended tointroduce any substitution or substitution patterns that are stericallyimpractical and/or synthetically non-feasible.

Certain compound, reactant, or reaction parameter abbreviations aredefined as follows:

-   “DCM” refers to dichloromethane or methylene chloride-   “t-Bu” refers to t-butyl-   “Boc” refers to tert-butoxycarbonyl-   “DIC” refers to N,N-diisopropylcarbodiimide-   “DIPEA” refers to diisopropyl ethylamine-   “DMAP” refers to 4-N,N-dimethylamino pyridine-   “DMF” refers to N,N-dimethyl formamide-   “Eq.” refers to equivalent-   “MeOH” refers to methanol-   “TsOH” refers to toluene sulfonic acid-   “EtOH” refers to ethanol-   “PSC” refers to poly(styrene)carbodiimide-   “HOBt” refers to 1-hydroxybenzotriazole-   “DMTr” refers to dimethoxy trityl-   “TBDMS” refers to t-butyl di-methyl silyl-   “THF” refers to tetrahydrofuran-   “TBAF” refers to tetrabutyl ammonium fluoride-   “TMEDA” refers to N,N,N′,N′-tetramethylethylenediamine-   “EtOAc” refers to ethyl acetate.-   “TEA” refers to triethylamine-   “DCM” refers to dichloromethane-   “DMSO” refers to dimethylsulfoxide

The term “acyl” refers to the groups —C(O)—H, —C(O)-(optionallysubstituted alkyl), —C(O)-(optionally substituted cycloalkyl),—C(O)-(optionally substituted alkenyl), —C(O)-(optionally substitutedcycloalkenyl), —C(O)-(optionally substituted aryl), —C(O)-(optionallysubstituted heteroaryl) and —C(O)-(optionally substituted heterocyclyl).

The term “alkenyl” refers to a monoradical branched or unbranched,unsaturated or polyunsaturated hydrocarbon chain, having from about 2 to20 carbon atoms (i.e. C₂₋₂₀alkenyl), more preferably about 2 to 10carbon atoms. This term is exemplified by groups such as ethenyl,but-2-enyl, 3-methyl-but-2-enyl (also referred to as “prenyl”),octa-2,6-dienyl, 3,7-dimethyl-octa-2,6-dienyl (also referred to as“geranyl”), and the like.

The term “amino” refers to a nitrogen moiety having two furthersubstituents where a hydrogen or carbon atom is attached to thenitrogen. For example, representative amino groups include —NH₂, —NHCH₃,—N(CH₃)₂, —NHC₂₋₃-alkyl, —N(C₂₋₃-alkyl)₂ and the like. Unless indicatedotherwise, the compounds of the invention containing amino moieties mayinclude protected derivatives thereof. Suitable protecting groups foramino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyland the like.

The term “substituted amino” refers to the group —NHR or —NRR where eachR is independently selected from the group: optionally substitutedalkyl, optionally substituted cycloalkyl, optionally substitutedalkenyl, optionally substituted cycloalkenyl, optionally substitutedalkynyl, optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocyclyl, acyl, optionally substitutedalkoxy, carboxy and alkoxycarbonyl.

The term “amino acid residue” means the divalent group —NH—CHR—COO— or—OOC—CHR—NH—, where R is the side chain of an amino acid as known in theart.

The term “substituted alkenyl” refers to an alkenyl group in which 1 ormore (up to about 5, preferably up to about 3) hydrogen atoms isreplaced by a substituent independently selected from the group:optionally substituted anthraquinone, optionally substituted aryl,(optionally substituted aryl)carbonyl, optionally substitutedheteroaryl, or optionally substituted heterocyclyl. Preferred optionalsubstituents for alkenyl are substituted aryl and substitutedheteroaryl.

The term “alkoxy” refers to the groups —O-alkyl, —O-alkenyl,—O-cycloalkyl, —O-cycloalkenyl, and —O-alkynyl. Preferred alkoxy groupsare —O-alkyl and —O-alkenyl and include, by way of example, methoxy,ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy,n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, 3,7-dimethyl-octa-2,6-dienyloxyand the like.

The term “substituted alkoxy” refers to the groups —O-(substitutedalkyl), —O-(substituted alkenyl), —O-(substituted cycloalkyl),—O-(substituted cycloalkenyl), —O-(substituted alkynyl) and—O-(optionally substituted alkylene)-alkoxy. One preferred substitutedalkoxy group is “polyalkoxy” or —O-(substituted alkylene)-alkoxy, andincludes groups such as, —OCH₂CH₂OCH₃, and (or PEG) groups such as—O(CH₂CH₂O)_(x)CH₃ and —O(CH₂CH₂O)_(x)H where x is an integer of about2-20, preferably about 2-10, and more preferably about 2-5. Anotherpreferred substituted alkoxy group is trifluoromethoxy.

The term “alkyl” refers to a monoradical branched or unbranchedsaturated hydrocarbon chain preferably having from about 1 to 20 carbonatoms, more preferably about 1 to 10 carbon atoms, and even morepreferably about 1 to 6 carbon atoms. This term is exemplified by groupssuch as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl,n-hexyl, n-decyl, tetradecyl, and the like.

The term “substituted alkyl” refers to an alkyl group in which 1 or more(up to about 5, preferably up to about 3) hydrogen atoms is replaced bya substituent independently selected from the group: ═O, ═S, acyl,acyloxy, optionally substituted alkoxy, optionally substituted amino,azido, carboxyl, (optionally substituted alkoxy)carbonyl, (optionallysubstituted amino)carbonyl, cyano, optionally substituted cycloalkyl,optionally substituted cycloalkenyl, halogen, hydroxyl, sulfanyl,sulfinyl and sulfonyl. One of the preferred optional substituents foralkyl is hydroxy, exemplified by hydroxyalkyl groups, such as2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, and thelike; dihydroxyalkyl groups (glycols), such as 2,3-dihydroxypropyl,3,4-dihydroxybutyl, 2,4-dihydroxybutyl, and the like; mixed hydroxy andcarboxy substituted alkyl groups, such as pyruvates; and those compoundsknown as polyethylene glycols, polypropylene glycols and polybutyleneglycols, and the like.

The term “alkylene” refers to a diradical derived from the above-definedmonoradical, alkyl. This term is exemplified by groups such as methylene(—CH₂—), ethylene (—CH₂CH₂—), the propylene isomers [e.g., —CH₂CH₂CH₂—and —CH(CH₃)CH₂—] and the like.

The term “substituted alkylene” refers to a diradical derived from theabove-defined monoradical, substituted alkyl. Examples of substitutedalkylenes are chloromethylene (—CH(Cl)—), aminoethylene (—CH(NH₂)CH₂—),methylaminoethylene (—CH(NHMe)CH₂—), 2-carboxypropylene isomers(—CH₂CH(CO₂H)CH₂—), ethoxyethylene (—CH₂CH₂O—CH₂CH₂—),ethyl(N-methyl)aminoethylene (—CH₂CH₂N(CH₃)CH₂CH₂—),1-ethoxy-2-(2-ethoxy-ethoxy)ethylene (—CH₂CH₂O—CH₂CH₂—OCH₂CH₂—OCH₂CH₂—),and the like.

The term “aromatic” refers to a cyclic or polycyclic moiety having aconjugated unsaturated (4n+2) π electron system (where n is a positiveinteger), sometimes referred to as a delocalized π electron system.

The term “aryl” refers to an aromatic cyclic hydrocarbon group of from 6to 20 carbon atoms having a single ring (e.g., phenyl) or multiplecondensed (fused) rings (e.g., naphthyl or anthryl). Preferred arylsinclude phenyl, naphthyl and the like.

The term “substituted aryl” refers to an aryl group as defined above,which unless otherwise constrained by the definition for the arylsubstituent, is substituted with from 1 to 5 substituents, andpreferably 1 to 3 substituents, independently selected from the groupconsisting of: ═O, ═S, acyl, acyloxy, optionally substituted alkenyl,optionally substituted alkoxy, optionally substituted alkyl (such astri-halomethyl), optionally substituted alkynyl, optionally substitutedamino, optionally substituted aryl, optionally substituted aryloxy,azido, carboxyl, (optionally substituted alkoxy)carbonyl, (optionallysubstituted amino)carbonyl, cyano, optionally substituted cycloalkyl,optionally substituted cycloalkenyl, halogen, optionally substitutedheteroaryl, optionally substituted heteroaryloxy, optionally substitutedheterocyclyl, optionally substituted heterocyclooxy, hydroxyl,hydroxylamino, nitro, nitroso, phosphoryl, sulfanyl, sulfinyl, andsulfonyl. Preferred aryl substituents include: ═O (e.g., anthracenoneand anthraquinone), optionally substituted alkenyl, optionallysubstituted alkyl, alkoxy, substituted amino, halo, hydroxyl,alkoxycarbonyl, carboxy, cyano, nitro, phosphoryl,2,4-dihydro-pyrazol-3-one, thiazolidine-2,4-dione, trihalomethyl,sulfinyl, sulfonamide, methyl-sulfonamide.

The term “carbonyl” refers to the di-radical “—C(═O)-”, which is alsoillustrated as “—C(O)—”.

The term “(optionally substituted alkoxy)carbonyl” refers to the groups:—C(O)O-(optionally substituted alkyl), —C(O)O-(optionally substitutedcycloalkyl), —C(O)O-(optionally substituted alkenyl), —C(O)O-(optionallysubstituted alkynyl), —C(O)O-(optionally substituted aryl),—C(O)O-(optionally substituted heteroaryl), and —C(O)O-(optionallysubstituted heterocyclyl). These moieties are also referred to asesters.

The term “(optionally substituted amino)carbonyl” refers to the group—C(O)-(optionally substituted amino). This moiety is also referred to asa primary, secondary or tertiary carboxamide.

The term “carboxy” or “carboxyl” refers to the moiety “—C(O)O—”, whichis also illustrated as “—COO—”.

The term “compound of Formula” is intended to encompass the derivativesof the invention as disclosed, and/or the pharmaceutically acceptablesalts of such compounds. In addition, the compounds employed in thisinvention include the individual stereochemical isomers (arising fromthe selection of substituent groups) and mixtures of isomers. For thesake of brevity, except where specifically indicated to the contrary(e.g., by designation of a single salt, isomer or mixture) the termshould be understood to include single stereoisomers, mixtures ofstereoisomers, and the pharmaceutically acceptable salts thereof.

The term “cycloalkyl” refers to non-aromatic cyclic hydrocarbon groupsof having 3 to about 20 (preferably about 4 to 10) carbon atoms having asingle ring or multiple condensed rings. Such cycloalkyl groups include,by way of example, single ring structures such as cyclopropyl,cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ringstructures such as adamantanyl, and the like.

The term “halo” or “halogen” refers to fluoro, chloro, bromo and iodo.

In certain aspect of the present application, for the radiolabeledcompounds of the present application, a radionuclide may be attached tothe variable X′ of the compound of the present application, or a2-(18F-fluoroethyl)-, 2-(18F-fluoromethyl)-, a ¹¹C-methoxy-group that isattached to a compound of Formula I, Ia, Ib, IIa or IIb, for example,and/or the radionuclide may be attached to any one or more of thevariables X, Y, R and/or Z of a ¹⁸F-fluoroethyl-group, a¹⁸F-fluoromethyl-group, a ¹⁸F-fluoroethoxy-group, a ¹¹C-methoxy-group, a¹⁸F-fluoropropyloxy-group and the like, a ¹²I, a ¹²⁴I, a ¹²⁵ or a ¹³¹Igroup, and the like. Unless otherwise noted, a compound represented asbeing substituted by an atom, such as the generic representation by theatom fluorine in F—CH₂CH₂— or F—CH₂CH₂O— as attached to a compound ofthe Formula I, Ia, Ib, IIa or IIb, for example, is intended to coverboth the naturally occurring element ¹⁹F (fluorine-19) as well as the¹⁸F (fluorine-18) isotope(s) of the element itself.

The term “heteroaryl” refers to an aromatic cyclic hydrocarbon grouphaving about 1 to 40 (preferably from about 3 to 15) carbon atoms andabout 1 to 10 hetero atoms (preferably about 1 to 4 heteroatoms,selected from nitrogen, sulfur, phosphorus, and/or oxygen) within atleast one ring. Such heteroaryl groups can have a single ring (e.g.,pyridyl) or multiple condensed rings (e.g., indolizinyl, benzothiazolyl,and benzo[1,3]dioxo-5-yl). Preferred heteroaryls include pyridyl,[2,2′]bipyridinyl, pyrrolyl and benzothiazolyl.

The term “substituted heteroaryl” refers to a heteroaryl group asdefined above, which unless otherwise constrained by the definition forthe heteroaryl substituent, is substituted with from 1 to 5substituents, and preferably 1 to 3 substituents, independently selectedfrom the group consisting of: ═O, ═S, acyl, acyloxy, optionallysubstituted alkenyl, optionally substituted alkoxy, optionallysubstituted alkyl (such as tri-halomethyl), optionally substitutedalkynyl, optionally substituted amino, optionally substituted aryl,optionally substituted aryloxy, azido, carboxyl, (optionally substitutedalkoxy)carbonyl, (optionally substituted amino)carbonyl, cyano,optionally substituted cycloalkyl, optionally substituted cycloalkenyl,halogen, optionally substituted heteroaryl, optionally substitutedheteroaryloxy, optionally substituted heterocyclyl, optionallysubstituted heterocyclooxy, hydroxyl, nitro, sulfanyl, sulfinyl, andsulfonyl.

The term “heteroaralkyl” refers to the moiety “-alkylene-heteroaryl”each having the meaning as defined herein.

The term “substituted heteroaralkyl” refers to the moiety “-(optionallysubstituted alkylene)-(optionally substituted heteroaryl)”, each havingthe meaning as defined herein.

The terms “heterocycle”, “heterocyclic” and “heterocyclyl” refer to amonoradical, saturated or unsaturated, non-aromatic cyclic hydrocarbongroup having about 1 to 40 (preferably from about 3 to 15) carbon atomsand about 1 to 10 hetero atoms (preferably about 1 to 4 heteroatoms,selected from nitrogen, sulfur, phosphorus, and/or oxygen) within thering. Such heterocyclic groups can have a single ring or multiplecondensed rings. The heterocycle may include pyrrolidinyl,tetrahydrofuranyl, oxazolidinyl and imidazolidinyl and the like. Theheterocycle may also include carbohydrates and their derivatives.Preferred heterocyclics include morpholino, piperidinyl, furanyl,thiazolyl, imidazolidinyl, and the like.

The terms “substituted heterocycle”, “substituted heterocyclic” and“substituted heterocyclyl” refer to a heterocyclyl group as definedabove, which unless otherwise constrained by the definition for theheterocycle, is substituted with from 1 to 5 substituents, andpreferably 1 to 3 substituents, independently selected from the groupconsisting of: ═O, ═S, acyl, acyloxy, optionally substituted alkenyl,optionally substituted alkoxy, optionally substituted alkyl (such astri-halomethyl), optionally substituted alkynyl, optionally substitutedamino, optionally substituted aryl, optionally substituted aryloxy,azido, carboxyl, (optionally substituted alkoxy)carbonyl, (optionallysubstituted amino)carbonyl, cyano, optionally substituted cycloalkyl,optionally substituted cycloalkenyl, halogen, optionally substitutedheteroaryl, optionally substituted heteroaryloxy, optionally substitutedheterocyclyl, optionally substituted heterocyclooxy, hydroxyl, nitro,sulfanyl, sulfinyl, and sulfonyl. Preferred substituted heterocyclesinclude 2-thioxo-thiazolidin-4-one and thiazolidine-2,4-dione.

The term “heterocycloalkyl” refers to the moiety “-alkylene-heterocycle”each having the meaning as defined herein.

The term “substituted heterocycloalkyl” refers to the moiety“-(optionally substituted alkylene)-(optionally substitutedheterocycle)”, each having the meaning as defined herein.

The term “pharmaceutically acceptable salt” refers to salts which retainthe biological effectiveness and properties of the compounds of thisinvention and which are not biologically or otherwise undesirable. Inmany cases, the compounds of this invention are capable of forming acidand/or base salts by virtue of the presence of amino and/or carboxylgroups or groups similar thereto. Pharmaceutically acceptable baseaddition salts can be prepared from inorganic and organic bases. Saltsderived from inorganic bases, include by way of example only, sodium,potassium, lithium, ammonium, calcium and magnesium salts. Salts derivedfrom organic bases include, but are not limited to, salts of primary,secondary and tertiary amines, such as alkyl amines, dialkyl amines,trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines,tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines,trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl)amines, tri(substituted alkenyl) amines, cycloalkyl amines,di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkylamines, disubstituted cycloalkyl amine, trisubstituted cycloalkylamines, cycloalkenyl amines, di(cycloalkenyl) amines, tri(cycloalkenyl)amines, substituted cycloalkenyl amines, disubstituted cycloalkenylamine, trisubstituted cycloalkenyl amines, aryl amines, diaryl amines,triaryl amines, heteroaryl amines, diheteroaryl amines, triheteroarylamines, heterocyclic amines, diheterocyclic amines, triheterocyclicamines, mixed di- and tri-amines where at least two of the substituentson the amine are different and are selected from the group consisting ofalkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl,heteroaryl, heterocyclic, and the like. Also included are amines wherethe two or three substituents, together with the amino nitrogen, form aheterocyclic or heteroaryl group.

Specific examples of suitable amines include, by way of example only,isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine,tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine,lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline,betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine,purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and thelike.

Pharmaceutically acceptable acid addition salts may be prepared frominorganic and organic acids. Salts derived from inorganic acids includehydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like. Salts derived from organic acids includeacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid,malic acid, malonic acid, succinic acid, maleic acid, fumaric acid,tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid,salicylic acid, and the like.

The term “phosphoryl” refers to the group —P(O)(OR″)₂, where R″ isindependently selected from hydrogen or alkyl and aryl, which group issometimes also referred to as “phosphono” or as a “phosphate” or“phosphonic acid.”

The term “sulfonyl” refers to the groups: —S(O₂)-(optionally substitutedalkyl), —S(O₂)-(optionally substituted amino), —S(O₂)-optionallysubstituted aryl), —S(O₂)-(optionally substituted heteroaryl),—S(O₂)-(optionally substituted heterocyclyl). Preferred sulfonyl groupsinclude, by way of example, methylsulfonyl, ethylsulfonyl,aminosulfonyl, piperidin-1-sulfonyl and morpholine-4-sulfonyl.

The term “biological target” can be any biological molecule involved inbiological pathways associated with any of various diseases andconditions, including cancer (e.g., leukemia, lymphomas, brain tumors,breast cancer, lung cancer, prostate cancer, gastric cancer, as well asskin cancer, bladder cancer, bone cancer, cervical cancer, colon cancer,esophageal cancer, eye cancer, gallbladder cancer, liver cancer, kidneycancer, laryngeal cancer, oral cancer, ovarian cancer, pancreaticcancer, penile cancer, glandular tumors, rectal cancer, small intestinecancer, sarcoma, testicular cancer, urethral cancer, uterine cancer, andvaginal cancer), diabetes, neurodegenerative diseases, cardiovasculardiseases, respiratory diseases, digestive system diseases, infectiousdiseases, inflammatory diseases, autoimmune diseases, and the like.Exemplary biological pathways include, for example, cell cycleregulation (e.g., cellular proliferation and apoptosis), angiogenesis,signaling pathways, tumor suppressor pathways, inflammation (COX-2),oncogenes, hypoxia-related pathways and growth factor receptors. Thebiological target may also be referred to as the “targetbiomacromolecule” or the “biomacromolecule.” The biological target canbe a receptor, such as enzyme receptors, ligand-gated ion channels,G-protein-coupled receptors, and transcription factors. The biologicallytarget is preferably a protein or protein complex, such as enzymes,membrane transport proteins, hormones, and antibodies. In oneparticularly preferred embodiment, the protein biological target is anenzyme, such as carbonic anhydrase-II and its related isozymes such ascarbonic anhydrase IX and XII.

The term “leaving group”, as used herein refers to groups that arereadily displaced, for example, by a nucleophile, such as an amine, athiol or an alcohol nucleophile or its salt. Such leaving groups arewell known and include, for example carboxylates, N-hydroxysuccinimide,N-hydroxybenzotriazole, halides, triflates, tosylates, nosylates, —ORand —SR and the like.

The term “ligand” is a molecule, preferably having a molecular weight ofless than about 800 Da., more preferably less than about 600 Da.,comprising a first group exhibiting affinity for a first binding site ona biological target molecule, such as a protein, and a second groupexhibiting affinity for a second binding site on the same biologicaltarget molecule. The two binding sites can be separate areas within thesame binding pocket on the target molecule. The ligands preferablyexhibit nanomolar binding affinity for the biological target molecule.In certain aspects as disclosed herein, a ligand is used synonomouslywith a “substrate.” A ligand may comprise a “molecular structure” asdefined herein.

The term “linker” as used herein refers to a chain comprising 1 to 10atoms and may comprise of the atoms or groups, such as C, —NR—, O, S,—S(O)—, —S(O)₂—, CO, —C(NR)— and the like, and wherein R is H or isselected from the group consisting of (C₁₋₁₀)alkyl, (C₃₋₈)cycloalkyl,aryl(C₁₋₅)alkyl, heteroaryl(C₁₋₅)alkyl, amino, aryl, heteroaryl,hydroxy, (C₁₋₁₀)alkoxy, aryloxy, heteroaryloxy, each substituted orunsubstituted. The linker chain may also comprise part of a saturated,unsaturated or aromatic ring, including polycyclic and heteroaromaticrings.

The terms “patient” and “subject” refer to any human or animal subject,particularly including all mammals.

The term “radiochemical” is intended to encompass any organic, inorganicor organometallic compound comprising a covalently-attached radioactiveisotope, any inorganic radioactive ionic solution (e.g., Na[¹⁸F]F ionicsolution), or any radioactive gas (e.g., [¹¹C]CO₂), particularlyincluding radioactive molecular imaging probes intended foradministration to a patient (e.g., by inhalation, ingestion, orintravenous injection) for tissue imaging purposes, which are alsoreferred to in the art as radiopharmaceuticals, radiotracers, orradioligands. Although the present invention is primarily directed tosynthesis of positron-emitting molecular imaging probes for use in PETimaging systems, the invention could be readily adapted for synthesis ofany radioactive compound comprising a radionuclide, includingradiochemicals useful in other imaging systems, such as single photonemission computed tomography (SPECT).

The term “radioactive isotope” refers to isotopes exhibiting radioactivedecay (i.e., emitting positrons) and radiolabeling agents comprising aradioactive isotope (e.g., [¹¹C]methane, [¹¹C]carbon monoxide,[¹¹C]carbon dioxide, [¹¹C]phosgene, [¹¹C]urea, [¹¹C]cyanogen bromide, aswell as various acid chlorides, carboxylic acids, alcohols, aldehydes,and ketones containing carbon-11). Such isotopes are also referred to inthe art as radioisotopes or radionuclides. Radioactive isotopes arenamed herein using various commonly used combinations of the name orsymbol of the element and its mass number (e.g., ¹⁸F, F-18, orfluorine-18). Exemplary radioactive isotopes include I-124, F-18fluoride, C-11, N-13, and O-15, which have half-lives of 4.2 days, 110minutes, 20 minutes, 10 minutes, and 2 minutes, respectively. Theradioactive isotope is preferably dissolved in an organic solvent, suchas a polar aprotic solvent. Preferably, the radioactive isotopes used inthe present method include F-18, C-11, I-123, I-124, I-127, I-131,Br-76, Cu-64, Tc-99m, Y-90, Ga-67, Cr-51, Ir-192, Mo-99, Sm-153 andTl-201. Other radioactive isotopes that may be employed include: As-72,As-74, Br-75, Co-55, Cu-61, Cu-67, Ga-68, Ge-68, I-125, I-132, In-111,Mn-52, Pb-203, Ru-97.

The term “optical imaging agent” refers to molecules that havewavelength emission greater than 400 nm and below 1200 nm. Examples ofoptical imaging agents are Alex Fluor, BODIPY, Nile Blue, COB,rhodamine, Oregon green, fluorescein and acridine.

In a particular aspect of the method with the ligand radiochemicalembodiment, one of the precursor molecules may also comprise a leavinggroup that can be readily displaced by nucleophilic substitution inorder to covalently attach a radioisotope to the precursor. Exemplaryreactive precursors include small molecules bearing structuralsimilarities to existing PET probe molecules, EGF, cancer markers (e.g.,p185HER2 for breast cancer, CEA for ovarian, lung, breast, pancreas, andgastrointestinal tract cancers, and PSCA for prostrate cancer), growthfactor receptors (e.g., EGFR and VEGFR), glycoproteins related toautoimmune diseases (e.g., HC gp-39), tumor or inflammation specificglycoprotein receptors (e.g., selectins), integrin specific antibody,virus-related antigens (e.g., HSV glycoprotein D, EV gp), and organspecific gene products.

Nomenclature

In general, the nomenclature used in this Application was generatedusing the AUTONOM™ naming package within the ChemOffice® version 10.0suite of programs by CambridgeSoft Corp (Cambridge, Mass.). A compoundin Formula I, for example, wherein B is a benzothiazolesulfonamide, Y ismethyleneoxy, A is a triazole, X is butanamide, and Z is4-trifluorobenzyl may be named(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)butanamide.

SYNTHESIS OF THE COMPOUNDS OF THE INVENTION Synthetic ReactionParameters

The terms “solvent”, “inert organic solvent” or “inert solvent” mean asolvent inert under the conditions of the reaction being described inconjunction therewith. Solvents employed in synthesis of the compoundsof the invention include, for example, methanol, acetone, water,acetonitrile, 1,4-dioxane, dichloromethane (“DCM”), dimethylformamide(“DMF”), benzene, toluene, tetrahydrofuran (“THF”), chloroform, diethylether, pyridine and the like, as well as mixtures thereof. Unlessspecified to the contrary, the solvents used in the reactions of thepresent invention are inert organic solvents.

Unless specified to the contrary, the reactions described herein takeplace at atmospheric pressure within a temperature range from 0° C. to110° C. (preferably from 0° C. to 25° C.; most preferably at “room” or“ambient” temperature, e.g., 20° C.). Further, unless otherwisespecified, the reaction times and conditions are intended to beapproximate, e.g., taking place at about atmospheric pressure within atemperature range of about 0° C. to about 110° C. (preferably from about0° C. to about 25° C.; most preferably at about “room” or “ambient”temperature, e.g., approximately 20° C.) over a period of about 1 toabout 20 hours (preferably about 5 hours). Parameters given in theExamples are intended to be specific, not approximate.

Isolation and purification of the compounds and intermediates describedherein can be effected, if desired, by any suitable separation orpurification procedure such as, for example, filtration, extraction,crystallization, column chromatography, thin-layer chromatography orthick-layer chromatography, or a combination of these procedures.Specific illustrations of suitable separation and isolation procedurescan be had by reference to the examples herein below. However,asymmetric synthetic approaches and other equivalent separation orisolation procedures can, of course, also be used.

Synthesis of Compound Libraries

Compounds of Formula I of the present invention wherein A is a triazole,B is a benzene or benzothiazole, X and Z taken together by R, and Y areas described above, can be prepared following the Synthetic Scheme I.

The benzenesulfonamide alkyne of Formula II a/b, wherein Y is a covalentbond, can be prepared from 4-ethynylphenylsulfonamide using a literatureprocedure (Hayman, D. F.; Jackman, G. B.; Petrow, V.; Stephenson, O. andWild, A. M., J. Pharma. Pharmacol., 1964, 16, 677-689) Alternatively, itcan also be prepared from 4-bromobenzenesulfonamide andtrimethylsilylacetelene using Sonogashira reaction conditions. Thebenzenesulfonamide alkyne of Formula II a/b, wherein Y is a methyleneamido carbonyl (—CH2NHC(O)—), can be prepared from 4-sulfamoylbenzoicacid and propargyl amine. The azido compounds of R—N3, wherein R istaken together of X and Z in Formula I are either commercially availableor can be made using the methods well known in the art. Thebenzothiazolesulfonamide alkyne of Formula II c, wherein Y ismethyleneoxy (—CH₂O—), can be prepared from4-hydroxybenzothiazolesulfonamide and propargyl bromide under inertcondition using a base, such as potassium carbonate. The alkynes, suchas in Formula II a/b and II c, and azides (R—N3) in the presence ofCu(I) salts can undergo 1,3-dioplar cycloaddition forming1,4-disubstituted 1,2,3-triazoles, as shown in Formula IV a/b andFormula IV c. The Cu (I) salts can be generated from Cu(II) SO4 andNa-L-ascorbate, or can be used directly from Cu(I) I or CuOAc, and thelike.

Compounds of Formula I of the present invention wherein A is a triazole,B is a benzene or benzothiazole, X is a-substituted acetamide, Y is thesame as described above, and Z equals R and as the same as describedabove, can be prepared following the Synthetic Scheme II. The precursorsof Formula III a/b and Formula III c/d can both be prepared in the sameway as illustrated in Synthetic Scheme I, wherein R—N₃ is a R₁substituted azidoacetic acid. These R₁ substituted azidoacetic acid ingeneral can be made from various amino acids using a diazo transferreaction (Lundquist IV, J. T. and Pelletier, J. C. Org. Lett., 2001, 3,781-783). Alternatively, they can be also synthesized using nucleophilicreplacement reaction of NaN₃ with α-bromo-substituted acids. Reaction ofthese precursors with a wide variety of amines (R—NH₂) in the presenceof the coupling reagents, for example Poly(styrene)carbodiimide (PSC),in suitable solvents, such as dichloromethane (DCM) and DMF, can givethe desired compound libraries of Formula V a/b and Formula V c/d.

Synthesis of Radio-labeled Compounds

Radio-labeling a small molecule usually involves displacement of asuitably activated precursor with a radioactive moiety in a compatiblereaction media. In the case of ¹⁸F-labeling, the [¹⁸F] fluorideattachment to the precursor occurs via nucleophilic substitution of aleaving group, such as mesylate, tosylate, bromide, iodide, or diazoniumsalt, or nitro. The preparation of a radio-labeled compound hencegenerally consists of two sequences. The first sequence involves thepreparation of radio-labeling precursor, in which various functionalgroups have been appropriately protected and a proper leaving group hasbeen incorporated. The second sequence then involves the radio-labeling,and removal of the protecting group. The Synthetic Schemes III and IVserve to exemplarily demonstrate the preparative sequences of an¹⁸F-labeled compound.

The preparation of a radio-labeling precursor of Labeling series 1/2 isshown in Synthetic Scheme III. The starting intermediates of FormulaVIa, VIIa and Formula VIb, VII b, wherein R is a linker and can be analkyl, alkenyl, alkynyl, or aryl, G is a functional group and can beselected from hydroxyl, nitro, or amino, can be made in the same way asdescribed in Scheme II. Converting the functional group G in theintermediate VI b into a suitable leaving group L can be effected bymaking a mesylate, tosylate, bromide, iodide, diazonium salt, and thelike. The prepared compound of Formula VI c, VII c is then subjected tooptional amide protection. The protecting group P1 can be selected frommany NH protecting groups known in the art, preferably a Boc group. Thechoices of protecting groups of the sulfonamide of Formula II c can bemade from Boc, trityl, dimethoxytrityl (DMTr), Fmoc, orN,N-dimethylformimide, preferably DMTr. The click chemistry reaction ofintermediates VI c/d, VII c and protected Formula II c in the presenceof Cu(I) salts in a suitable media at ambient temperature gives theradio-labeling precursor of Labeling series 1/2.

The radio-labeling process involves two sequential steps. The first isthe radioactive nucleophilic F* displacement of the leaving group L ofthe labeling series 1/2. Then, the protecting groups of P₁ and P₂ areremoved under appropriate conditions, leading to a radio-labeled, PETimaging probe Protected Tracer 1/2. In a preferred embodiment of thepresent invention, the radioactive element is [¹⁸F] and the leavinggroup L is a nosylate or tosylate. In this case, the radio-labeling stepis generally affected in the presence of tetra-N-butyl ammoniumbicarbonate or K222, K₂CO₃ at an elevated temperature for 5-10 minutesin acetonitrile. The removal of protecting groups is achieved usingeither a) an aqueous HCl solution at an elevated temperature for 5-10minutes or b) LiOH saponification at RT for 30 min followed by treatmentwith an aqueous HCl solution at an elevated temperature for 5-10minutes. It must be understood, however, that as described above, theradioactive element can be incorporated in either X, Y, or Z of FormulaI. The structures used herein can only serve to show the general processof preparing the radio-labeled PET imaging agents and should not be usedas the description of the scope of the present invention.

Alternatively, the azide may be radiolabeled by nucleophilicdisplacement of F* of the leaving group L of the labeling precursorFormula VI c/d and VII c. Then the protecting groups are removed and thematerial is then clicked with an alkyne to afford radiolabled Tracer 3.In a preferred embodiment of the present invention, the radioactiveelement is [¹⁸F] and the leaving group L is a tosylate. In this case,the radio-labeling step is generally affected in the presence oftetra-N-butyl ammonium bicarbonate or K222, K₂CO₃ at an elevatedtemperature for 5-10 minutes in acetonitrile. The removal of protectinggroups is achieved using either a) an aqueous HCl solution at anelevated temperature for 5-10 minutes or b) LiOH saponification at RTfor 30 min followed by treatment with an aqueous HCl solution at anelevated temperature for 5-10 minutes. The click reaction is performedin the presence of an alkyne and heat and/or a metal catalyst to effectthe coupling. A reducing agent such as sodium ascorbate may be added. Apreferred metal catalyst is copper in the Cu(I) oxidation state.

Preferred Compounds

The following combinations and permutations of substituent groups(sub-grouped, respectively, in increasing order of preference) definecompounds that are preferred as composition of matter and compounds foruse in the methods as PET imaging agents according to the invention.

The compounds of any of Formula I where B is cycloalkyl, cycloalkenyl,heterocyclyl, aryl, heteroaryl, particularly B is a benzene, andpreferably B is a benzothiazole.

The compounds of any of Formula I where Y is optionally substitutedalkyl, alkoxy, alkenyl, cycloalkyl, cycloalkenyl, aryl. The preferredsubstituent groups are H, lower alkyl, haloalkyl, hydroxyalkyl,carboxyalkyl, aminoalkyl and arylalkyl. Particularly those where Y is analkyl (amido carbonyl), preferably Y is a covalent bond, and morepreferably Y is a methyleneoxy. The compounds of any of Formula I whereA is 3- to 7-membered heterocycle, more preferably a triazole, and mostpreferably a 1,4-substituted triazole. The compounds of any of Formula Iwhere X is optionally substituted lower alkyl, alkoxy, C₃-C₇ cycloalkyl,cycloalkenyl, and 3- to 7-membered heterocycle, preferably (amidocarbonyl)alkyl, more preferably optionally substituted acetamide. Thepreferred substitutent groups are halo, lower alkyl, alkoxy, haloalkyl,carboxyalkyl, aminoalkyl, hydroxyalkyl, cyanoalkyl, sulfonylalkyl,sulfamoylalkyl, (amido carbonyl)alkyl, alkenyl, alkynyl, optionallysubstituted aryl, arylalkyl and amino acid. The more preferredsubstituent groups are H, isopropyl, methylene carboxylate, and benzyl.The most preferred are 4-(2-fluoroethoxy)benzyl,4-(4-fluoro-2,3-dihydroxybutoxy)benzyl,4-(3-fluoro-2-hydroxypropoxy)benzyl, 2-fluoroethyl and3-fluoro-2-hydroxypropyl. The compounds of any of Formula I where Z isoptionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocycle, or optionally substituted aminoacid. The more preferred Z include trifluorobenzyl, furan-2-yl-methyl,pyridinium salt, piperidine-4-carboxylic acid, and substituted aminoacid Phe, Cys and Pro. The preferred substituted groups are hydroxyl,amino or substituted amino, substituted lower alkyl, substituted loweralkenyl, alkoxy, halogen, optionally substituted carboxy, substitutedamino carbonyl, nitro and sulfonyl. The more preferred substituentgroups are haloalkyl, hydroxyalkyl, aminoalkyl, haloalkoxy and cyano.The most preferred groups are trifluoromethyl, 2-fluoroethoxy,4-fluoro-2,3-dihydrobutoxy and 3-fluoro-2-hydroxypropoxy.

The compounds of any of Formula I wherein a charged moiety is includedin either X, Y, or Z. The preferred location of the charged moiety is inX or Z. The preferred charged moieties include quaternary ammoniumsalts, pyridinium salts, boronic acids, sulfonic acids, phosphonicacids, and carboxylic acids.

The compounds of any of Formula I wherein a radioactive element isincluded in either X, Y, or Z. The preferred location of the radioactiveelement is in X or Z. The preferred radioactive element includes ¹¹C,¹³N, ¹⁵O, and ¹⁸F. The most preferred one is ¹⁸F.

The preferred compounds include the following, as well as theirstereoisomers, tautomers, salts, and mixtures thereof:

-   (R)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (2S)-2-((2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethoxy)benzyl)propanamide;-   (S)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(1H-indol-3-yl)propanoic    acid;-   (S)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(3-(trifluoromethyl)phenyl)propanoic    acid;-   (S)-3-(4-cyanophenyl)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)propanoic    acid;-   (S)-methyl    3-(3-(2-fluoroethoxy)benzylthio)-2-((S)-4-hydroxy-2-(4-(((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;-   (R)-3-(3-(2-fluoroethoxy)benzylthio)-2-((R)-4-hydroxy-2-(4-(((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (R)-3-(3-(2-fluoroethoxy)benzylthio)-2-(S)-4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-2-(S)-3-(4-(4S,5R)-5-(fluoromethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (S)-2-(R)-3-(4-4(4S,5R)-5-(fluoromethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   3-(3-(2-fluoroethoxy)benzylthio)-2-(4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-2-((S)-3-(4-((2S,3R)-4-fluoro-2,3-dihydroxybutoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (S)-2-((R)-3-(4-((2S,3R)-4-fluoro-2,3-dihydroxybutoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (2R)-3-(3-((1-(1-fluoro-3-hydroxypropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2R)-3-(3-(2-fluoroethoxy)benzylsulfinyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (S)-3-(3-(2-fluoroethoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2S)-3-(3-(3-fluoro-2-hydroxypropoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-((R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-((R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-3-(4-(2-fluoroethoxy)phenyl)-2-((R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-3-(4-(2-fluoroethoxy)phenyl)-2-((R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-3-(4-(2-fluoroethoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2S)-3-(4-(1-fluoro-3-hydroxypropan-2-yloxy)phenyl)-2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid; and-   (2S)-3-(4-(1-fluoro-3-hydroxypropan-2-yloxy)phenyl)-2-4R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid.

Also provided herein are the following compounds:

-   Propyl    4-(2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)acetamido)benzoate;-   (R)-Methyl    3-(benzylthio)-2-(2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate;-   4-(1-(2-Morpholinoethyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)—N-(4-Methylpyridin-2-yl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   4-(1-(3-(1,3-Dioxoisoindolin-2-yl)-2-hydroxypropyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)—N-Benzyl-4-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)pentanamide;-   4-(1-(3-(Dimethylamino)-2-methylpropyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(1-(3-Bromobenzyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   Ethyl    4-((4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)methyl)benzoate;-   4-(1-(3-(6-Chloro-2-methoxyacridin-9-ylamino)propyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   N-(1,3-Dimethyl-1H-pyrazol-5-yl)-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)acetamide;-   4-(1-((1H-Benzo[d]imidazol-2-yl)methyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(1-(2-(2-Oxo-2H-chromen-7-yloxy)ethyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(1-(2-(1H-Indazol-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(3-Methoxy-3-oxo-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propyl)benzoic    acid;-   4-(1-(4-((1S,2R)-1,2-Dihydroxyoctyl)benzyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(1-(7-Chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(1-((1R)-(6-Methoxyquinolin-4-yl)((2R)-8-vinylquinuclidin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(1-(6-Hydroxyhexyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(1-(2-(2,4-Dioxo-1,2-dihydroquinazolin-3(4H)-yl)ethyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;

(E)-4-(1-(1-Cinnamoylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;

-   2-(4-(4-Sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)-N-(thiazol-2-yl)acetamide;-   N-Phenyl-3-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   N-Morpholino-3-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)benzamide;-   3-(1H-Imidazol-5-yl)-2-(2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   4-(1-(2-(4-(3,5-Dichlorophenyl)piperazin-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(1-(3-Aminopropyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (E)-4-(1-(1-(Styrylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   4-(1-(2-(1,2-Dihydroxyethyl)-4,5-dihydroxytetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (R)-Methyl    3-(benzylthio)-2-(2-(4-((4-sulfamoylbenzamido)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate;-   N-((1-(2-Morpholinoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (S)—N-((1-(1-(4-Methylpyridin-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-Morpholino-3-(4-((4-sulfamoylbenzamido)methyl)-1H-1,2,3-triazol-1-yl)benzamide;-   (S)—N-((1-(1-(2,5-Difluorobenzylamino)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (S)—N-((1-(1-(Benzylamino)-4-methyl-1-oxopentan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-(3-(Dimethylamino)-2-methylpropyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-((2R)-3-Methyl-1-(3-methylpiperidin-1-yl)-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (S)—N-((1-(1-(2,5-Dimethylbenzylamino)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-(3-Bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   4-Sulfamoyl-N-((1-((2-thioxobenzo[d]thiazol-3(2H)-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)benzamide;-   N-((1-(1-(3-Fluoro-4-methylbenzylamino)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (S)—N-((1-(1-(Cyclohexylamino)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   Ethyl    4-((4-((4-Sulfamoylbenzamido)methyl)-1H-1,2,3-triazol-1-yl)methyl)benzoate;-   (S)—N-((1-(1-(Benzylamino)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (S)—N-((1-(1-(Furan-2-ylmethylamino)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-((1H-Benzo[d][1,2,3]triazol-1-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   4-(3-Methoxy-3-oxo-2-(4-((4-sulfamoylbenzamido)methyl)-1H-1,2,3-triazol-1-yl)propyl)benzoic    acid-   Propyl    4-(2-(4-((4-sulfamoylbenzamido)methyl)-1H-1,2,3-triazol-1-yl)acetamido)benzoate;-   (S)—N-((1-(3-Methyl-1-(3-morpholinopropylamino)-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-(2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (S)-3-Methyl-2-(4-(((4-sulfamoylbenzamido)methyl)-1H-1,2,3-triazol-1-yl)butano    ic acid;-   (S)—N-((1-(1-(Biphenyl-4-ylamino)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-(4-((1S,2R)-1,2-Dihydroxyoctyl)benzyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-(7-Chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-((1R)-(6-Methoxyquinolin-4-yl)((2R)-8-vinylquinuclidin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-(6-Hydroxyhexyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-((1S,2S)-2-(Cinnamyloxy)-1,2-diphenylethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (S)—N-((1-(3-Methyl-1-oxo-1-(2-(thiophen-3-yl)ethylamino)butan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   3-(1H-Imidazol-5-yl)-2-(2-(4-(((4-sulfamoylbenzamido)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   N-((1-(2-(2,4-Dioxo-1,2-dihydroquinazolin-3(4H)-yl)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-(2-(4-(3,5-Dichlorophenyl)piperazin-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   N-((1-(3-Aminopropyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (E)-N-((1-(1-(Styrylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (E)-N-((1-(1-Cinnamoylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   (S)-3-Methyl-2-(444-sulfamoylbenzamido)methyl)-1H-1,2,3-triazol-1-yl)butanoic    acid;-   2-(4-(((4-Sulfamoylbenzamido)methyl)-1H-1,2,3-triazol-1-yl)dodecanoic    acid;-   N-((1-(2-(1,2-Dihydroxyethyl)-4,5-dihydroxytetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide;-   6-((1-(2-Morpholinoethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)—N-(4-Methylpyridin-2-yl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   N-Morpholino-3-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)benzamide;-   (S)—N-Benzyl-4-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide;-   6-((1-((2R)-3-Methyl-1-(3-methylpiperidin-1-yl)-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)—N-(2,5-Dimethylbenzyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-Cyclohexyl-3-methyl-2-(4-(((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-Benzyl-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   4-(3-Methoxy-3-oxo-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)benzoic    acid;-   Propyl    4-(2-(4-(((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)benzoate;-   6-((1-(2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (R)—N-(Biphenyl-4-yl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   6-((1-(4-((1S,2R)-1,2-Dihydroxyoctyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   6-((1-(7-Chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   6-((1-(6-Hydroxyhexyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   6-((1-((1S,2S)-2-(Cinnamyloxy)-1,2-diphenylethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)-3-Methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(thiophen-3-yl)ethyl)butanamide;-   6-((1-(2-(2,4-Dioxo-1,2-dihydroquinazolin-3(4H)-yl)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   6-((1-(2-(4-(3,5-Dichlorophenyl)piperazin-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (E)-6-((1-(1-(Styrylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (E)-6-((1-(1-Cinnamoylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   4-(1-((2R)-3-Methyl-1-(3-methylpiperidin-1-yl)-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)—N-(2,5-Difluorobenzyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-(3-Fluoro-4-methylbenzyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-Benzyl-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-3-Methyl-2-(4-(4-sulfamoyl-phenyl)-1H-1,2,3-triazol-1-yl)butanoic    acid;-   (S)-3-Methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)-N-(2-(thiophen-3-yl)ethyl)butanamide;-   (S)—N-(4-Fluorobenzyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-Benzyl-N,3-dimethyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-3-Methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)butanamide;-   (S)-4-(1-(3-Methyl-1-oxo-1-(4-(pyridin-2-yl)piperazin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (R)-Ethyl    2-((S)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-phenylpropanoate;-   (S)-Ethyl    3-methyl-2-((S)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamido)butanoate;-   (S)-Methyl    2-((S)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;-   (S)-3-Methyl-N-(pyridin-2-ylmethyl)-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-Cyclohexyl-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-(Cyclopropylmethyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-(3-Hydroxypropyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-3-Methyl-N-((5-methyl-3-phenylisoxazol-4-yl)methyl)-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-Ethyl    3-(N-(furan-2-ylmethyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;-   (S)-Ethyl    1-(3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanoyl)piperidine-4-carboxylate;-   (S)-4-(1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (2S)—N-((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-4-(1-(3-Methyl-1-oxo-1-(4-(pyrrolidin-1-yl)piperidin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)-3-Methyl-N-((1-methyl-1H-benzo[d]imidazol-2-yl)methyl)-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-4-(1-(3-Methyl-1-oxo-1-(4-(pyrimidin-2-yl)piperazin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)—N-(2-(4-Benzylpiperazin-1-yl)ethyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-2-Fluoro-N,N-dimethyl-N-((5-((3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamido)methyl)furan-2-yl)methyl)ethanaminium    bromide;-   (S)—N-(4-Fluorobenzyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-Benzyl-N-methyl-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-(2-((5-((Dimethylamino)methyl)furan-2-yl)methylthio)ethyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)-4-(1-(1-Oxo-3-phenyl-1-(4-(pyrimidin-2-yl)piperazin-1-yl)propan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)-3-Phenyl-N-((5-(pyridin-2-yl)thiophen-2-yl)methyl)-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)-Ethyl    3-(N-(furan-2-ylmethyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;-   (S)-Ethyl    1-(3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanoyl)piperidine-4-carboxylate;-   (S)-4-(1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (2S)—N-((2,3-Dihydrobenzo[1)][1,4]dioxin-2-yl)methyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-4-(1-(3-Methyl-1-oxo-1-(4-(pyrrolidin-1-yl)piperidin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)-3-Methyl-N-((1-methyl-1H-benzo[d]imidazol-2-yl)methyl)-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-4-(1-(3-Methyl-1-oxo-1-(4-(pyrimidin-2-yl)piperazin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)—N-(2-(4-Benzylpiperazin-1-yl)ethyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-2-Fluoro-N,N-dimethyl-N-((5-((3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamido)methyl)furan-2-yl)methyl)ethanaminium    bromide;-   (S)—N-(4-Fluorobenzyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-Benzyl-N-methyl-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-(2-((5-((Dimethylamino)methyl)furan-2-yl)methylthio)ethyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)-4-(1-(1-Oxo-3-phenyl-1-(4-(pyrimidin-2-yl)piperazin-1-yl)propan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)-3-Phenyl-N-((5-(pyridin-2-yl)thiophen-2-yl)methyl)-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   4-(1-((S)-1-((R)-2-(Hydroxymethyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)-4-(1-(1-Oxo-3-phenyl-1-(4-(pyridin-2-yl)piperazin-1-yl)propan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (R)-Ethyl    3-phenyl-2-((S)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamido)propanoate;-   (S)-Ethyl    3-methyl-2-((S)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamido)butanoate;-   (S)-Methyl    2-((S)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamido)propanoate;-   (S)-3-Phenyl-N-(pyridin-2-ylmethyl)-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-Cyclohexyl-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-(Cyclopropylmethyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-(3-Hydroxypropyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-((5-Methyl-3-phenylisoxazol-4-yl)methyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)-Ethyl    3-(N-(furan-2-ylmethyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamido)propanoate;-   (S)-Ethyl    1-(3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanoyl)piperidine-4-carboxylate;-   (S)-4-(1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (2S)—N-((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)-4-(1-(1-Oxo-3-phenyl-1-(4-(pyrrolidin-1-yl)piperidin-1-yl)propan-2-yl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide;-   (S)—N-((1-Methyl-1H-benzo[d]imidazol-2-yl)methyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-(2-(4-Benzylpiperazin-1-yl)ethyl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-(4-Fluorobenzyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-Benzyl-N,3-dimethyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-(2-45-((Dimethylamino)methyl)furan-2-yl)methylthio)ethyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-6-((1-(3-Methyl-1-oxo-1-(4-(pyrimidin-2-yl)piperazin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)-3-Methyl-N-((5-(pyridin-2-yl)thiophen-2-yl)methyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   6-((1-((S)-1-((R)-2-(Hydroxymethyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)-6-((1-(3-Methyl-1-oxo-1-(4-(pyridin-2-yl)piperazin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)-Ethyl    2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-phenylpropanoate;-   (S)-Ethyl    3-methyl-2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)butanoate;-   (S)-Methyl    2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;-   (S)-3-Methyl-N-(pyridin-2-ylmethyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-Cyclohexyl-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-(Cyclopropylmethyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)—N-(3-Hydroxypropyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-3-Methyl-N-((5-methyl-3-phenylisoxazol-4-yl)methyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-6-((1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-6-((1-(3-Methyl-1-oxo-1-(4-(pyrrolidin-1-yl)piperidin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)—N-(2-(4-Benzylpiperazin-1-yl)ethyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;-   (S)-Ethyl    3-(1H-indol-3-yl)-2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;-   (S)—N-(4-Fluorobenzyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-Benzyl-N-methyl-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-(245-((Dimethylamino)methyl)furan-2-yl)methylthio)ethyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)-6-((1-(1-Oxo-3-phenyl-1-(4-(pyrimidin-2-yl)piperazin-1-yl)propan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)-3-Phenyl-N-((5-(pyridin-2-yl)thiophen-2-yl)methyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   6-((1-((S)-1-((R)-2-(Hydroxymethyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)-6-(1-(1-Oxo-3-phenyl-1-(4-(pyridin-2-yl)piperazin-1-yl)propan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (R)-ethyl    3-Phenyl-2-((S)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)propanoate;-   (S)-Ethyl    3-methyl-2-((S)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)butanoate;-   (S)-3-Phenyl-N-(pyridin-2-ylmethyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-Cyclohexyl-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-(Cyclopropylmethyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N-(3-Hydroxypropyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)-6-((1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (2S)—N-((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)-6-((1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)-6-((1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;-   (S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;-   (S)—N,N,N-Trimethyl-2-oxo-2-(6-oxo-5-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-6-(4-(trifluoromethyl)benzylamino)hexylamino)ethanaminium;-   (S)-3,10-Dioxo-4-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-1-(4-(trifluoromethyl)phenyl)-13,16,19,22,25-pentaoxa-2,9-diazaoctacosan-28-oic    acid;-   (S)-4-Oxo-4-(6-oxo-5-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-6-(4-(trifluoromethyl)benzylamino)hexylamino)butanoic    acid;-   (S)-4-(6-(4-(Ethoxycarbonyl)cyclohexyl)-6-oxo-5-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)hexylamino)-4-oxobutanoic    acid; and-   (S)-6-((S)-2-Amino-3-hydroxypropanamido)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(Trifluoromethyl)benzyl)hexanamide    hydrochloride.

The more preferred compounds include the following, as well as theirstereoisomers, tautomers, salts, and mixtures thereof:

-   (S)—N-(4-Methylpyridin-2-yl)-3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamide-   4-(1-((2-Thioxobenzo[d]thiazol-3(2H)-yl)methyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide-   4-(1-((1H-Benzo[d][1,2,3]triazol-1-yl)methyl)-1H-1,2,3-triazol-4-yl)benzenesulfonamide-   (S)—N-(2,5-Difluorobenzyl)-3-methyl-2-(4-(((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide-   6-((1-(3-Bromobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide-   (S)—N-(3-Fluoro-4-methylbenzyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide-   Ethyl    4-44-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)benzoate-   (S)—N-(Furan-2-ylmethyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide-   6-((1-((1H-Benzo[d][1,2,3]triazol-1-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide-   4-((4-((2-Sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)benzoic    acid-   (S)-1,4-Dimethyl-2-(3-phenyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)propanamido)pyridinium    iodide-   (R)-3-(Benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid-   (R)-Methyl    3-(3-(2-fluoroethoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate-   (S)-1-(3-Methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanoyl)piperidine-4-carboxylic    acid-   (S)-Methyl    2-((S)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)propanoate-   (S)-1-(3-Phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoyl)piperidine-4-carboxylic    acid-   (S)-Methyl    3-((S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-phenylpropanoate-   (R)-2-Hydroxy-N,N,N-trimethyl-4-oxo-44(S)-6-oxo-5-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-6-(4-(trifluoromethyl)benzylamino)hexylamino)butan-1-aminium    chloride.

The most preferred compounds include the following, as well as theirstereoisomers, tautomers, salts, and mixtures thereof:

-   (S)—N-(Furan-2-ylmethyl)-3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamide-   (R)-Methyl    3-(benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate-   (R)-3-(3-(2-Fluoroethoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid-   (2S)—N-((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide-   (S)-Methyl    2-((S)-3-methyl-2-(4-(((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-(4-(trifluoromethyl)phenyl)propanoate-   (S)-Methyl    3-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-(4-(trifluoromethyl)phenyl)propanoate-   (S)-3-(S)-3-Methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid-   (S)-3-Phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)propanamide-   (S)—N-((5-Methyl-3-phenylisoxazol-4-yl)methyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide-   (S)-Ethyl    1-(3-phenyl-2-(4-02-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoyl)piperidine-4-carboxylate-   (2S)—N-((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide-   (S)-ethyl    1-(3-(4-(2-Fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoyl)piperidine-4-carboxylate-   (S)-3-(4-(2-Fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)propanamide-   (S)-1-(3-(4-(2-Fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoyl)piperidine-4-carboxylic    acid-   (S)-Methyl    2-((S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate-   (S)-2-(S)-3-Methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid-   (S)-2-(S)-3-(4-(2-Fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid.-   (R)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (2S)-2-((2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethoxy)benzyl)propanamide;-   (S)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-(((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(1H-indol-3-yl)propanoic    acid;-   (S)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(3-(trifluoromethyl)phenyl)propanoic    acid;-   (S)-3-(4-cyanophenyl)-24S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)propanoic    acid;-   (S)-methyl    3-(3-(2-fluoroethoxy)benzylthio)-2-((S)-4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;-   (R)-3-(3-(2-fluoroethoxy)benzylthio)-2-(R)-4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (R)-3-(3-(2-fluoroethoxy)benzylthio)-2-((S)-4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-2-((S)-3-(4-(((4S,5R)-5-(fluoromethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (S)-2-(R)-3-(4-(((4S,5R)-5-(fluoromethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   3-(3-(2-fluoroethoxy)benzylthio)-2-(4-hydroxy-2-(4-02-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-2-(S)-3-(4-(((2S,3R)-4-fluoro-2,3-dihydroxybutoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (S)-2-((R)-3-(4-((2S,3R)-4-fluoro-2,3-dihydroxybutoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic    acid;-   (2R)-3-(3-((1-(1-fluoro-3-hydroxypropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2R)-3-(3-(2-fluoroethoxy)benzylsulfinyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (S)-3-(3-(2-fluoroethoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2S)-3-(3-(3-fluoro-2-hydroxypropoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-((R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-((R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-3-(4-(2-fluoroethoxy)phenyl)-2-((R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-3-(4-(2-fluoroethoxy)phenyl)-2-((R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (S)-3-(4-(2-fluoroethoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic    acid;-   (2S)-3-(4-(1-fluoro-3-hydroxypropan-2-yloxy)phenyl)-2-(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid;-   (2S)-3-(4-(1-fluoro-3-hydroxypropan-2-yloxy)phenyl)-2-(R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic    acid.    Utility, Testing, and Administration    Utility

The radiolabeled triazole compounds can be used as imaging agents toimage CA-IX expression in a subject.

In one aspect, the radiolabeled triazole compounds have a high affinityand specificity to CA-IX. As reflected in K_(d) values, lead compoundsbind to CA-IX at the nanomolar level. In addition, the CA-IX-based andCA-II-based assay determined that lead compounds are good inhibitors forCA-IX as well as for CA-H. The selectivity between CA-IX and CA-II isabout 10-fold. The red blood cell membrane permeability assay indicatedthat the lead compounds exhibit minimal penetration of the red bloodcell membrane, and thus the lead compounds are unlikely to participatein a CA-II cross-reaction.

In addition, the present invention relates to the use of radiolabeledtriazole compounds for detecting CA-IX expression in vivo. Inparticular, the present methods for detecting CA-TX expression in vivoutilize PET, where the imaging tracer is a radiolabeled triazolecompound of the present invention. PET is useful for visualizing asubject's condition in relation to various tissues, especially bone andsoft tissues, such as cartilage, synovium and organs. Specific organsand tissues including, but not limited to, the brain, heart, kidney,liver, spleen, colon, spinal cord, lymph nodes, or any combinationthereof, of the subject. By using PET, a computer tomogram can beobtained of the desired organ tissue, enabling the localization andquantification of CA-IX.

The radiolabeled triazole compounds of the present invention can be usedto detect and/or quantitatively measure CA-IX levels in a subject,including humans. The radiolabeled triazole compounds can also be usedto measure and/or detect CA-IX in CA-IX associated diseases, disordersand conditions, including, but not limited to, apreneoplastic/neoplastic disease, including carcinomas, such as,colorectal, ovarian, uterine, cervical, endometrial, squamous cell andadenosquamous carcinomas; head and neck cancers; mesodermal tumors, suchas, neuroblastomas and retinoblastomas; sarcomas, such as osteosarcomas;and melanomas. Of particular interest are cancers of the breast, of thegastrointestinal tract, of the stomach including esophagus, of thecolon, of the kidney, of the prostate, of the liver, of the urinarytract including bladder, of the lung, and of the head and neck. Also ofparticular interest are gynecological cancers including ovarian,uterine, cervical, vaginal, vulval and endometrial cancers, particularlyovarian, uterine cervical and endometrial cancers. Furthermore, theradiolabeled triazole compounds can be used to screen for individuals todetermine the efficacy of CA-IX inhibitors administered to treat adisease or disorder that involve the upregulation of CA-IX expression.

Administration of the Radiolabeled Triazole Compounds

As described above, the radiolabeled triazole compounds are useful forimaging a CA-IX subject. When administered to a subject, theradiolabeled triazole compounds can be administered as a component of acomposition that comprises a physiologically acceptable carrier orvehicle. The present compositions, which comprise a radiolabeledtriazole compound, can be administered by any convenient route, forexample, by infusion, bolus injection, or by absorption throughepithelial or mucocutaneous linings and can be administered togetherwith another biologically active agent. Administration can be systemicor local. Methods of administration include, but are not limited to,intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous,intranasal, sublingual, epidural, intracerebral, intravaginal,transdermal, rectal, or topical.

In one embodiment, it can be desirable to administer the radiolabeledtriazole compounds locally. This can be achieved, for example, and notby way of limitation, by local infusion during surgery, by injection, bymeans of a catheter, by means of a suppository or enema, or by means ofan implant, with said implant being of a porous, non-porous, orgelatinous material, including membranes, such as sialastic membranes,or fibers.

In another embodiment, the radiolabeled triazole compounds can bedelivered in a controlled-release system or sustained-release system.The controlled-release system or sustained-release system can be placedin proximity to a target of the radiolabeled triazole compounds, e.g.,the spinal column, brain, heart, kidney or gastrointestinal tract, thusrequiring only a fraction of the systemic dose.

The compositions can optionally comprise a suitable amount of aphysiologically acceptable excipient so as to provide the form forproper administration to the subject. Such physiologically acceptableexcipients can be liquids, such as water for injection, bactereostaticwater for injection, or sterile water for injection. The physiologicallyacceptable excipients are sterile when administered to a subject. Wateris a particularly useful excipient when the radiolabeled triazolecompound is administered intravenously. Saline solutions can also beemployed as liquid excipients, particularly for injectable solutions.The pharmaceutical excipients can be saline, gum acacia, starch,glucose, lactose, glycerol, ethanol and the like.

The radiolabeled triazole compounds can be formulated for intravenousadministration. Typically, compositions for intravenous administrationcomprise sterile isotonic aqueous buffer. Where the radiolabeledtriazole compounds are administered by injection, an ampule of sterilewater for injection or saline can be provided so that the ingredientscan be mixed prior to administration. Where the radiolabeled triazolecompounds are to be administered by infusion, they can be dispensed, forexample, with an infusion bottle containing sterile pharmaceutical gradewater or saline.

The amount of the radiolabeled triazole compound that is effective as animaging agent to detect CA-IX in a subject can be determined usingstandard clinical and nuclear medicine techniques. In addition, in vitroor in vivo testing can optionally be employed to help identify optimaldosage ranges. The precise dose to be employed will also depend on theroute of administration, the identity of the subject and the identity ofthe particular radionuclide being detected and should be decidedaccording to the judgment of the practitioner and each subject'scircumstances in view of published clinical studies. The radiolabeledtriazole compounds will have a specific activity of >1000 Ci/mmol at thetime of administration to insure a low injected mass and adequate countsfor imaging.

EXAMPLES

General. CA-IX human recombinant enzyme was expressed with a C-terminalHis tag in a mouse myeloma cell line, NS0 (R&D Systems Inc., catalognumber 2188-CA). The human red blood cells were obtained from ResearchBlood Components, LLC. All absorbance measurements were performed on aSPECTRA MAX M2 plate reader at 25° C. The LC/MS analyses were performedon an Agilent 1100 series LC/MSD (SL) using a 30×2.1 mm Zorbax C8 columnwith a Phenomenex C18 pre-column. Compound detection was accomplished byelectrospray mass spectroscopy in positive selected ion mode(LC/MS-SIM). The elution solvents were acetonitrile and water, contained0.05% TFA. Nuclear magnetic resonance (NMR) spectra were obtained on aBruker AMX 300 MHz spectrometer or a Varian 400. 19F NMR spectra wererecorded on a Bruker AMX 282.35 MHz or a Varian 400 spectrometer. Themass spectra were recorded on an Agilent 1100 series LC/MSD withelectrospray mass spectroscopic detection. Flash column chromatographywas performed on Merck silica gel (40-63 μm) using the solvent systemindicated. The radiochemical and chemical purities were analyzed byRP-HPLC.

General Combinatorial Library Screening Protocol for CA-IX

The CA-IX screening assay was employed for testing libraries derivedfrom the various “anchor” molecules, using ethoxzolamide as a positivecontrol. The assay was performed at a substrate (dansylamide, DNSA)concentration of 200 μM, and sample concentrations of 100 nM and 1000nM, respectively. A modified competitive fluorescence-based assay (A.Jain, S. G. Huang, G. M. Whitesides, J. Am. Chem. Soc. 1994, 116, 5057)was used to measure CA-IX activity. The enzymatic assay was carried outin a 96-well plate. To the wells, deionized water, 40 μL of phosphatebuffer (250 mM, pH 7.4), 2.4 μL of CA-IX (17 μM), and 2 μL or 20 μL ofinhibitor (concentration of 100 nM or 1000 nM) were added to achieve afinal volume of 180 μL. Reactions were initiated by adding 20 μL DNSA(200 μM) to each well and the plate was incubated at 25° C. for 1 hour.The fluorescence intensities from each well of the plate were then readat 460 nm using a plate reader with an excitation wavelength of 290 nm.

General Procedure of Binding Affinity (K_(a)) Determination for CA-IXInhibitors

The fluorescence competition assay developed by Whitesides et al. (A.Jain, S. G. Huang, G. M. Whitesides, J. Am. Chem. Soc. 1994, 116, 5057)and J. C. Kernohan (R. F. Chen, J. C. Kernohan, J. Biol. Chem. 1967,242, 5813) using DNSA as a reporting ligand that is displaced by thetest compound was used for the measurement of binding affinities. Theassay was based on the observation that the only fluorescence signaldetected at 460 nm upon excitation at 290 nm, an absorption minimum forDNSA, was that of the DNSA.CA complex. With increasing sampleconcentration, the fluorescence intensity due to DNSA.CA decreases as aresult of competition with the test compound, allowing the determinationof dissociation constants from Scatchard plots. The latter weredeveloped for each test compound using mass balance for calculating theconcentration of CA bound to DNSA [DNSA.CA], bound to thenon-fluorescent sample [CA.Inh] and free CA [CA] in solution. The K_(d)values were determined from Scatchard plots using the equation below asdescribed by Whitesides et al.[CA.Inh]/[CA] _(tot) .[Inh]=K ₁₁ ^(inh) −K ₁₁ ^(inh){[CA.Inh]+[CA.DNSA]}/([CA] _(tot))

The terms [CA.DNSA], [CA.Inh], and free CA were calculated using themass balance based on the known values for the dissociation constant ofCA.DNSA and the total concentration of CA in each reaction.

General Procedure of Red Blood Cell Membrane Permeability Assay

The isolated human red blood cells were treated with or without 1 mMethoxzolamide for 30 minutes, followed by incubation with 0.2 mM ofindividual compound, respectively, for 60 minutes. After the incubation,the red blood cells were washed three times to eliminate all unboundinhibitor. The cells were then lysed and centrifuged and thesupernatants were analyzed by LC/MS to measure the levels of thecompounds within red blood cells.

Preparation of Compounds

Equivalents (equiv) refer to molar equivalents. Volumes (vol) refer toml to gram equivalents of the limiting reagent.

General Experimental Procedure for Phenolic Alkylation: (A)

To a round bottomed flask equipped with a magnetic stir bar, rubberseptum, and argon inlet containing DMF (10 vol) was placed phenol (1equiv). To this solution was added alkylating agent (1.1 equiv), Cs₂CO₃(1.2 equiv) and the reaction was allowed to stir at 90° C. for 15 h. Thereaction was then poured into water (25 vol) and extracted into EtOAc(3×20 vol). The combined organic extracts were washed with brine (25vol), dried (Na₂SO₄) and concentrated in vacuo. The residue was purifiedover silica gel using Hexanes:EtOAc as an eluent to afford the finalproduct.

General Experimental Procedure for Boc, THP and Ketal Deprotections: (B)

To a round bottomed flask equipped with a magnetic stir bar was placedprotected material (1 equiv). To this compound was added HCl (4Msolution in dioxane, 3.8 vol) and the reaction was allowed to stir atroom temperature for 2 h. To this solution was added conc. HCl (0.08vol) in MeOH (3.8 vol) and the reaction was allowed to stir at roomtemperature for 2 h. After the reaction was complete, the solvents wereremoved in vacuo to afford the final compound.

General Experimental Procedure for Coupling: (C)

To a round bottomed flask equipped with a magnetic stir bar, rubberseptum, and argon inlet containing DMF (20 vol) was placed amine (1equiv). To this solution was added the azidoacid (1 equiv), EDC (1equiv), HOBt (1 equiv), NaHCO₃ or TEA (5 equiv using NaHCO₃ or 2 equivusing TEA) and the reaction was allowed to stir at room temperature for15 h. The reaction was then poured into water (50 vol) and extractedinto EtOAc (4×40 vol). The combined organic extracts were washed withH₂O (3×40 vol) brine (50 vol), dried (Na₂SO₄) and concentrated in vacuo.The residue was purified over silica gel using Hexanes:EtOAc as theeluent to afford the final coupled product.

General Experimental Procedure of Tosylation of Alcohol: (D)

To a round bottomed flask equipped with a magnetic stir bar containingDCM (17 vol) was placed alcohol (1 equiv) cooled to 0° C. To thissolution was added Ts₂O (1.5 equiv), Et₃N (3 equiv) and the reaction wasallowed to stir at room temperature for 1 h. After the reaction wascomplete, DCM was removed in vacuo. The residue was purified over silicagel using Hexanes:EtOAc as the eluent to afford the final tosylate.

General Experimental Procedure for Click Reaction Between Azides andAcetylenes Using CuI and DIPEA: (E)

To a round bottomed flask equipped with a magnetic stir bar, rubberseptum, and argon inlet containing THF (29 vol) was placed azide (1equiv). To this solution was added acetylene (1 equiv), CuI (0.2 equiv),DIPEA (0.4 equiv) and the reaction was allowed to stir at roomtemperature for until deemed complete by LCMS. After the reaction wascomplete, the solvents were removed in vacuo. The residue was purifiedover silica gel (that was neutralized with 5-10% triethylaminc:Hexanesmixture) using Hexanes:EtOAc as the eluent to afford the final triazole.

General Experimental Procedure of Serine Alkylation with Sodium Hydride:(F)

To a round bottomed flask equipped with a magnetic stir bar, rubberseptum, and argon inlet containing DMF (17 vol) was placed N-Boc-Serine(1.2 equiv). To this solution was added NaH (60% dispersion in oil, 3equiv) at 0° C. and the reaction was allowed to stir at 0° C. for 30min. To this reaction was added the alkylating agent (1 equiv) at 0° C.and the reaction was allowed to stir at room temperature for 15 h. Afterthe reaction was complete by LCMS, solvent was removed in vacuo. Thereaction was then poured into water (54 vol), pH was adjusted to >10 andextracted into EtOAc (2×21 vol). Organic layer was discarded and the pHof the aqueous layer was adjusted to pH=4 with 1N HCl and extracted intoEtOAc (3×27 vol). The combined organic extracts were washed with brine(11 vol), dried (Na₂SO₄) and concentrated in vacuo to afford thealkylated product.

General Experimental Procedure of Acid Esterification withTrimethylsilyl Azide: (G)

To a round bottomed flask equipped with a magnetic stir bath containingtoluene:MeOH (2:1.5, 23 vol) was placed the acid (1 equiv). To thissolution was added TMSCHN₂ (2M solution in ether, 1.5 equiv) and thereaction was allowed to stir at room temperature for 30 min. After thereaction was complete, solvent was removed in vacuo. The residue waspurified over silica gel using Hexanes:EtOAc as the eluent to afford theesterified material.

General Experimental Procedure for Selective Monotosylation of Diol: (H)

To a round bottomed flask equipped with a magnetic stir bar containingACN or DCM (67 vol) was placed diol (1 equiv). To this solution wasadded Bu₂SnO (0.2 equiv), TsCl (0.95 equiv), Et₃N (1 equiv) and thereaction was allowed to stir at room temperature for 1 h. After thereaction was complete, the solvent was removed in vacuo. The residue waspurified over silica gel using Hexanes:EtOAc as the eluent to afford themonotosylate.

General Experimental Procedure for Acetylation of Alcohols: (I)

To a round bottomed flask equipped with a magnetic stir bar containingDCM (26 vol) was placed alcohol (1 equiv), cooled to 0° C. To thissolution was added Ac₂O (2 equiv), DMAP (1 equiv), Et₃N (2 equiv) andthe reaction was allowed to stir at room temperature for 1 h. Thereaction was then poured into water (53 vol) and extracted into DCM(3×53 vol). The combined organic extracts were washed with brine (53vol), NaHCO₃ solution (53 vol), dried (Na₂SO₄) and concentrated invacuo. The residue was purified over silica gel using Hexanes:EtOAc asthe eluent to afford the acetylated material.

General Experimental Procedure for Fluorination: (J)

To a round bottomed flask or vial equipped with a magnetic stir bar, wasplaced the precursor (1 equiv). To this compound was added Bu₄NF (4Msolution in THF, 20 vol) and the reaction was allowed to stir at 90° C.for 30 min. To this reaction was added HCl (1N, 40 vol) and the reactionwas allowed to stir at 65° C. for 30 min. The reaction mixture wasdiluted with water/acetonitrile (1 mL), filtered through 0.45 μm filterprior to purification by HPLC using ACN: Water both containing 0.05% TFAto afford the fluorinated product.

General Experimental Procedure for Ester Hydrolysis Using LiOH: (K)

To a round bottomed flask equipped with a magnetic stir bar containingTHF:Water (1:1) (20 vol) was placed the ester (1 equiv) and LiOH (2-5equiv), and the reaction was allowed to stir at room temperature for 30min to 1 h. The reaction was then concentrated and product was isolatedby HPLC purification as a colorless solid.

General Experimental Procedure for Boc and Ketal Deprotections usingTFA: (L)

To a round bottomed flask equipped with a magnetic stir bar was placedprotected material (1 equiv) in DCM (200 vol). To this compound wasadded TFA (10 vol) and the reaction was allowed to stir at roomtemperature for 15 h. The reaction was then poured into water (200 vol)and extracted into DCM (2×100 vol). The combined organic extracts werewashed with brine (50 vol), NaHCO₃ solution (50 vol), dried (Na₂SO₄) andconcentrated in vacuo. The residue was purified over silica gel usingHexanes:EtOAc as the eluent to afford the deprotected material.

General Experimental Procedure for Azidation: (M)

To a round bottomed flask equipped with a magnetic stir bar containingpyridine (12 vol) was placed NaN₃ (5 equiv) at 0° C. The reaction wasstirred at 0° C. for 5 h. To this solution was added amine (1 equiv) inMeOH (100 vol), CuSO₄ (0.3 equiv) and the reaction was allowed to stirat room temperature for 15 h. The reaction was then poured into NaHCO₃solution (100 vol) and extracted into EtOAc (3×100 vol). The combinedorganic extracts were washed with CuSO₄ solution (100 vol), dil. HClsolution (100 vol), brine (2×100 vol), dried (Na₂SO₄) and concentratedin vacuo. The residue was purified over silica gel using Hexanes:EtOAcas the eluent to afford the azide.

General Procedures Used in the Combinatorial Library Synthesis:

General Experimental Procedure for Click Reaction Between Azides andAcetylenes Using CuSO₄.H₂O and Sodium Ascorbate: (N)

To a round bottomed flask equipped with a magnetic stir bar, rubberseptum, and argon inlet containing t-BuOH: H₂O (1:1, 100 vol) was placedazide (1 equiv). To this solution was added acetylene (0.9 equiv),CuSO₄.5H₂O (0.2 equiv), sodium L-ascorbate (0.4 equiv) and the reactionwas allowed to stir at room temperature for until deemed complete byLCMS. After the reaction was complete, the solvents were removed invacuo. The residue was washed with water (100 vol), cooled at 0° C.,filtered, washed with ether (50 vol) dried in vacuo to afford the finaltriazole. If the solid appeared to contain trace amounts of copper, aswas evidenced by a green color, the solid was washed with an add'nportion of 0.1% NH₄OH (100 vol), with water (100 vol), washed with ether(50 vol) and dried in vacuo. All library members were submitted forLC/MS analysis to evaluate purity. Compounds with purities above 85%were submitted for biological assay. Compounds with purities below 85%were re-purified via flash chromatography and then subjected tobiological assay.

General Experimental Procedure for Amide Coupling with PS-Carbodiimide(O)

A 5 mL microwave tube was charged with acid (1 equiv), PS-Carbodiimide(2 equiv), 1-hydroxybenzotriazole (0.99 equiv) and amine (0.95 equiv) indichloromethane (50 vol) and dimethylformamide (5 vol). The suspensionwas irradiated in a Biotage Emrys Optimizer microwave reactor (250 W) at100° C. for 10 min. After cooling to room temperature the reactionmixture was filtered through an SPE-cartridge (pre-packed with 500 mgsilica-bound carbonate and preconditioned with CH₂Cl₂(100 vol) andwashed with dichloromethane (100 vol)). The dichloromethane washes werediscarded. The cartridge was further washed with methanol (3×100 vol)and the eluents were collected via gravity filtration in a scintillationvial. Evaporation of all volatile components in a centrifugal vacuumevaporator (Genevac HT-4) provided the amide. All library members weresubmitted for LC/MS analysis to evaluate purity. Compounds with puritiesabove 85% were submitted for biological assay. Compounds with puritiesbelow 85% were re-purified via flash chromatography and then subjectedto biological assay.

HPLC Purifications:

All the HPLC purifications were done on a Shimadzu semi prep systemusing a gradient acetonitrile:water mixture (with 0.05-0.1% TFA) as theeluent starting from 5% ACN: 95% Water (both containing 0.05-1% TFA) atT_(o) and going to 100% ACN (containing 0.05-0.1% TFA) over 30 to 40minutes.

Preparation of 6-Hydroxybenzo[d]thiazole-2-sulfonamide (1)

To a 1 L round bottomed flask equipped with a magnetic stir bar, rubberseptum, and argon inlet containing DCM (500 mL) was placed6-ethoxybenzo[d]thiazole-2-sulfonamide (25 g, 108.7 mmol). To thissolution at 0° C. (ice bath) was added AlCl₃ (50 g, 376 mmol)portion-wise and the reaction was allowed to stir at rt for 24 h.Solvent was removed in vacuo and the residue was cautiously quenchedinto 3 M HCl (600 mL). The mixture was filtered and the solid was washedwith cooled 3 M HCl (2×50 mL). The product was dried under high vacuumfor 48 h to afford compound 1 as a yellow solid (24 g).

¹H NMR (300 MHz, CD₃OD) δ: 7.91 (d, J=9.2 Hz, 1H), 7.37 (d, J=2.4 Hz,1H), 7.10 (dd, J=9.2, 2.4 Hz, 1H); MS (ESI) m/z 231 (M+H⁺).

Preparation of 6-(Prop-2-ynyloxy)benzo[d]thiazole-2-sulfonamide (3)

Preparation ofN,N-Dimethyl-N′-(6-(prop-2-ynyloxy)benzo[d]thiazol-2-ylsulfonyl)formimidamide(2)

To a 100 mL round bottomed flask equipped with a magnetic stir bar,rubber septum, and argon inlet containing DMF (25 mL) in an ice bath wasplaced 1 (17.5 g, 76.1 mmol) and the reaction was stirred at rt untilthe solid dissolved. To this solution was added N,N-dimethylformamidedimethyl acetal (60 g) and the mixture was heated at 40° C. for 4 h.Solvent was removed in vacuo at 42° C. and the residue was dissolved inanhydrous DMF (60 mL). To this solution at 0° C. was added portion wiseNaH (4.56 g, 60% in oil, 114 mmol) and the reaction was stirred at 0° C.for 30 min. To this mixture was added propargyl bromide (18 g, 80%toluene solution, 121.7 mmol) dropwise. Ice bath was removed and themixture was stirred at rt for 1 h. The residue was poured into a mixtureof water and EtOAc (200 mL/200 mL). The mixture was filtered and solidwas collected and dissolved in DCM (300 mL) and washed with saturatedNaHCO₃ (3×200 mL) and water (200 mL). To this solution was added 100 gof silica gel and dried in vacuo. The solid mixture was loaded on silicagel column and eluted with 10% EtOAc in DCM to afford compound 2 as ayellow solid (9.2 g, 37.4%).

¹H NMR (300 MHz, acetone-d₆) δ: 8.29 (s, 1H), 8.00 (d, J=9.2 Hz, 1H),7.76 (d, J=2.4 Hz, 1H), 7.27 (dd, J=9.2, 2.4 Hz, 1H), 4.92 (d, J=2.8 Hz,2H), 3.34 (s, 3H), 3.14 (t, J=2.4 Hz, 1H), 3.07 (s, 3H); MS (ESI) m/z324 (M+H⁺).

Preparation of 6-(Prop-2-ynyloxy)benzo[d]thiazole-2-sulfonamide (3)

To a 500 mL round bottomed flask equipped with a magnetic stir bar,rubber septum, and argon inlet was placed 2 (9 g, 27.8 mmol) and 200 mLof ammonia in methanol (7 N). The mixture was stirred at rt for 24 h.The solution was bubbled with air for 1 h and filtered. The filtrate wasacidified with concentrated HCl to pH=2 and concentrated and dried. Thissolid was again treated with ammonia methanol solution (7 N, 200 mL) for24 h at rt. The solution was bubbled with air for 1 h and filtered. Thefiltrate was added concentrated HCl to pH=2 and concentrated. It wasfiltered and the solid was washed with cooled water and dried to affordcompound 3 as a yellow solid (5.2 g, 70%).

¹H NMR (300 MHz, acetone-d₆) δ: 8.03 (d, J=9.2 Hz, 1H), 7.78 (d, J=2.8Hz, 1H), 7.38 (s, 2H), 7.30 (dd, J=9.2, 2.4 Hz, 1H), 4.93 (d, J=2.4 Hz,2H), 3.15 (t, J=2.4 Hz, 1H); MS (ESI) m/z 269 (M+H⁺).

Alternate preparation of6-(Prop-2-ynyloxy)benzo[d]thiazole-2-sulfonamide (3)

To a stirring solution of NaOH in MeOH (2.5 M, 18.8 mL) and DMF (60 mL)was added 1 (4.33 g, 18.8 mmol). The mixture was allowed to stir for 45min at 23° C. before propargyl bromide (80% in PhMe, 3.36 mL, 22.56mmol) was added slowly over 10 min. After 2.5 h, an aqueous solution of1 M HCl was added to achieve pH=6, where upon a white precipitate forms.Water was then added and the organic layer was extracted 3×EtOAc and thecombined organic extracts washed 1×H₂O, 1× brine, and then dried overMgSO₄. The solvents were removed in vacuo and the crude residue purifiedby flash chromatography using Hexanes:EtOAc on a Biotage purificationsystem to yield 3 as a pale yellow solid (1.43 g, 29%).

¹H NMR (300 MHz, CDCl₃) δ: 8.27 (2H, s), 8.09 (d, J=9.0 Hz, 1H), 7.86(d, J=2.6 Hz, 1H), 7.31 (dd, J=9.0, 2.6 Hz, 1H), 4.93 (d, J=2.3 Hz, 2H),3.65 (t, J=2.3 Hz, 1H).

Preparation ofN-(bis(4-Methoxyphenyl)(phenyl)methyl)-6-(prop-2-ynyloxy)benzo[d]thiazole-2-sulfonamide(4)

To a stirring slurry of 3 (0.2 g, 0.76 mmol) and dimethoxytritylchloride (0.31 g, 0.91 mmol) (DMTr-Cl) in DCM (15 mL) was added TEA(0.15 mL). The resulting clear solution was allowed to stir at roomtemperature for 4 h. Silica gel (0.5 g) was added to the solution andfollowed by rotary evaporation of solvent in vacuo. The sample absorbedsilica gel was then loaded onto a pre-equilibrated column (with 10% TEAin hexanes). Flash chromatography using 0-50% EtOAc in hexane as theeluent gave the product 4 as a yellow solid (0.30 g, 69%).

Preparation ofN-(bis(4-Methoxyphenyl)(phenyl)methyl)-4-ethynylbenzenesulfonamide (5)

To a stirring slurry of 4-ethynylbenzenesulfonamide (1.81 g, 10.0 mmol)and DMTr-C1 (4.07 g, 12.0 mmol) in DCM (100 mL) was added TEA (2.8 mL).The resulting solution was allowed to stir at room temperature forovernight. Silica gel (3 g) was added to the solution followed by rotaryevaporation of solvent in vacuo. The sample was absorbed onto silica gelwas then loaded onto a pre-equilibrated column (with 10% TEA in hexane).Flash chromatography using 0-30% EtOAc in hexane as the gradient eluentsgave the product 5 as a yellow solid (4.8 g, 99%).

Preparation of(S)-2-(4-(4-(N-(bis(4-Methoxyphenyl)(phenyl)methyl)sulfamoyl)phenyl)-1H-1,2,3-triazol-1-yl)-3-methylbutanoicacid (6)

Click reaction was done according to the general procedure (E).Performed on a 0.97 g scale with DIEA in 1.1 equiv. After evaporation ofTHF, the residue was dissolved in DCM, washed with water (2×), driedover anhydrous sodium sulfate, and concentrated before loading onto thecolumn. Flash chromatography on a silica gel column (40 g) using 5-20%MeOH in DCM gave the desired product 6 (0.545 g, 65%).

Preparation of2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)aceticacid (7),(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanoicacid (8), and(S)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoicacid (9)

Compounds 7, 8 and 9 were prepared via general procedure (N). The crudereaction mixture for each compound was independently concentrated invacuo onto silical gel and purified by flash chromatography first usingHexanes:EtOAc followed by dichloromethane/methanol on a Biotagepurification system, furnishing triazoles 7-9 as off-white crystallinesolids (77-100%).

Preparation of VM4047 precursor

Preparation of(S)-methyl-2-(tert-butoxycarbonylamino)-3-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)propanoate(10)

General experimental procedure for alkylation (A) was followed.Performed on a 5 g scale, using the ketal tosylate, andtetrabutylammonium sulfate. Reaction mixture was purified over silicagel using DCM first followed by Hexanes:EtOAc to afford 10 (6 g, 85%) asa yellow liquid. MS: [M+Na]⁺: 432

Preparation of (S)-methyl2-amino-3-(4-(2,3-dihydroxypropoxy)phenyl)propanoate (11)

General procedure for deprotection (B) was followed. Performed on a 1.5g scale. After the completion of the reaction, solvent was evaporated,triturated with Et₂O, washed and the resulting product 11 was obtainedas a white solid (100% yield).

Preparation of(S)-methyl-2-((S)-2-azido-3-methylbutanamido)-3-(4-(2,3-dihydroxypropoxy)phenyl)propanoate (12)

Coupling reaction was done according to the general procedure (C).Performed on a 0.5 g scale using valine azido acid and triethyl amine asbase. In this specific case, racemization at the valine centre occurredduring this step. Isolated 0.65 g (86%) of 12 as mixture of isomers. MS:[M+H]⁺: 353.4

Preparation of (S)-methyl2-((S)-2-azido-3-methylbutanamido)-3-(4-(2-hydroxy-3-(tosyloxy)propoxy)phenyl)propanoate(13)

Tosylation was done according to the general procedure (H). Performed ona 0.55 g scale. Isolated 0.6 g (100%) of 13. MS: [M+H]⁺: 549.2

Preparation of (S)-methyl3-(4-(2-acetoxy-3-(tosyloxy)propoxy)phenyl)-2-((S)-2-azido-3-methylbutanamido)propanoate(14)

Acetylation was done according to the general procedure (I). Performedon a 0.55 g scale. EtOAc:Hexanes (45:55) were used as the eluent.Isolated 0.6 g (100%) of 14 as a colorless oil. MS: [M+H]⁺: 591.1

Preparation of (S)-methyl3-(4-(2-acetoxy-3-(tosyloxy)propoxy)phenyl)-2-((S)-2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-3-methylbutanamido)propanoate(15)

Click reaction was done according to the general procedure (E).Performed on a 0.5 g scale with DIEA in 1.1 eq. Product 15 was obtained(0.7 g, 75%) as off colorless solid.

LCMS for C₅₈H₆₀N₆O₁₄S₃, calc'd: 1160.33, found: 1161.4, 1183.4 (M+H,M+Na)

Preparation of VM4047 Standard (VM4047A and VM4047B)

Preparation of(S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid (VM4047A and VM4047B)

General experimental procedure for fluorination (J) was followed.Performed on a 0.6 g scale. The reaction mixture purified by HPLC toafford two isomers in a 3:2 ratio (16% overall, A: 2.51 mg, B: 2.95 mg)as colorless solid. MS: for A and B [M+H]⁺: 651.2 (M+H).

VM4047A: ¹H NMR (400 MHz, Acetone-d₆) δ: 8.21 (d, J=2.2 Hz, 1H), 8.03(d, J=9.0 Hz, 2H), 7.91 (d, J=2.5 Hz, 1H), 7.39 (s, 2H), 7.34 (dd,J=9.2, 2.5 Hz, 1H), 6.99 (d, J=8.4 Hz, 2H), 6.75 (d, J=8.6 Hz, 2H), 5.35(s, 2H), 5.13 (d, J=10 Hz, 1H), 4.74-4.68 (m, 1H), 4.60 (dq, J=9.6, 3.2Hz, 1H), 4.49 (dq, J=9.8, 4.3 Hz, 1H), 4.20-4.12 (m, 1H), 4.03-3.99 (m,2H), 3.48-3.44 (m, 1H), 3.12 (dd, J=13.9, 5.3 Hz, 2H), 2.95 (dd, J=14.3,8.0 Hz, 2H), 2.49-2.44 (m, 1H), 1.84-1.82 (m, 1H), 1.47-1.41 (m, 1H),1.04 (d, J=6.7 Hz, 3H), 0.68 (d, J=6.7 Hz, 3H).

VM4047B: ¹H NMR (400 MHz, Acetone-d₆) δ: 8.25 (s, 1H), 8.08 (d, J=8.2Hz, 1H), 8.02 (d, J=9.0 Hz, 1H), 7.95 (d, J=2.5 Hz, 1H), 7.40 (s, 1H),7.33 (dd, J=9.0, 2.5 Hz, 1H), 7.16 (d, J=8.6 Hz, 1H), 5.33 (s, 2H), 5.05(d, J=9.8 Hz, 1H), 4.74-4.69 (m, 1H), 4.62 (dq, J=9.6, 3.9 Hz, 1H), 4.49(dq, J=9.6, 3.9 Hz, 1H), 4.21-4.14 (m, 1H), 4.04-4.01 (m, 1H), 3.19 (dd,J=14.1, 4.7 Hz, 2H), 2.97 (dd, J=14.0, 9.4 Hz, 2H), 2.40-2.35 (m, 1H),0.81 (d, J=6.7 Hz, 3H), 0.63 (d, J=6.7 Hz, 3H).

Alternate preparation of VM4047 Standard (VM4047):

Preparation of (2S)-methyl2-(tert-butoxycarbonylamino)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)propanoate(16)

General experimental procedure for phenolic alkylation (A) was followed.Reaction was performed on a 2 g scale. Hexanes:EtOAc (50:50) used as theeluent for purification. Isolated 1.9 g (76%) of 16 as a colorless oil.MS: [M-Boc+H]⁺: 271.

Preparation of(2S)-methyl2-amino-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl) propanoatehydrochloride (17)

General experimental procedure for deprotection (B) was followed.Reaction was performed on a 2.4 g scale. Isolated 1.9 g (96%) of 17 as acolorless solid. MS: [M+H]⁺: 308.

Preparation of(2S)-methyl2-((S)-2-azido-3-methylbutanamido)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)propanoate(18)

General experimental procedure for coupling (C) was followed. Reactionwas performed on a 1.9 g scale. Hexanes:EtOAc (60:40) used as the eluentfor purification. Isolated 1.6 g (67%) of 18 as a colorless solid. MS:[M+H]⁺: 397.

Preparation of (2S)-methyl3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate(19)

General experimental procedure for click reaction (E) was followed.Reaction was performed on a 0.025 g scale. Hexanes:EtOAc (10:90) used asthe eluent for purification. Isolated 0.02 g (48%) of 19 as a colorlesssolid. MS: [M+H]⁺: 665

Preparation of VM4047a

General experimental procedure for hydrolysis (K) can be used to prepareVM4047a

Preparation of VM391 Precursor:

Preparation of(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)methanol (20)

General experimental procedure for phenolic alkylation (A) was followed.Reaction was performed on a 20 g scale. Hexanes:EtOAc (40:60) used asthe eluent for purification. Isolated 17 g (72%) of 20. MS: [M+H]⁺: 239.

Preparation of3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)benzyl4-methylbenzenesulfonate (21)

General experimental procedure for tosylation (D) was followed. Reactionwas performed on a 17 g scale. Hexanes:EtOAc (50:50) used as the eluentfor purification. Isolated 9.5 g (35%) of 21. MS: [M+H]⁺: 393.

Preparation of(2S)-2-(tert-butoxycarbonylamino)-3-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)benzyloxy)propanoicacid (22)

General experimental procedure for serine alkylation (F) was followed.Reaction was performed on a 5.8 g scale. Isolated 6 g (60%) of 22. MS:[M-Boc+H]⁺: 326.

Preparation of (2S) methyl2-(tert-butoxycarbonylamino)-3-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)benzyloxy)propanoate(23)

General experimental procedure for esterification (G) was followed.Reaction was performed on a 6 g scale. Hexanes:EtOAc (60:40) was used asthe eluent for purification. Isolated 4 g (66%) of 23. MS: [M-Boc+H]⁺:340.

Preparation of (2S)methyl2-amino-3-(3-(2,3-dihydroxypropoxy)benzyloxy)propanoatehydrochloride (24)

General experimental procedure for deprotection (B) was followed.Reaction was performed on a 4 g scale. Isolated 2.7 g (90%) of 24 as acolorless solid. MS: [M+H]⁺: 300.

Preparation of (2S) methyl2-(2-azidoacetamido)-3-(3-(2,3-dihydroxypropoxy)benzyloxy)propanoate(25)

General experimental procedure for coupling (C) was followed. Reactionwas performed on a 2.7 g scale. EtOAc was used as the eluant forpurification. Isolated 1.5 g (50%) of 25. MS: [M+H]⁺: 383.

Preparation of (2S) methyl2-(2-azidoacetamido)-3-(3-(2-hydroxy-3-(tosyloxy)propoxy)benzyloxy)propanoate(26)

General experimental procedure for selective monotosylation of diol (H)was followed. Reaction was performed on a 1.5 g scale. Hexanes:EtOAc(30:70) used as the eluent for purification. Isolated 1.9 g (90%) of 26.MS: [M+H]⁺: 537.

Preparation of (2S)-methyl3-(3-(2-acetoxy-3-(tosyloxy)propoxy)benzyloxy)-2-(2-azidoacetamido)propanoate(27)

General experimental procedure for acetylation of alcohols (I) wasfollowed. Reaction was performed on a 1.9 g scale. Hexanes:EtOAc (30:70)used as the eluent for purification. Isolated 1.9 g (95%) of 27. MS:[M+H]⁺: 579.

Preparation of methyl3-(3-(2-acetoxy-3-(tosyloxy)propoxy)benzyloxy)-2-(2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(28)

General experimental procedure for click reaction (E) was followed.Reaction was performed on a 0.45 g scale. Hexanes:EtOAc (20:80) was usedas the eluent for purification. Isolated 0.88 g (99%) of 28 as acolorless solid. MS: [M+H]⁺: 1149.

Preparation of VM391 Standard:

Preparation of(S)-3-(3-(3-fluoro-2-hydroxypropoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic acid (VM391)

General experimental procedure for fluorination (J) was followed.Performed on a 0.1 g scale. The reaction mixture purified by HPLC toafford two compounds (yield not determined) (VM391 and compound 29) ascolorless solids. MS: (VM391) [M+H]⁺: 639.1. MS: (compound 29) [M+H]⁺:621.0

Preparation of VM2133 Precursor:

Preparation of (3-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)phenyl)methanol(30)

General alkylation procedure (A) was followed. Performed on a 15 gscale. Product eluted out in 65:35 Hexanes:EtOAc in a gradient elutionon a Combiflash purification system. Product 30 was isolated as a yellowoil (24 g, 79%).

Preparation of 3-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)benzyl4-methylbenzene sulfonate (31)

General tosylation procedure (D) was followed. Performed on a 23 gscale. Reaction time 10 min. Product eluted out in about 25% EtOAc:Hexanes using a gradient elution on a Combiflash system. Productisolated as yellow color oil (17 g, 45%)

Preparation of(2S)-2-(tert-butoxycarbonylamino)-3-(3-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)benzyloxy)propanoicacid (32)

General experimental procedure for alkylation using NaH (F) wasfollowed. Performed on a 5 g scale using N-boc L-serine. After work up,product was isolated as a thick yellow oil (˜7 g, 62%) and used as isfor next step. MS: [M+Na]⁺: 462.4

Preparation of (S)-methyl2-amino-3-(3-(2-hydroxyethoxy)benzyloxy)propanoate (33)

General experimental procedure for acid esterification (G) usingTMS-diazomethane was followed. Reaction was performed on a 7 g scale andthe addition was done at 0° C. and TMS-diazomethane was added slowlydropwise. Compound eluted out in 28% EtOAc: Hexanes using gradientelution on a Combiflash purification system. Isolated product as acolorless oil (4.9 g, 72%). MS: [M+Na]⁺: 476.2

Boc and THP groups were removed using the general experimental procedure(B). Performed on a 4.9 g scale. After removal of solvent, the residuewas triturated with ether. Product 33 was isolated as the HCl salt(colorless solid, 3.1 g, 94%). MS: [M+Na]⁺: 270.1

Preparation of (S)-methyl2-(2-azidoacetamido)-3-(3-(2-hydroxyethoxy)benzyloxy) propanoate (34)

General experimental procedure for coupling reactions (C) was followed.Performed on a 2 g scale, using Et₃N as base and THF:DMF (1:1) assolvent. Compound eluted out in 65% EtOAc: Hexanes in a gradient elutionon a Combiflash purification system. Isolated 34 (1.6 g, 70%) as lightyellow oil. MS: [M+Na]⁺: 375.1, [M+H]⁺: 353.2

Preparation of (S)-methyl2-(2-azidoacetamido)-3-(3-(2-(tosyloxy)ethoxy)benzyloxy) propanoate (35)

General experimental procedure for tosylation (D) was followed.Performed on a 1 g scale and at 0° C. for 10 min. Product eluted out in58% EtOAc: Hexanes in a gradient elution on a Combiflash purificationsystem. Isolated 35 (1.4 g, 95%) as yellow oil.

Preparation of(S)-methyl2-(2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)-3-(3-(2-(tosyloxy)ethoxy)benzyloxy)propanoate(36)

General experimental procedure for click reaction (E) was followed.Performed on a 0.3 g scale and 1.1 eq of base. Product eluted out in 78%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. Isolated 36 (pure 0.5 g, impure 0.13 g, overall quantitative) asan off colorless solid. MS: [M+Na]: 1099.6, [M+H]⁺: 1077.5

¹H-NMR (400 MHz, Acetone-d₆) δ: 8.15 (s, 1H), 8.08 (br s, 2H), 7.91 (d,J=9.0 Hz, 1H), 7.83 (d, J=8.4 Hz, 2H), 7.37 (d, J=2.5 Hz, 1H), 7.49-7.46(m, 4H), 7.30-7.16 (m, 9H), 6.90-6.78 (m, 3H), 6.35 (d, J=8.8 Hz, 4H),5.33 (d, J=6.1 Hz, 4H), 4.75-4.73 (m, 1H), 4.52 (d, J=12.3 Hz, 1H),4.43-4.41 (m, 2H), 4.26-4.24 (m, 2H), 3.90 (dd, J=9.8, 4.1 Hz, 1H), 3.74(dd, J=9.8, 3.3 Hz, 1H), 3.70 (s, 3H), 3.65 (s, 6H), 2.46 (s, 3H).

Preparation of VM2131 and VM2133 Including Alternate Preparation ofVM2133:

Preparation of (3-(2-fluoroethoxy)phenyl)methanol (37)

General procedure for alkylation of phenol (A) was followed. Performedon a 10 g scale using K₂CO₃ as base. Isolated 37 as a brown oil afterwork up (13 g, 95% yield).

Preparation of 3-(2-fluoroethoxy)benzyl 4-methylbenzenesulfonate (38)

General experimental procedure for tosylation (D) was followed.Performed on a 12 g scale. Product eluted out in 30% EtOAc:Hexanesmixture in a gradient elution on a Combiflash purification system.Isolated 38 (14.2 g, 62% yield) as a yellow oil.

MS: [M+Na]⁺: 347.1

Preparation of(S)-2-(tert-butoxycarbonylamino)-3-(3-(2-fluoroethoxy)benzyloxy)propanoicacid (39)

General experimental procedure for alkylation (F) was followed.Performed on a 10 g scale. Adjusted pH to 3-4. Product eluted out in 45%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. Isolated 39 (pure 6.2 g, 36%) as a thick yellowish oil.

MS: [M+Na]⁺: 380.1, [M-Boc]⁺: 258.1

Preparation of (S)-methyl2-amino-3-(3-(2-fluoroethoxy)benzyloxy)propanoate (40)

General experimental procedure for esterification of acids (G) anddeprotection (B) was followed. Performed on 3 g of Boc-acid. Isolated 40(2.25 g, 100% yield) product as a colorless solid as the HCl salt. MS:[M+Na]⁺: 294.0, [M+H]⁺: 272.1

Preparation of (S)-methyl2-(2-azidoacetamido)-3-(3-(2-fluoroethoxy)benzyloxy)propanoate (41)

General experimental procedure for coupling (C) was followed. Performedon 0.125 g scale, Et₃N as base and THF as solvent. Product eluted out in51% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 41 (0.27 g, 68%) as an off colorlesssolid. MS: [M+H]⁺: 355.1

Preparation of (S)-methyl3-(3-(2-fluoroethoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(VM2131)

General experimental procedure for click reaction (E) was followed.Performed on 0.09 g scale and 1.1 eq of base. Product eluted out in 96%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. Isolated VM2131 (0.074 g, 45%) as a colorless solid. MS: [M+H]⁺:623

Preparation of (S)-3-(3-(2-fluoroethoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid (VM2133)

General experimental procedure for ester hydrolysis (K) was followed.Performed on 0.03 g scale. HPLC purification afforded (0.017 g, 55%)VM2133 as a colorless solid.

MS: [M+H]⁺: 609.1

Preparation of(S)-3-(3-(2-fluoroethoxy)benzyloxy)-2-(2-(4-((2-sulfamoyl-benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(VM2133) starting from 36

General experimental procedure for fluorination (J) was followed.Performed on a 0.1 g scale. The reaction mixture purified by HPLC toafford VM2133 (30, 38%) as a colorless solid. [M+H]⁺: 609.0

¹H NMR (400 MHz, Acetone-d₆) δ: 8.17 (s, 1H), 8.06 (br s, 1H), 8.03 (d,J=9.0 Hz, 1H), 7.90 (d, J=2.5 Hz, 1H), 7.39 (s, 2H), 7.32 (dd, J=9.0,2.4 Hz, 1H), 7.27 (t, J=8.0 Hz, 1H), 6.97-6.88 (m, 3H), 5.37 (d, J=16.4Hz, 1H), 5.34 (s, 2H), 5.33 (d, J=16.6 Hz, 1H), 4.84-4.82 (m, 1H),4.76-4.70 (m, 2H), 4.55 (d, J=12.5 Hz, 1H), 4.52 (d, J=12.5 Hz, 1H),4.32-4.30 (m, 1H), 4.25-4.23 (m, 1H), 3.98 (dd, J=9.6, 3.9 Hz, 1H), 3.78(dd, J=9.6, 3.3 Hz, 1H).

Preparation of VM241 Precursor:

Preparation of Azido Acetic Acid:

To a solution of ethyl azido acetate (30% by weight in dichloromethane,63 g, 146 mmol, 1 equiv) in THF (90 ml) and water (90 ml), was addedLiOH monohydrate (12.3 g, 293 mmol, 2 equiv). The reaction was stirredat room temperature for 2 h. Reaction was then quenched by slow additionof HCl (conc. 22.5 ml, 293 mmol, 2 equiv) at ice bath temperature. Themixture was stirred in ice bath for another 20 min and poured into aseparation funnel. The aqueous layers was separated from organic layers,and extracted with dichloromethane (3×100 mL). The combined organiclayers were washed with brine (2×40 mL). The organic layers was driedover MgSO₄ and filtered. The solution was carefully concentrated toremove 100-150 mL of dichloromethane under vacuum without heating toafford 2-azidoacetic acid solution in THF and dichloromethane (5.65% byweight (c.a.), 223 g, 125 mmol, 85% yield). ¹H NMR (400 MHz, DMSO-d₆),δ: 13.16 (br s, 1H), 3.95 (s, 2H).

Preparation of 2-(3-(bromomethyl)phenoxy)tetrahydro-2H-pyran (42)

3-Hydroxybenzyl bromide (1.00 g, 5.35 mmol), DHP (0.89 g, 10.09 mmol),pyridinium-p-toluenesulfonate (0.20 g, 0.80 mmol) were dissolved inmethylene chloride (20 mL) and stirred at room temperature for 5 h. Themixture was concentrated and chromatographed without workup. The product42 was obtained as colorless oil (1.25 g, 87% yield).

Preparation ofMethyl-2-amino-3-(3-(tetrahydro-2H-pyran-2-yloxy)benzylthio) propanoate(43)

To the cysteine methyl ester hydrochloride (0.63 g, 3.69 mmol) dissolvedin DMF and cooled to 0° C., Cs₂CO₃ (1.21 g, 3.69 mmol) andtetrabutylammonium iodide (1.36 g, 3.69 mmol) were added and stirred.After 10 min, the ice bath was removed and the reaction mixture wasallowed to react for 1 h at room temperature. It was then cooled to 0°C. and bromide (1.00 g, 3.69 mmol) was added. Ice bath was removed after10 min and the mixture was allowed to react at room temperature. After 2h, the reaction was quenched with water, extracted with ethyl acetate,washed with water, brine and dried over MgSO₄. After evaporation of thesolvent, the reaction mixture was chromatographed (5% methanol/methylenechloride) to yield product 43 as thick colorless oil (0.74 g, 62%yield).

Preparation of Methyl2-(2-azidoacetamido)-3-(3-(tetrahydro-2H-pyran-2-yloxy)benzylthio)propanoate(44)

General peptide coupling procedure (C) was followed. Azidoacetic acid(0.9 g of ˜40% solution in THF/CH₂Cl₂), Et₃N and THF were used. Afterpurification, 44 was isolated as colorless oil (0.89 g, 95% yield).

Preparation of Methyl2-(2-azidoacetamido)-3-(3-hydroxybenzylthio)propanoate (45)

Few drops of cone. HCl (5 drops) were added to the 44 (0.25 g) inmethanol and stirred for 30 min until no starting material was seen byLCMS. After evaporation of methanol, brine was added to the reactionmixture and extracted with ethyl acetate, dried over MgSO₄, concentratedand chromatographed (Hexanes/EtOAc) then 5% methanol/methylene chloride)to obtain the 0.2 g of 45 as colorless oil in quantitative yield.

Preparation of Methyl2-(2-azidoacetamido)-3-(3-(2-(tosyloxy)ethoxy)benzylthio) propanoate(46)

Phenol (0.47 g, 1.45 mmol), Ethylene glycol ditosylate (1.62 g, 4.37mmol) and K₂CO₃ (1.01 g, 7.27 mmol) were taken in a round bottom flaskand dissolved in DMF (4 mL). The slurry was heated to 75° C. for 2 h.The reaction was then quenched with water, extracted with ethyl acetate.The organic layer washed several times with water followed by brine anddried over MgSO₄. After concentration and purification by flashchromatography (methylene chloride/ethyl acetate) 46 was obtained aslight yellow colored oil (0.11 g).

Preparation ofMethyl2-(2-azido-N-(tert-butoxycarbonypacetamido)-3-(3-(2-(tosyloxy)ethoxy)benzylthio)propanoate(47)

To the amide 46 (0.11 g, 0.21 mmol) in acetonitrile (3 mL), Bocanhydride (0.07 g, 0.32 mmol) and DMAP (0.002 g, 0.011 mmol) were added.The reaction was allowed to stir at room temperature for 18 h. Solventwas evaporated and the reaction mixture purified by flash chromatography(Hexanes/ethyl acetate) to afford 47 as an oil (0.05 g).

Preparation of methyl2-(2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(tert-butoxycarbonyl)acetamido)-3-(3-(2-(tosyloxy)ethoxy)benzylthio)propanoate(48)

General experimental procedure for click reaction (E) was followed.Performed on 0.046 g scale and 1.1 eq of base. Purified by Combiflashpurification system using

EtOAc:Hexanes as the gradient eluent. Isolated 48 (0.027 g) as acolorless solid.

MS: [M+H]⁺: 1193.5

¹H NMR (400 MHz, Acetone-d₆) δ: 8.15 (s, 1H), 7.90 (d, J=9.0 Hz, 1H),7.80 (d, J=8.2 Hz, 2H), 7.33 (d, J=2.4 Hz, 1H), 7.47-7.44 (m, 4H),7.29-7.15 (m, 9H), 6.87 (d, J=8.0 Hz, 1H), 7.69 (t, J=2.4 Hz, 1H),6.73-6.71 (m, 1H), 6.15 (d, J=9.0 Hz, 1H), 5.97 (d, J=18.2 Hz, 1H), 5.90(d, J=18.2 Hz, 1H), 5.52-5.48 (m, 1H), 5.33 (s, 2H), 4.41-4.39 (m, 2H),4.21-4.18 (m, 1H), 3.70 (s, 3H), 3.66 (s, 2H), 3.64 (s, 6H), 3.18 (dd,J=14.5, 5.5 Hz, 1H), 2.93 (dd, J=14.5, 9.6 Hz, 1H), 1.52 (s, 9H).

Preparation of VM241 Standard:

Preparation of 1-(bromomethyl)-3-(2-fluoroethoxy)benzene (49)

PPh₃ (3.08 g, 11.8 mmol) and CBr₄ (2.93 g, 8.82 mmol) were added to asolution of 37 (1.00 g, 5.88 mmol) in DCM (20 mL) under nitrogen andstirred at room temperature for 1 h. The reaction mixture was filtered,concentrated and chromatographed to isolate the 49 as a colorless solid(0.85 g, 62% yield).

Preparation of Methyl-2-amino-3-(3-(2-fluoroethoxy)benzylthio)propanoate(50)

To the L-cysteine methyl ester hydrochloride (0.037 g, 0.215 mmol)dissolved in DMF and cooled to 0° C., Cs₂CO₃ (0.069 g, 0.215 mmol) andtetrabutyl ammonium iodide (0.079 g, 0.215 mmol) were added and stirred.After 10 min, the ice bath was removed and the reaction mixture wasallowed to react for 1 hr at room temperature. It was then cooled to 0°C. and bromide (0.05 g, 0.215 mmol) was added. Ice bath was removedafter 10 min and the mixture was allowed to react at room temperature.After 2 h, the reaction was quenched with water, extracted with ethylacetate, washed with water, brine and dried over MgSO₄. Afterevaporation of the solvent, the reaction mixture was chromatographed toyield 50 as thick colorless oil (0.025 g, 41% yield).

Preparation of Methyl3-(3-(2-fluoroethoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(VM236)

General experimental procedure for coupling (O) was followed. Performedon 0.01 g scale and 1.1 eq of base. Purified by Combiflash purificationsystem using EtOAc:Hexanes as the gradient eluent. Isolated VM236 (20%)as a colorless solid.

Preparation of Methyl3-(3-(2-fluoroethoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid (VM241)

General experimental procedure for ester hydrolysis (K) was followed.Reaction was carried out on a 0.008 g scale. Isolated VM241 (0.005 g,64% yield) as a colorless solid. MS: [M+H]⁺: 625.2

¹H NMR (400 MHz, Acetone-d₆s) δ: 8.35 (s, 1H), 8.19 (d, J=9.0 Hz, 1H),8.06 (d, J=2.5 Hz, 1H), 7.55 (s, 2H), 7.48 (dd, J=9.0, 2.5 Hz, 2H), 7.39(t, J=7.8 Hz, 1H), 7.12-7.09 (m, 3H), 7.01-6.99 (m, 1H), 5.5 (s, 4H),4.98-4.96 (m, 1H), 4.93-4.91 (m, 1H), 4.86-4.85 (m, 1H), 4.45-4.43 (m,1H), 4.38-4.36 (m, 1H), 3.94 (s, 2H), 3.16 (dd, J=14.1, 5.1 Hz, 1H),2.91 (dd, J=14.2, 5.2 Hz, 1H).

VM4037 Nosylate Precursor:

Preparation of (2S)-methyl2-(tert-butoxycarbonylamino)-3-(4-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)phenyl)propanoate(51)

General experimental procedure for phenolic alkylation (A) was followed.Reaction was performed on a 10 g scale. Product eluted out in 30%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. Isolated 13 g (91% yield) of 51 as a colorless oil. MS: [M+H]⁺:424.

Preparation of (S)-methyl2-amino-3-(4-(2-hydroxyethoxy)phenyl)propanoate hydrochloride (52)

General experimental procedure for deprotection (B) was followed.Reaction was performed on a 13 g scale. Isolated 7.5 g (69% yield) of 52as a colorless solid. MS: [M+H]⁺: 240.

Preparation of (S)-methyl2-((S)-2-azido-3-methylbutanamido)-3-(4-(2-hydroxyethoxy)phenyl)propanoate (53)

General experimental procedure for coupling (C) was followed. Reactionwas performed on a 5 g scale. Product eluted out in 50% EtOAc:Hexanesmixture in a gradient elution on a Combiflash purification system.Isolated 5.2 g (79% yield) of 53 as a colorless oil. MS: [M+H]⁺: 365.

Preparation of (S)-methyl2-((S)-2-azido-3-methylbutanamido)-3-(4-(2-(2-nitrophenylsulfonyloxy)ethoxy)phenyl)propanoate(54)

To a 100 mL round bottomed flask equipped with a magnetic stir barcontaining DCM (100 mL) was placed 62 (1.3 g, 3.6 mmol). To thissolution was added nosyl chloride (0.87 g, 3.9 mmol), Et₃N (0.4 g, 3.9mmol) and the reaction was allowed to stir at room temperature for 15 h.After the reaction was complete, DCM was removed in vacuo. The residuewas purified over silica gel using Hexanes:EtOAc (50:50) as the eluentto afford 54 (1.5 g, 77% yield) as a colorless oil. MS: [M+H]⁺: 560.

Preparation of (S)-methyl 2-((S)-2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-3-methylbutanamido)-3-(4-(2-(2-nitrophenylsulfonyloxy)ethoxy)phenyl)propanoate(55)

General experimental procedure for click reaction (E) was followed.Reaction was performed on a 0.34 g scale. Product eluted out in 90%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. Isolated 0.55 g (79% yield) of 55 as a colorless solid. MS:[M+H]⁺: 1120.

Preparation of VM 4037a:

Preparation of (methyl2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)propanoate (56)

Compound 56 was prepared through general experimental procedure (A) andisolated 56 as a colorless solid (6 g scale, yield 80%). LRMS forC₁₇H₂₄FNO₅+H⁺, calc'd: 342.2, found: 342.2 (M+H⁺), 364.1 (M+Na).

¹H NMR (CDCl₃, 400 MHz) δ: 7.04 (d, J=8.8 Hz, 2H), 6.85 (d, J=8.8 Hz,2H), 4.96 (d, J=8.4 Hz, 1H), 4.79-4.82 (m, 1H), 4.67-4.70 (m, 1H),4.53-4.56 (m, 1H), 4.21-4.24 (m, 1H), 4.09-4.17 (m, 1H), 3.72 (s, 3H),3.00-3.05 (m, 2H), 1.42 (s, 9H).

Preparation of methyl2-amino-3-(4-(2-fluoroethoxy)phenyl)propanoatehydrochloride (57)

57 was prepared through general experimental procedure (B) and isolatedas a colorless solid (5.5 g scale, yield 99%). LRMS for C₁₂H₁₆FNO₃+H⁺,calc'd: 242.2, found: 242.2 (M+H⁺).

Preparation of (S)-methyl2-((S)-2-azido-3-methylbutanamido)-3-(4-(2-fluoroethoxy)phenyl)propanoate(58)

Compound 58 was prepared through general experimental procedure (C) andisolated as a colorless solid (4.5 g scale, yield 72%). LRMS forC₁₇H₂₃FN₄O₄ ⁺H⁺, calc'd: 367.2, found: 367.2 (M+H).

¹H NMR (400 MHz, DMSO-d_(b)) δ: 8.60 (br s, 1H), 7.12 (d, J=8.8 Hz, 2H),6.82 (d, J=8.4 Hz, 2H), 4.75-4.60 (m, 2H), 4.45-4.40 (m, 1H), 4.20-4.10(m, 2H), 3.56 (s, 3H), 3.44 (d, J=8.0 Hz, 1H), 3.00-2.80 (m, 2H),2.00-1.90 (m, 1H); 0.84 (d, J=2.0 Hz, 3H), 0.82 (d, J=2.0 Hz, 3H).

Preparation of (S)-methyl3-(4-(2-fluoroethoxy)phenyl)-2-(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate (59)

Compound 59 was prepared through general experimental procedure (E) andisolated as a colorless solid (4.1 g scale, yield 98%). LRMS forC₂₇H₃₁FN₆O7₄S₂+H⁺, calc'd: 635.2, found: 635.2 (M+H⁺).

¹H, NMR (400 MHz, DMSO-d₆) δ: 9.05 (br s, 1H), 8.31 (s, 1H), 8.27 (s,2H), 8.05 (d, J=9.2 Hz, 1H), 7.96 (d, J=2.8 Hz, 1H), 7.36 (m, 1H), 7.06(d, J=8.8 Hz, 2H), 6.78 (d, J=8.4 Hz, 2H), 5.24 (s, 2H), 5.06 (d, J=9.2Hz, 1H), 4.75-4.60 (m, 2H), 4.42-4.40 (m, 1H), 4.21-4.10 (m, 2H), 3.58(s, 3H), 3.00-2.80 (m, 2H), 2.40-2.30 (m, 1H); 0.98 (d, J=6.0 Hz, 3H)0.63 (d, J=6.0 Hz, 3H).

Preparation of(S)-3-(4-(2-fluoroethoxy)phenyl)-2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid (4037a)

VM-4037a was prepared through general experimental procedure (K) andisolated as a colorless solid (7.0 g scale, yield 60%). LRMS forC₂₆H₂₉FN₆O7₄S₂+H⁺, calc'd: 621.2, found: 621.2 (M+H⁺).

¹H NMR (400 MHz, DMSO-d₆) δ: 8.90 (br s, 1H), 8.26 (s, 1H), 8.24 (s,2H), 8.01 (d, J=9.2 Hz, 1H), 7.92 (d, J=2.4 Hz, 1H), 7.30 (m, 1H), 6.99(d, J=9.2 Hz, 2H), 6.72 (d, J=8.4 Hz, 2H), 5.20 (s, 2H), 5.03 (d, J=9.6Hz, 1H), 4.70-4.58 (m, 2H), 4.38-4.30 (m, 1H), 4.17-4.07 (m, 2H),2.95-2.75 (m, 2H), 2.40-2.30 (m, 1H); 0.93 (d, J=6.0 Hz, 3H) 0.58 (d,J=6.0 Hz, 3H).

¹³C NMR (100 MHz, DMSO-d₆) δ: 173.0, 168.0, 167.2, 158.9, 158.6, 158.1,157.4, 146.9, 142.8, 138.0, 129.9, 125.6, 124.5, 118.6, 118.4, 115.5,114.8, 106.6, 83.6, 82.0, 69.0 (d), 67.3 (d), 62.3, 54.5, 36.3, 31.9,19.3. ¹⁹F NMR (376 MHz, DMSO-d₆) δ: −222.4.

Preparation of VM4041 Precursor:

Preparation of (S)-methyl2-(2-azidoacetamido)-3-(4-(2,3-dihydroxypropoxy)phenyl)propanoate (60)

Coupling reaction was done according to the general procedure (C).Performed on a 0.8 g scale using glycine azido acid and triethyl amineas base. EtOAc:Hexanes (95:5) used as the eluent. Product 60 wasisolated (0.52 g, 60%) as a colorless solid. MS: [M+H]⁺: 353.4

Preparation of (S)-methyl2-(2-azidoacetamido)-3-(4-(2-hydroxy-3-(tosyloxy)propoxy)phenyl)propanoate(61)

Tosylation was done according to the general procedure (H). Performed ona 0.5 g scale. EtOAc: Product eluted out in 50% EtOAc:Hexanes mixture ina gradient elution on a Combiflash purification system. 61 was isolatedas colorless oil in 88% yield. MS: [M+H]⁺: 507.1

Preparation of (S)-methyl3-(4-(2-acetoxy-3-(tosyloxy)propoxy)phenyl)-2-(2-azidoacetamido)propanoate (62)

Acetylation was done according to the general procedure (I). Performedon a 0.6 g scale. Product eluted out in 55% EtOAc:Hexanes mixture in agradient elution on a Combiflash purification system. 62 isolated as acolorless oil in 95% yield. LCMS for C₂₄H₂₈N₄O₉S, calc'd: 548.16, found:549.1 (M+H).

Preparation of (S)-methyl3-(4-(2-acetoxy-3-(tosyloxy)propoxy)phenyl)-2-(2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(63)

Click reaction was done according to the general procedure (E).Performed on a 0.6 g scale and 1.1 eq of base. Product eluted out in 80%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. 63 was obtained (1.0 g, 87%) as a yellow solid. MS: [MA-Na]⁺:1141.2

¹H NMR (400 MHz, Acetone-d₆) δ: 8.09 (s, 1H), 7.92 (d, J=9.0 Hz, 1H),7.86-7.80 (m, 3H), 7.74 (d, J=2.5 Hz, 1H), 7.50-7.45 (m, 4H), 7.30-7.10(m, 9H), 6.80 (d, J=8.6 Hz, 2H), 6.63 ((d, J=9.0 Hz, 4H), 5.32 (s, 2H),5.32-5.29 (m, 1H), 5.25 (s, 2H), 4.74-4.69 (m, 1H), 4.36 (d, J=4.5 Hz,2H), 4.10 (t_(br), J=4.3 Hz, 2H), 3.68 (s, 3H), 3.65 (s, 6H), 3.10 (dd,J=25.5, 13.9 Hz, 1H), 2.98 (dd, J=13.9, 7.6 Hz, 1H), 1.98 (s, 3H).

Preparation of VM4041 Standard:

Preparation of(S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid (VM4041)

General experimental procedure for fluorination (J) was followed.Performed on a 0.1 g scale. The reaction mixture purified by HPLC toafford two compounds (64 and VM4041) (yield not determined) as colorlesssolids.

MS: (VM4041) [M+H]⁺: 609.1

MS: (compound 64) [M+H]⁺: 591.1

VM4041: ¹H NMR (400 MHz, Acetone-do) δ: 8.11 (s, 1H), 8.03 (d, J=9.2 Hz,1H), 7.91 (d, J=2.5 Hz, 1H), 7.76 (d, J=7.2 Hz, 1H), 7.33 (dd, J=9.0,2.5 Hz, 1H), 7.15 (d, J=8.6 Hz, 2H), 6.87 (d, J=8.6 Hz, 2H), 5.34 (s,2H), 5.24 (s, 2H), 4.73-4.68 (m, 1H), 4.57-4.67 (m, 1H), 4.50 (dq,J=9.6, 3.9 Hz, 1H), 4.23-4.14 (m, 1H), 4.04-4.02 (m, 2H), 3.15 (dd,J=14.1, 5.3 Hz, 1H), 3.01 (dd, J=13.9, 7.6 Hz, 1H).

Preparation of VM4021:

Preparation of(S)-methyl3-(4-(2-hydroxyethoxy)phenyl)-2-(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1H-yl)butanamido)propanoate (64)

Click reaction was done according to the general procedure (E).Performed on a 0.05 g scale. The reaction was not purified bychromatography rather triturated with ether/EtOAc mixture after removalof THF from the reaction mixture. Isolated 0.05 g, (58%) of 64 greenishsolid. MS: [M+H]: 633.5

Preparation of(S)-3-(4-(2-hydroxyethoxy)phenyl)-2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid (VM4021)

Hydrolysis was done using the general procedure (K). After HPLCpurification, the product was obtained as colorless solid. The yield wasnot calculated. MS: [M+H]⁺: 619.1.

¹H NMR (400 MHz, Acetone-d₆) δ: 8.12 (br s, 1H), 8.03 (d, J=9.0 Hz, 1H),8.00 (d, J=7.6 Hz, 1H), 7.92 (d, J=2.5 Hz, 1H), 7.39 (s, 1H), 7.34 (dd,J=9.0, 2.5 Hz, 1H), 6.98 (d, J=8.6 Hz, 2H), 6.72 (d, J=8.8 Hz, 2H), 5.35(s, 2H), 5.12 (d, J=10.0 Hz, 1H), 4.74-4.69 (m, 1H), 3.98 (t, J=4.7 Hz,2H), 3.83 (t, J=9.6 Hz, 2H), 3.12 (dd, J=14.1, 5.3 Hz, 1H), 2.95 (dd,J=13.9, 7.8 Hz, 1H), 2.49-2.43 (m, 1H), 1.04 (d, J=6.7 Hz, 3H), 0.68 (d,J=6.6 Hz, 3H).

Preparation of VM4009:

Preparation of (S)-methyl3-(4-(2-hydroxyethoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(65)

Coupling reaction was done according to the general procedure (C).Performed on 0.1 g scale, using Et₃N as base and THF/DMF as solvent(5:1). During the work up, the solid that was not soluble, was alsocollected and mixed along with the organic layer. After evaporation, theresidue was carried over to the next step, hydrolysis without furtherpurification. The yield was not determined. MS: [M+H]⁺: 591.2

Preparation of (S)-3-(4-(2-hydroxyethoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid (VM4009)

Hydrolysis was done using the general procedure (K). After HPLCpurification, the product was obtained as colorless solid. Yield notcalculated. MS: [M+H]⁺: found: 577.0

¹H NMR (400 MHz, Acetone-d₆) δ: 8.09 (s, 1H), 8.03 (d, J=9.0, Hz, 1H),7.92 (d, J=2.5 Hz, 1H), 7.70 (d, J=8.0 Hz, 1H), 7.38 (s, 1H), 7.34 (dd,J=9.0, 2.5 Hz, 1H), 7.14 (d, J=8.4 Hz, 2H), 7.85 (d, J=8.8 Hz, 2H), 5.34(s, 2H), 5.25 (s, 2H), 4.75-4.70 (m, 1H), 4.04-4.02 (m, 2H), 3.84 (m,2H), 3.15 (dd, J=14.1, 5.3 Hz, 1H), 3.00 (dd, J=14.1, 7.8 Hz, 1H).

Preparation of VM3167:

Preparation of(S)-3-(4-fluorophenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoicacid (66)

Click reaction was done with according to the general procedure (E).Performed on a 0.1 g scale. Reaction mixture was triturated withether/EtOAc mixture after removal of THF under vacuum. Isolated 0.2 g(100%) of 66 as greenish solid. MS: [M+H]⁺: 478.3

Preparation of (S)-methyl 2-((S)-3-(4-fluorophenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(3-(2-hydroxyethoxy)benzyloxy)propanoate(67)

Coupling reaction was done with according to the general procedure(C).Product was isolated as colorless solid (yield not calculated) afterchromatography. MS: [M+H]⁺: 729.1

Preparation of(S)-2-(S)-3-(4-fluorophenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(3-(2-hydroxyethoxy)benzyloxy)propanoicacid (VM4167A and VM4167B)

Hydrolysis of ester was done according the general procedure (K).Performed on a 0.03 g scale. After HPLC purification, two isomers (A:B,2:1) were isolated as colorless solids in 73% overall yield. MS: [M+H]⁺:715.1

VM4167A: ¹H NMR (400 MHz, Acetone-d₆) δ: 8.37 (s, 1H), 8.25 (d, J=8.3Hz, 1H), 8.03 (d, J=9.0 Hz, 1H), 7.87 (d, J=2.5 Hz, 1H), 7.34 (s, 2H),7.30 (dd, J=9.0, 2.5 Hz, 1H), 7.24-7.17 (m, 3H), 6.89-6.82 (m, 5H), 5.93(dd, J=10.2, 5.5 Hz, 1H), 5.29 (s, 2H), 4.74-4.71 (m, 1H), 4.48 (s, 1H),4.47 (s, 1H), 4.06 (t, J=4.7 Hz, 2H), 3.96 (dd, J=9.8, 4.1 Hz, 1H), 3.86(t, J=5.1 Hz, 2H), 3.74 (dd, J=9.8, 3.3 Hz, 1H), 3.58 (dd, J=14.3, 5.5Hz, 1H), 3.44 (dd, J=14.3, 10.2 Hz 1H).

VM4167B: ¹H NMR (400 MHz, Acetone-d₆) δ: 8.36 (s, 1H), 8.21 (d, J=8.2Hz, 2H), 8.03 (d, J=9.0 Hz, 2H), 7.88 (d, J=2.5 Hz, 2H), 7.39 (s, 2H),7.31 (dd, J=9.2, 2.7 Hz, 1H), 7.26-7.21 (m, 3H), 6.95-6.84 (m, 5H), 5.91(dd, J=9.4, 6.5 Hz, 1H), 5.31 (s, 2H), 4.73-4.69 (m, 1H), 4.46 (s, 2H),4.05 (t, J=4.9 Hz, 2H), 3.93 (dd, J=9.6, 3.9 Hz, 1H), 3.84 (t, J=5.1 Hz,2H), 3.64 (dd, J=9.6, 3.3 Hz, 1H), 3.55 (dd, J=13.0, 6.5 Hz, 1H), 3.44(dd, J=14.1, 9.4 Hz, 1H).

Preparation of VM3165:

Preparation of (S)-methyl3-(3-(2-hydroxyethoxy)benzyloxy)-2-(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate(68)

Coupling reaction was done according to the general procedure (C).Performed on a 0.12 g scale using Et₃N as base and THF as solvent.Product eluted out in 85% EtOAc:Hcxanes mixture in a gradient elution ona Combiflash purification system. 68 was isolated as colorless solid(yield not calculated). MS: [M+H]⁺: 663.6

Preparation of(S)-3-(3-(2-hydroxyethoxy)benzyloxy)-2-(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid (VM3165A and VM3165B)

Hydrolysis of ester was done according the general procedure (K).Performed on a 0.01 g scale. After HPLC purification, two isomers (A:B,2:1) were isolated as colorless solids (A: 4.4 mg, B: 2.1 mg, 67%overall). MS: (A and B)[M+H]⁺: 649.1

VM3165B: ¹H NMR (400 MHz, Acetone-d₆) δ: 8.32 (s, 1H), 8.29 (s, 1H),8.02 (d, J=9.0 Hz, 1H), 7.91 (d, J=2.5 Hz, 1H), 7.39 (s_(br), 2H), 7.33(dd, J=9.0, 2.5 Hz, 1H), 7.24 (t, J=7.8 Hz, 1H), 6.93-6.85 (m, 3H), 5.34(s, 2H), 5.30 (d, J=9.8 Hz, 1H), 4.78-4.74 (m, 1H), 4.53 (s, 2H), 4.07(t, J=4.7 Hz, 2H), 3.97 (dd, J=9.6, 4.3 Hz, 1H), 3.87 (t, J=5.1 Hz, 2H),3.80 (dd, J=9.6, 3.3 Hz, 1H), 2.52-2.46 (m, 1H), 1.07 (d, J=6.7 Hz, 3H),0.73 (d, J=6.7 Hz, 3H).

Preparation of VM3163:

Preparation of (S)-methyl3-(3-(2-((S)-2-(tert-butoxycarbonylamino)-3-hydroxypropanamido)ethoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(70)

Coupling reaction was done with amine 69 and N-Boc serine according tothe general procedure (C). Performed on a 0.02 g scale. Isolated 0.02 g(67%) of 70. MS: [M+H]⁺: 707.1

Preparation of(S)-3-(3-(2-((S)-2-amino-3-hydroxypropanamido)ethoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic acid (VM3163)

To a 10 mL vial with magnetic stir bar was added DCM (0.5 mL) and TFA(0.5 mL). To this, compound 70 was added and let to react for 30 min.After the completion of the reaction, solvents were removed in vacuo,THF was added (0.2 mL) followed by aq. LiOH (0.4 mL) and the reactionstirred for 30 min. After completion of the reaction, THF was removedand the crude residue was purified by HPLC to afford VM3163 (33%) as acolorless solid. LCMS for C₂₇H₃₂N₈O₁₀S₂, calc'd: 692.17, found: 693.0(M+H).

Preparation of VM2126 and VM2128:

Preparation of (S)-methyl2-(2-azidoacetamido)-3-(3-(2-fluoroethoxy)benzylthio)propanoate (71)

General procedure for peptide coupling (C) was followed. Performed on0.33 g scale, Et₃N as base and THF as solvent with 2 equiv of azidoacid. Product eluted out in 55% EtOAc:Hcxanes mixture in a gradientelution on a Combiflash purification system.

Isolated (0.42 g, 100%) of 71 as a colorless solid. MS: [M+H⁺]: 371.1

Preparation of (2S)-methyl2-(2-azidoacetamido)-3-(3-(2-fluoroethoxy)benzyl sulfinyl)propanoate(72)

To a round bottomed flask equipped with a magnetic stir bar, rubberseptum, and argon inlet containing acetonitrile/water (10 mL, 3:5 v/v)was placed thioether 71 (0.2 g, 0.54 mmol). To this solution was addedsodium metaperiodate (0.23 g, 1.08 mmol) and the reaction was allowed tostir at room temperature for until deemed complete by LCMS (2-3 h).After the reaction was complete, the solvents were removed in vacuo. Thereaction was then poured into water and extracted into EtOAc (4×20 mL).The combined organic extracts were washed with H₂O, brine, dried (MgSO₄)and concentrated in vacuo, to afford the final coupled product 72 (0.12g, 58%) as colorless solid. MS: [M+H]⁺: 387.1

Preparation of ((2S)-methyl3-(3-(2-fluoroethoxy)benzylsulfinyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate (VM2126)

General experimental procedure for click reaction (E) was followed.Performed on 0.10 g scale and 1.1 eq of base. Methanol:DCM (eluted outin 20% methanol) was used as the eluent. Isolated 0.123 g (73%) of VM126as an yellow solid. MS: [M+H]⁺: 654.9

¹H NMR (400 MHz, Acetone-d₆) δ: 8.17 (s, 1H), 8.15 (s, 1H), 8.02 (d,J=9.0 Hz, 1H), 7.89 (d, J=2.6 Hz, 1H), 7.36-7.28 (m, 4H), 7.01-6.95 (m,3H), 5.34 (s, 2H), 5.28 (s, 2H), 4.92-4.88 (m, 1H), 4.84-4.82 (m, 1H),4.72-4.70 (m, 1H), 4.33-4.30 (m, 1H), 4.26-4.23 (m, 1H), 4.20-3.99 (m,2H), 3.69 (s, 3H), 3.25 (dd, J=13.4, 9.2 Hz, 1H), 3.16 (dd, J=13.5, 3.9Hz, 1H).

Preparation of(2S)-3-(3-(2-fluoroethoxy)benzylsulfinyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic acid (VM2128B and VM2128C)

General experimental procedure for ester hydrolysis (K) was followed.Performed on a 0.02 g scale. HPLC purification afforded two isomers ascolorless solids (yield not determined). MS: B and C [M+H]⁺: 641.1

VM128B: ¹H NMR (400 MHz, Acetone-d₆) δ: 8.19 (br s, 1H), 8.16 (s, 1H),8.02 (d, J=8.8 Hz, 1H), 7.89 (d, J=2.35, 1H), 7.37 (s, 2H), 7.33-7.29(m, 2H), 7.03-6.95 (m, 2H), 5.35 (s, 2H), 5.32 (d, J=19.4, 2H),4.92-4.91 (m, 1H), 4.84-4.82 (m, 1H), 4.72-4.70 (m, 1H), 4.33-4.31 (m,1H), 4.25-4.22 (m, 1H), 4.21 (d, J=12.7 Hz, 1H), 4.09 (d, J=12.9 Hz,1H), 3.29-3.12 (m, 4H).

Preparation of VM2106 Precursor:

Preparation of (2S)-methyl2-((S)-2-azido-4-hydroxybutanamido)-3-(3-(tetrahydro-2H-pyran-2-yloxy)benzylthio)propanoate(73)

General procedure for peptide coupling (C) was followed. Performed on0.05 g scale, Et₃N as base and THF as solvent with 2 equiv of azidoacid. Product eluted out in 65% EtOAc:Hexanes mixture in a gradientelution on a Combiflash purification system.

Isolated 0.06 g (86%) of 73 as an yellow oil. MS: [M+Na]⁺: 475.2

Preparation of (S)-methyl2-((S)-2-azido-4-hydroxybutanamido)-3-(3-hydroxybenzyl thio)propanoate(74)

THP group was removed using the general experimental procedure (B).Performed on a 0.06 g scale, using HCl/MeOH. Product eluted out in 65%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. Isolated 0.018 g (40%) of 74 as a colorless oil. MS: [M+Na]⁺:369.2

Preparation of (S)-methyl2-((S)-2-azido-4-hydroxybutanamido)-3-(3-(2-(tosyloxy)ethoxy)benzylthio)propanoate (75)

General procedure for alkylation of phenol (A) was followed. Performedon a 0.57 g scale using K₂CO₃ as the base and ethylene glycolditosylate. Product eluted out in 30% EtOAc:DCM mixture in a gradientelution on a Combiflash purification system. Isolated 0.09 g of 75 as anyellow oil. MS: [M+H]⁺: 567.1

Preparation of (S)-methyl2-((S)-2-azido-N-(tert-butoxycarbonyl)-4-(tert-butoxy carbonyloxy)butanamido)-3-(3-(2-(tosyloxy)ethoxy)benzylthio)propanoate (76)

To a round bottomed flask equipped with a magnetic stir bar containingDCM (26 vol) was placed azido alcohol 75 (0.09 g, 0.16 mmol). To thissolution was added (Boc)₂O (0.1 g, 0.47 mmole), DMAP (0.1 equiv) and thereaction was allowed to stir at room temperature for 3 h. Afterevaporation of the solvent, the residue was purified over silica gelusing Hexanes:EtOAc as the eluent to afford the Diboc protected compound76 (0.07 g) as a thick colorless oil.

Preparation of(S)-2-((S)-2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(tert-butoxycarbonyl)-4-(tert-butoxycarbonyloxy)butanamido)-3-(3-(2-(tosyloxy)ethoxy)benzylthio)propanoicacid (77)

General experimental procedure for click reaction (E) was followed.Performed on a 0.07 g scale and 1.1 eq of base. Product eluted out in55% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 0.07 g (56%) of 77 as an off colorlessfoam. MS: [M+H]⁺: 1337.5

Preparation of VM2-106 and VM2-107:

Preparation of (S)-methyl2-((S)-2-azido-4-hydroxybutanamido)-3-(3-(2-fluoroethoxy)benzylthio)propanoate(78)

General procedure for peptide coupling (C) was followed. Performed on0.18 g scale, Et₃N as base and THF as solvent with 2 equiv of azidoacid. Product eluted out in 65% EtOAc:Hexanes mixture in a gradientelution on a Combiflash purification system. Isolated 0.07 g (28%) of 78as a colorless oil. MS: [M+H]⁺: 415.2

Preparation of (S)-methyl3-(3-(2-fluoroethoxy)benzylthio)-2-(S)-4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate (VM2106)

General experimental procedure for click reaction (E) was followed.Performed on a 0.07 g scale and 1.1 eq of base. Product eluted out in55% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 0.1 g (84%) of VM2106 as light yellowsolid. MS: [M+H]⁺: 682.2

Preparation of(S)-3-(3-(2-fluoroethoxy)benzylthio)-2-(S)-4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid (VM2107A and VM2107B)

General experimental procedure for ester hydrolysis (K) was followed.Performed on a 0.08 g scale. THF removal followed by acidification andEtOAc extraction afforded pure VM2107A and VM2107B (0.05 g, 66%) as offcolorless solids. MS: A and B[M+H]⁺: 669.5

Preparation of VM3143:

Preparation of(3-(2-(2-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)ethoxy)ethoxy)phenyl)methanol(79)

General procedure for alkylation of phenol (A) was followed. Yield wasnot calculated. MS: [M+Na]⁺: 363.2

Preparation of3-(2-(2-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)ethoxy)ethoxy)benzyl4-methylbenzenesulfonate (80)

General procedure for tosylation (D) was followed. Yield was notcalculated. MS: [M+Na]⁺: 517.4

Preparation of(2S)-2-(tert-butoxycarbonylamino)-3-(3-(2-(2-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)ethoxy)ethoxy)benzyloxy)propanoicacid (81)

General experimental procedure for alkylation (F) was followed. Adjustedreaction to pH=4.5-5. Product eluted out in 55% EtOAc:Hexanes mixture ina gradient elution on a Combiflash purification system. Isolated 81 as athick colorless oil. The yield was not calculated.

Preparation of (S)-methyl2-amino-3-(3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)benzyloxy)propanoate(82)

General experimental procedure for esterification of acid (G) anddeprotection (B) was followed. Performed on 1.45 g of Boc-acid. Isolated1.4 g, (quantitative) of 82 as a colorless solid. MS: [M+H]⁺: 358.2

Preparation of (S)-methyl2-(2-azidoacetamido)-3-(3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)benzyloxy)propanoate(83)

General procedure for peptide coupling (C) was followed. Performed on1.4 g scale, using Et₃N as base and THF as solvent with 1.5 equi ofazido acid. Product eluted out in 75% EtOAc:Hexanes mixture in agradient elution on a Combiflash purification system. Isolated 0.36 g(23%) of 83 as yellow oil. MS: [M+H]⁺: 441.2

Preparation of (S)-methyl2-(2-azidoacetamido)-3-(3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)benzyloxy)propanoate(84)

General experimental procedure for tosylation (D) was followed.Performed on a 0.34 g scale and at 0° C. for 10 min. Product eluted outin 58% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 0.33 g (72%) of 84 as a colorless oil. MS:[M+H]⁺: 595.2

Preparation of(S)-methyl2-(2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)-3-(3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)benzyloxy)propanoate(VM3143)

General experimental procedure for click reaction (E) was followed.Performed on 0.14 g scale and 1.1 equiv of base. Product eluted out in85% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 0.13 g (48%) of VM3143 as an off colorlessfoam. MS: [M+Na]⁺: 1187.2

Preparation of VM3147:

Preparation of (S)-methyl2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)-3-(3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)benzyloxy)propanoate(85)

General experimental procedure for click reaction (E) was followed.Performed on 0.12 g (alkyne) scale and 1.1 equiv of base. Reactionmixture was triturated with ether/DCM mixture after removal of THF undervacuum. Isolated 0.04 g (93%) of 85 as green solid. MS: [M+Na]⁺: 863.1

Preparation of(S)-3-(3-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic acid (VM3147)

General experimental procedure for fluorination (J) was followed.Performed on 0.04 g scale. Reaction mixture was triturated withether/DCM mixture after removal of THF in vacuo. Isolated 8.7 mg (27%)of VM3147 as colorless solid. MS: [M+H]⁺: 697.1

Preparation of DH1(3183 precursor:

Preparation of (2,2-dimethyl-1,3-dioxan-5-yl)methanol (86)

To a 100 mL round bottomed flask equipped with a magnetic stir barcontaining THF (75 mL) was placed a (4 g, 38 mmol, 1 equiv). To thissolution was added b (4.5 g, 43 mmol, 1.15 equiv), PTSA (0.2 g, 1.1mmol, 0.03 equiv) and the reaction was allowed to stir at roomtemperature for 2 h. After the reaction was complete, solvent wasremoved in vacuo. The residue was purified over silica gel. Producteluted out in 60% EtOAc:Hexanes mixture in a gradient elution on aCombiflash purification system. Isolated 86 (5 g, 91%) as a colorlessoil. MS: [M+H]⁺: 147.

Preparation of 2,2-dimethyl-1,3-dioxan-5-yl)methyl methanesulfonate (87)

To a 500 mL round bottomed flask equipped with a magnetic stir barcontaining DCM (200 mL) was placed 87 (5 g, 34 mmol, 1 equiv). To thissolution was added mesyl chloride (4.3 g, 38 mmol, 1.1 equiv), Et₃N (5g, 51 mmol, 1.5 equiv) and the reaction was allowed to stir at roomtemperature for 3 h. The reaction was then poured into water (100 mL)and extracted into DCM (3×100 mL). The combined organic extracts werewashed with brine (100 mL), NaHCO₃ solution (100 mL), dried (Na₂SO₄) andconcentrated in vacuo. The residue was purified over silica gel. Producteluted out in 50% EtOAc:Hexanes mixture in a gradient elution on aCombiflash purification system. Isolated 87 (7 g, 91%) as a colorlesssolid. MS: [M+H]⁺: 225.

Preparation of (S)-methyl2-(tert-butoxycarbonylamino)-3-(4-((2,2-dimethyl-1,3-dioxan-5-yl)methoxy)phenyl)propanoate(88)

General experimental procedure for phenolic alkylation: (A) wasfollowed. Reaction was performed on a 3.5 g scale. Product eluted out in40% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 4.5 g (100%) of 88 as a colorless oil. MS:[M+H]⁺: 424.

Preparation of (S)-methyl2-amino-3-(4-(3-hydroxy-2-(hydroxymethyl)propoxy)phenyl)propanoate (89)

General experimental procedure for deprotection (B) was followed.Reaction was performed on a 4.3 g scale. Isolated 3 g (92%) of 89 as acolorless solid. MS: [M+H]⁺: 284.

Preparation of (S)-methyl2-((S)-2-azido-3-methylbutanamido)-3-(4-(3-hydroxy-2-(hydroxymethyl)propoxy)phenyl)propanoate(90)

General experimental procedure for coupling (C) was followed. Reactionwas performed on a 1.7 g scale. Product eluted out in 100% EtOAc:Hexanesmixture in a gradient elution on a Combiflash purification system.Isolated 1 g (46%) of 90 as a colorless oil. MS: [M+H]⁺: 409.

Preparation of (2S)-methyl2-((S)-2-azido-3-methylbutanamido)-3-(4-(3-hydroxy-2-(tosyloxymethyl)propoxy)phenyl)propanoate(91)

General experimental procedure for selective monotosylation of diol (H)was followed. Reaction was performed on a 0.9 g scale. Product elutedout in 60% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 0.7 g (57%) of 91 as a colorless oil. MS:[M+H]⁺: 563.

Preparation of (2S)-methyl3-(4-(3-acetoxy-2-(tosyloxymethyl)propoxy)phenyl)-2-((S)-2-azido-3-methylbutanamido)propanoate(92)

General experimental procedure for acetylation of alcohols (I) wasfollowed. Reaction was performed on a 0.7 g scale. Product eluted out in40% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 0.68 g (42%) of 92 as a colorless oil. MS:[M+H]⁺: 605.

Preparation of3-acetoxy-2-(tosyloxymethyl)propoxy)phenyl)-2-(S)-2-(4-02-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-3-methylbutanamido)propanoate(93)

General experimental procedure for click reaction (E) was followed.Reaction was performed on a 0.15 g scale. Product eluted out in 65%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. Isolated 0.24 g (82%) of 93 as a colorless solid. MS: [M+H]⁺:1176.

Preparation of DHK3183:

General experimental procedure for fluorination (J) was followed.Reaction was performed on a 0.024 g scale. Isolated 0.013 g (56%) ofDHK3183 as a colorless solid. MS: [M+H]⁺: 665.

Preparation of DHK2173 Precursor:

Preparation of (S)-ethyl2-((S)-2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate (94)

General experimental procedure for coupling (C) was followed. Reactionwas performed on a 4 g scale. Product eluted out in 50% EtOAc:Hexanesmixture in a gradient elution on a Combiflash purification system.Isolated 1 g (81%) of 94 as a colorless solid. MS: [M-Boc+H]⁺: 425.

Preparation of (2S)-ethyl2-42S)-2-(tert-butoxycarbonylamino)-3-(4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(95)

General experimental procedure for phenolic alkylation (A) was followed.Reaction was performed on a 5 g scale. K₂CO₃ was used as a base. Producteluted out in 50% EtOAc:Hexanes mixture in a gradient elution on aCombiflash purification system. Isolated 1.5 g (25%) of 95. MS:[M-Boc+H]⁺: 539.

Preparation of (2S)-ethyl2-((2S)-2-amino-3-(4-(2,3-dihydroxypropoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(96)

General experimental procedure for deprotection (B) was followed.Reaction was performed on a 1.5 g scale. Isolated 1.1 g (100%) of 96 asa colorless solid. MS: [M+H]⁺: 499.

Preparation of (2S)-ethyl2-((2S)-2-azido-3-(4-(2,3-dihydroxypropoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(97)

General experimental procedure for azidation (M) was followed. Reactionwas performed on a 0.04 g scale. Product eluted out in 80% EtOAc:Hexanesmixture in a gradient elution on a Combiflash purification system.Isolated 0.25 g, 25% of 97 as a colorless solid. MS: [M+H]⁺: 525.

Preparation of (2S)-ethyl2-((2S)-2-azido-3-(4-(2-hydroxy-3-(tosyloxy)propoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(98)

General experimental procedure for selective monotosylation of diol (H)was followed. Reaction was performed on a 0.22 g scale. Product elutedout in 60% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 0.23 g (82%) of 98. MS: [M+H]⁺: 679.

Preparation of (2S)-ethyl2-42S)-3-(4-(2-acetoxy-3-(tosyloxy)propoxy)phenyl)-2-azidopropanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(99)

General experimental procedure for acetylation of alcohols (I) wasfollowed. Reaction was performed on a 0.043 g scale. Product eluted outin 40% EtOAc:Hexanes mixture in a gradient elution on a Combiflashpurification system. Isolated 0.032 g (71%) of 99. MS: [M+H]⁺: 721.

Preparation of (2S)-ethyl24(2S)-3-(4-(2-acetoxy-3-(tosyloxy)propoxy)phenyl)-2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(100)

General experimental procedure for click reaction (E) was followed.Reaction was performed on a 0.044 g scale. Product eluted out in 70%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. Isolated 0.075 g (96%) of 100 as a colorless solid. MS: [M+H]⁺:1192

Preparation of DHK2173:

Preparation of (S)-methyl2-((S)-2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(101)

General experimental procedure for coupling (C) was followed. Reactionwas performed on a 5 g scale. Product eluted out in 50% EtOAc:Hexanesmixture in a gradient elution on a Combiflash purification system.Isolated 6.1 g (81%) of 101 as a colorless solid. MS: [M-Boc+H]⁺: 411.

Preparation of (2S)-methyl2-((2S)-2-(tert-butoxycarbonylamino)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(102)

General experimental procedure for phenolic alkylation (A) was followed.Reaction was performed on a 0.22 g scale. K₂CO₃ was used as a base.Product eluted out in 30% EtOAc:Hexanes mixture in a gradient elution ona Combiflash purification system. Isolated 0.053 g (23%) of 102. MS:[M-Boc+H]⁺: 487.

Preparation of (2S)-methyl2-((2S)-2-amino-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(103)

General experimental procedure for deprotection (L) was followed.Reaction was performed on a 0.05 g scale. Isolated 0.04 g (75%) of 103.MS: [M+H]⁺: 487.

Preparation of (2S)-methyl2-((2S)-2-azido-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(104)

General experimental procedure for azidation (M) was followed. Reactionwas performed on a 0.04 g scale. Isolated 0.042 g (100%) of 104. MS:[M+H]⁺: 513.

Preparation of (2S)-methyl2-((2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(105)

General experimental procedure for click reaction (N) was followed.Reaction was performed on a 0.036 g scale. Isolated 0.037 g (69%) of 105as a colorless solid.

MS: [M+H]⁺: 781

Preparation of(2S)-2-((2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid (DHK2173)

General experimental procedure for ester hydrolysis (K) was followed.Reaction was performed on a 0.035 g scale. Isolated 0.0132 g (39%) ofDHK2173 as a colorless solid. MS: [M+H]⁺: 767

Preparation of DHK2134:

Preparation of (S)-methyl2-amino-3-(4-(trifluoromethyl)phenyl)propanoate (105)

To a 50 mL round bottomed flask equipped with a magnetic stir bar,rubber septum, and argon inlet containing MeOH (5 mL) was placed acid(0.13 g, 0.56 mmol). To this solution was added thionyl chloride (2Msolution in DCM, 5 mL) at 0° C. and the reaction was allowed to stir atroom temperature for 24 h. After the reaction was complete, MeOH wasremoved in vacuo, diluted with DCM (50 mL). The DCM layer was washedwith 10% NaHCO₃ solution (25 mL), H₂O (2×25 mL) dried (Na₂SO₄) andconcentrated in vacuo to afford 105 (0.08 g, 58%) as a colorless solid.MS: [M+H]⁺: 248

Preparation of (S)-methyl2-((S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(DHK2127)

General experimental procedure for amide coupling (O) was followed.Reaction was performed on a 0.007 g scale. Isolated 0.010 g (43%) ofDHK2127 as a colorless solid. MS: [M+H]⁺: 751

Preparation of(S)-2-((S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid (DHK2134)

General experimental procedure for ester hydrolysis (K) was followed.Reaction was performed on a 0.007 g scale. Isolated 0.003 g (40%) ofDHK2134 as a colorless solid. MS: [M+H]⁺: 737

Preparation of BW96:

Preparation of (S)-3-methyl2(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanoicacid (106)

General experimental procedure for click reaction (E) was followed.Reaction was performed on a 0.14 g scale. 0% to 40% MeOH in DCM was usedas the eluent for purification. Isolated 0.40 g (98%) of 106 as a solid.MS: [M+H]: 412.

Preparation of (S)-methyl2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-(4-(trifluoromethyl)phenyl)propanoate (BW96)

General experimental procedure for amide coupling (O) was followed.Reaction was performed on a 0.015 g scale. 0% to 80% EtOAc in DCM wasused as the eluent for purification. Isolated 0.019 g (49%) of BW96 as asolid. MS: [M+H]: 641.

Preparation of BW1391A and BW1391B:

Preparation of (S)-ethyl2-((S)-2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(107)

General experimental procedure for coupling (C) was followed. Reactionwas performed on a 3.9 g scale. 50% to 100% EtOAc in DCM was used as theeluent for purification. Isolated 7.0 g (90%) of 107 as a solid. MS:[M+Na]: 547.

Preparation of (S)-ethyl2-((S)-2-azido-3-(4-hydroxyphenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(108)

General experimental procedures for deprotection (L) was followed byazidation (M). Reaction was performed on a 1.1 g scale. 0% to 45% EtOAcin DCM was used as the eluent for purification. Isolated 0.31 g (41%) of108 as a solid. MS: [M+H]: 551.

Preparation of ethyl2-(2-azido-3-(4-4(4S,5R)-5-(fluoromethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate (109)

General experimental procedures for phenolic alkylation (A) wasfollowed. Reaction was performed on a 0.1 g scale and tetrabutylammoniumsulfate was used. The residue was purified over silica gel using 0% to50% EtOAc in Hexanes as an eluent to afford 0.07 g (49%) of 109. MS:[M+H]: 597.

Preparation of ethyl2-(3-(4-0(4S,5R)-5-(fluoromethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(110)

General experimental procedure for click reaction (E) was followed.Reaction was performed on a 0.07 g scale. 50% to 80% EtOAc in Hexaneswas used as the eluent for purification. Isolated 0.009 g (9%) of 110 asa solid. MS: [M+H]: 865.

Preparation of2-(3-(4-(04S,5R)-5-(fluoromethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid (BW1391A and BW1391B)

General experimental procedure for hydrolysis (K) was followed. Reactionwas performed on a 0.009 g scale. HPLC was used as the purificationmethod. Isolated 0.004 g (43%) of BW139 (A and B) as colorless solids.MS: [M+H]: 839.

Preparation of BW1411 and BW1412:

Preparation of2-(3-(4-((2S,3R)-4-fluoro-2,3-dihydroxybutoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid (BW-141-1 and BW-141-2)

General experimental procedure for deprotection (B) was followed.Reaction was performed on a 0.004 g scale. HPLC was used as thepurification method. Isolated 0.002 g (43%) of BW1411 and BW1412 ascolorless solids. MS: [M+H]: 797.

Preparation of BW1392C and BW1392D:

Preparation of ethyl2-(3-(4-hydroxyphenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate (111)

General experimental procedure for click reaction (E) was followed.Reaction was performed on a 0.07 g scale. 50% to 80% EtOAc in Hexaneswas used as the eluent for purification. Isolated 0.01 g (8%) of 111 asa colorless solid. MS: [M+H]: 719.

Preparation of2-(3-(4-hydroxyphenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-5-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoic acid (BW1392C and BW1392D)

General experimental procedure for hydrolysis (K) was followed. Reactionwas performed on a 10 mgs scale. HPLC was used as the purificationmethod. Isolated 4 mg (40%) of BW1392C and BW1392D as colorless solids.MS: [M+H]: 691.

Preparation of BW223:

Preparation (3-(2-azidoethoxy)phenyl)methanol (112)

General experimental procedure for phenolic alkylation (A) was followed.Reaction was performed on a 1.2 g scale. 0% to 50% EtOAc in Hexanes wasused as the eluent for purification. Isolated 0.61 g (63%) of 112 as acolorless oil. MS: [M+Na]: 216.

Preparation (3-(2-azidoethoxy)benzyl 4-methylbenzenesulfonate (113)

General experimental procedure for tosylation (D) was followed. Reactionwas performed on a 0.59 g scale. Isolated 1.0 g (99%) of 113 as a solid.MS: [M+Na]: 370.

Preparation (S)-methyl 2-amino-3-(3-(2-azidoethoxy)benzylthio)propanoate(114)

To a round bottomed flask equipped with a magnetic stir bar, rubberseptum, and argon inlet containing DMF (10 mL) was placed tosylate (1.0g, 3.1 mmol). The reaction was cooled to 0° C. To this pre-cooledsolution was added thiol (0.53 g, 3.1 mmol), Cs₂CO₃ (1.1 g, 3.4 mmol),tetrabutylammonium iodide (1.1 g, 3.1 mmol) and stirred at 0° C. After 1h, the reaction was allowed to stir at room temperature for 4 h. Thereaction was then poured into water (25 vol) and extracted into EtOAc(3×20 vol). The combined organic extracts were washed with brine (25vol), dried (Na₂SO₄) and concentrated in vacuo to afford 0.34 g (36%) of114. MS: [M+H]: 311.

Preparation (S)-methyl3-(3-(2-azidoethoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(BW223)

General experimental procedure for coupling (C) was followed. Reactionwas performed on a 0.1 g scale. 100% EtOAc used as the eluent forpurification. Isolated 0.068 g (32%) of BW223 as a solid. MS: [M+H]:662.

Preparation of BW227:

Preparation(S)-3-(3-(2-(4-(3-fluoropropyl)-1H-1,2,3-triazol-1-yl)ethoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid (BW227)

General experimental procedures for click reaction (E) was followed byhydrolysis (K). Reaction was performed on a 0.044 g scale. HPLC was usedas the purification method. Isolated 0.005 g (10%) of BW227 as acolorless solid. MS: [M+H]: 734.

Preparation of BW241:

Preparation of (3-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)phenyl)methanol(115)

General experimental procedure for phenolic alkylation (A) was followed.Reaction was performed on a 3.2 g scale. Isolated 4.1 g (62%) of 115 asa crude oil. MS: [M+H]: 281.

Preparation 3-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)benzyl4-methylbenzenesulfonate (116)

General experimental procedure for tosylation (D) was followed. Reactionwas performed on a 3.3 g scale. 0% to 50% EtOAc in Hexanes was used asthe eluent for purification. Isolated 3.3 g (63%) of 116 as a colorlessoil. MS: [M+Na]: 435.

Preparation of (S)-methyl2-amino-3-(3-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)benzylthio)propanoate(117)

To a round bottomed flask equipped with a magnetic stir bar, rubberseptum, and argon inlet containing DMF (10 mL) was placed tosylate (0.94g, 2.2 mmol). The reaction was cooled to 0° C. To this pre-cooledsolution was added thiol (0.39 g, 2.2 mmol), Cs₂CO₃ (0.79 g, 2.4 mmol),tetrabutylammonium iodide (0.81 g, 2.2 mmol) and stirred at 0° C. After1 h, the reaction was allowed to stir at room temperature for 4 h. Thereaction was then poured into water (25 vol) and extracted into EtOAc(3×20 vol). The combined organic extracts were washed with brine (25vol), dried (Na₂SO₄) and concentrated in vacuo. Purified by silica gelcolumn using 0% to 50% EtOAc in DCM to afford 0.34 g (46%) of 117 as acolorless oil. MS: [M+H]: 376.

Preparation (S)-methyl3-(3-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(BW241)

General experimental procedure for coupling (C) was followed. Reactionwas performed on a 0.35 g scale. 0% to 100% EtOAc in DCM was used as theeluent for purification. Isolated 0.1 g (15%) of BW241 as a solid. MS:[M+H]: 749.

Preparation of BW245:

Preparation of(S)-3-(3-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic acid (BW245)

General experimental procedure for hydrolysis (K) was followed. Reactionwas performed on a 10 mgs scale. Prep-HPLC was used as the purificationmethod. Isolated 0.005 g (50%) of BW245 as a solid. MS: [M+H]: 713.

Preparation of GC117a and GC117b:

Preparation of (S)-methyl2-(tert-butoxycarbonylamino)-3-(4-((2s,5r)-2-phenyl-1,3-dioxan-5-yloxy)phenyl)propanoate(118)

To a 200 mL round bottomed flask equipped with a magnetic stir bar,rubber septum, and argon inlet containing DCM (150 mL) was placedtrans-2-phenyl-1,3-dioxan-5-ol (8.0 g, 44 mmol). To this solution wasadded TEA (13.5 g, 133 mmol) and the reaction was allowed to stir at icebath temperature for 30 min. Trifluoromethanesulfonic anhydride (15 ml,89 mmol) was added drop wise in 30 min. After the reaction was complete(30 min), it was concentrated in vacuo. The residue was purified oversilica gel using Hexanes:EtOAc (5:1) as an eluent to affordtrans-2-phenyl-1,3-dioxan-5-yl trifluoromethanesulfonate (5.7 g, 41%) asa yellow solid. (S)-methyl2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanoate (6.4 g, 22mmol) and sodium hydride (95% suspended in mineral oil) (0.51 g, 20mmol) were dissolved in DMF (45 mL). After stirred at room temperaturefor 5 min, the above trans-2-phenyl-1,3-dioxan-5-yltrifluoromethanesulfonate (5.2 g, 17 mmol) was added into the reactionin the DMF (45 mL) solution. The reaction was allowed to stir at roomtemperature 15 h. The reaction was concentrated in vacuo. The residuewas diluted with EtOAc (150 mL) and washed with brine (50 mL). Theorganic layer was concentrated again and purified on a silica gel.Product eluted out in 50% EtOAc:Hexanes mixture in a gradient elution ona Combiflash purification system. Isolated 118 (1.9 g, 25%) as a yellowsolid.

LRMS for C₂₅H₃₁NO₇+Na⁺, calc'd: 480.2, found: 480.2 (M+Na⁺)

¹H NMR (400 MHz, CDCl₃) δ: 7.49 (d, J=2.0 Hz, 2H), 7.37 (m, 3H), 7.04,(d, J=8.4 Hz, 1H), 6.88 (d, J=8.4 Hz, 1H), 5.50 (s, 1H), 4.93 (br s,1H), 4.50-4.44 (m, 4H), 3.81 (t, J=10.2 Hz, 2H), 3.72 (s, 3H), 3.10-2.98(m, 2H), 1.42 (s, 9H).

Preparation of (S)-methyl2-amino-3-(4-(1,3-dihydroxypropan-2-yloxy)phenyl)propanoate (119)

119 was prepared through general experimental procedure (B) and isolatedas a colorless solid (40 mg scale, yield 85%).

¹H NMR (400 MHz, D₂O) δ: 7.03 (d, J=8.8 Hz, 2H), 6.87 (d, J=8.4 Hz, 3H),4.36 (m, 1H), 4.20 (t, J=4.0 Hz, 1H), 3.70-3.55 (m, 7H), 3.15-2.97 (m,2H); LRMS for C₁₃H₁₉NO₅+H⁺, calc'd: 269.1, found: 269.2 (M+H⁺)

Preparation of (S)-methyl2-((S)-2-azido-3-methylbutanamido)-3-(4-(1,3-dihydroxypropan-2-yloxy)phenyl)propanoate(120)

120 was prepared through general experimental procedure (C) and isolatedas a colorless solid (320 mg scale, yield 65%).

¹H NMR (400 MHz, CDCl₃) δ: 7.03 (d, J=8.8 Hz, 2H), 6.87 (d, J=8.8 Hz,3H), 6.70 (b, 1H), 4.85 (m, 1H), 4.40 (t, J=4.8 Hz, 1H), 3.90 (m, 4H),3.79 (d, J=4.4 Hz, 1H), 3.75 (s, 3H), 3.16-2.99 (m, 2H), 2.30-2.25 (m,1H), 1.02 (d, J=7.2 Hz, 3H), 0.79 (d, J=7.2 Hz, 3 Hz); LRMS forC₁₈H₂₆N₄O₆+H⁺, calc'd: 395.4, found: 395.6 (M+H⁺).

Preparation of (S)-methyl3-(4-(1-acetoxy-3-hydroxypropan-2-yloxy)phenyl)-2-((S)-2-azido-3-methylbutanamido)propanoate(121)

To a 25 mL round bottomed flask equipped with a magnetic stir bar,rubber septum, and argon inlet containing dichloromethane (5 mL) wasplaced (S)-methyl2-((S)-2-azido-3-methylbutanamido)-3-(4-(1,3-dihydroxypropan-2-yloxy)phenyl)propanoate(320 mg, 0.811 mmol). To this solution was added was added triethyloxyorthoacetate (197 mg, 1.22 mmol). The reaction was allowed to stir atroom temperature for 20 min.

To the reaction was added water (21.9 mg, 1.22 mmol). The reaction wasallowed to stir at room temperature 15 h. Product eluted out in 30%EtOAc:Hexanes mixture in a gradient elution on a Combiflash purificationsystem. Isolated 121 (230 mg, 65.0%) as a colorless solid.

¹H NMR (400 MHz, CDCl₃) δ: 7.03 (d, J=8.8 Hz, 2H), 6.90 (d, J=8.8 Hz,3H), 6.70 (b, 1H), 4.85 (m, 1H), 4.51 (m, 1H), 4.40 (m, 1H), 4.23-4.20(m, 2H), 3.85-3.79 (m, 3H), 3.74 (s, 3H), 3.16-2.99 (m, 2H), 2.30-2.25(m, 1H), 2.08 (s, 3H), 1.02 (d, J=6.8, 3H), 0.79 (d, J=7.2 Hz, 3 Hz).

LRMS for C₂₀H₂₈N₄O₇+H⁺, calc'd: 437.2, found: 437.3 (M+H⁺)

Preparation of (2S)-methyl3-(4-(1-acetoxy-3-(tosyloxy)propan-2-yloxy)phenyl)-2-((S)-2-azido-3-methylbutanamido)propanoate(122)

122 was prepared through general experimental procedure (D) and isolatedas a colorless solid (230 mg scale, yield 77%).

¹H NMR (400 MHz, CDCl₃) δ: 7.04 (d, J=8.8 Hz, 2H), 6.90 (d, J=8.8 Hz,3H), 6.70 (br s, 1H), 4.87 (m, 1H), 4.40 (t, J=4.8 Hz, 1H), 3.90-3.79(m, 4H), 3.78 (d, J=4.4 Hz, 1H), 3.75 (s, 3H), 3.16-2.97 (m, 2H),2.30-2.25 (m, 1H), 1.02 (d, J=7.2 Hz, 3H), 0.79 (d, J=7.2 Hz, 3 Hz)

LRMS for C₂₇H₃₄N₄O₉S+H⁺, calc'd: 591.2, found: 395.6 (M+H)

Preparation of (2S)-methyl3-(4-(1-acetoxy-3-(tosyloxy)propan-2-yloxy)phenyl)-2-4S)-2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-3-methylbutanamido)propanoate(123)

Compound 123 was prepared through general experimental procedure (E) andisolated as a colorless solid (225 mg scale, yield 77%).

¹H NMR (400 MHz, (CD₃)₂C0) δ: 8.21 (s, 1H), 8.10 (m, 2H), 7.89 (d, J=7.2Hz, 1H), 7.80-7.70, (m, 3H), 7.45-7.41 (m, 4H), 7.30-7.12 (m, 8H), 6.95(m, 2H), 6.75 (m, 2H), 6.60 (d, J=6.8 Hz, 4H), 5.30 (s, 2H), 5.10 (d,J=8.8 Hz, 1H), 4.71-4.65 (m, 2H), 4.35-4.15 (m, 4H), 3.84 (s, 1H), 3.79(s, 1H), 3.66 (s, 3H), 3.62 (6H), 3.06-2.90 (m, 2H), 2.65 (s, 2H), 2.59(s, 3H), 2.42 (s, 3H), 1.02 (d, J=7.2 Hz, 3H), 0.79 (d, J=7.2 Hz, 3H)LRMS for C₅₈H₆₀N₆O₁₄S₃+H⁺, calc'd: 1161.3, found: 1161.3 (M+H⁺)

Preparation of(2S)-3-(4-(1-fluoro-3-hydroxypropan-2-yloxy)phenyl)-2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid (GC2117a)

GC2117a was prepared through general experimental procedure (J) andisolated as a colorless solid (10 mg scale, yield 23%).

¹H NMR (400 MHz, (CD₃)₂C0) δ: 8.08 (d, J=2.8 Hz, 1H), 7.91 (s, 1H), 7.80(s, 1H), 7.78 (d, J=2.8, 1H), 7.27-7.10 (m, 3H), 6.86 (d, J=7.6 Hz, 2H),6.67 (d, J=7.6 Hz, 2H), 5.23 (s, 2H), 5.00 (m, 1H), 4.61-4.30 (m, 4H),3.63 (m, 2H), 2.40-2.30 (m, 2H), 0.91 (d, J=6.8 Hz, 3H), 0.56 (d, J=6.8Hz, 3H).

LRMS for C₂₇H₃₁FN₆O₈S₂+H⁺, calc'd: 651.2, found: 651.2 (M+H⁺)

Preparation of(2S)-3-(4-(1-fluoro-3-hydroxypropan-2-yloxy)phenyl)-2-((R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid (GC2117B)

GC2117b was prepared through general experimental procedure (J) andisolated as a colorless solid (10 mg scale, yield 23%).

¹H NMR (400 MHz, (CD₃)₂C0) δ: 8.12 (s, 1H), 8.00-7.88 (m, 2H), 7.80 (s,1H), 7.27, (s, 2H), 7.20 (d, J=6.4 Hz, 1H), 7.02 (d, J=6.0 Hz, 2H), 6.80(d, J=6.0 Hz, 1H), 5.21 (s, 2H), 4.90 (d, J=7.2 Hz, 1H), 4.61-4.40 (m,4H), 3.63 (m, 2H), 2.40-2.30 (m, 2H), 0.65 (d, J=6.8 Hz, 3H), 0.50 (d,J=6.8 Hz, 3H).

LRMS for C₂₇H₃₁FN₆O₈S₂+H⁺, calc'd: 651.2, found: 651.2 (M+H⁺).

Preparation of BD209:

Preparation of (S)-methyl 2-azido-3-(4-(2-fluoroethoxy)phenyl)propanoate(124)

To a 500 mL round bottom flask containing 56 (5.3 g, 15.5 mmol) at 0°C., was added 4M HCl in dioxane (310 mL). The temperature was raised toRT and stirred for 2.5 h. After the reaction is done, dioxane removed invacuo to get the colorless salt (4.29 g, 100%) and used for next step.To this, a slurry of NaN_(i) (1.51 g, 23.25 mmol) in pyridine (23 mL) at0° C., Tf₂O (3.91 mL, 23.25 mmol) was added, the reaction warmed to RTand stir for 1 hr. To this water (11 mL), CuSO₄.5H₂O (0.579 g, 2.325mmol) were added and stirred at RT for 12 h. Reaction was carefullyquenched with sat. NaHCO₃ (50 mL), taken up in EtOAc (100 mL) washedwith 10% CuSO₄.5H₂O (2×30 mL), brine (30 mL), dried over MgSO₄ andconcentrated in vacuo. The residue was purified over silica gel usingEtOAc:Hexanes (1:1) as an eluent to afford 124 (4.13 g, 100%) as acolorless oil. LC/MS: Expected for C₁₂H₁₄FN₃O₃: 267.1; found: 290.1(M+Na).

¹H NMR (400 MHz, CDCl₃) δ: 7.15 (d, J=8.8 Hz, 2H), 6.89 (d, J=8.8 Hz,2H), 4.80-4.82 (m, 1H), 4.68-4.70 (m, 1H), 4.23-4.25 (m, 1H), 4.16-4.18(m, 1H), 4.01-4.05 (m, 1H), 3.77 (s, 3H), 3.1-3.15 (m, 1H), 2.94-2.99(m, 1H).

Preparation of (S)-2-azido-3-(4-(2-fluoroethoxy)phenyl)propanoic acid(125)

General experimental procedure for hydrolysis (K) was followed. Reactionwas performed on a 4.13 g scale. After the reaction was done, THF wasremoved and the aqueous layer was acidified to pH=3 with 6M HCl. Thereaction was then poured into brine (50 mL) and extracted into CHCl₃(3×30 mL). The combined organic extracts were washed with water (50 mL),brine (50 mL), dried over MgSO₄ and concentrated in vacuo to afford 125(3.92 g, 100%) as a colorless oil.

LC/MS: Expected for C_(H)H₁₂FN₃O₃: 253.09; found: 276.1 (M+Na).

Preparation of(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoicacid (BD209)

General experimental procedure for click reaction (N) was followed.Performed on 0.7 g (alkyne) scale, purified over silica gel usingMeOH:CH₂Cl₂ (1:4) as an eluent to afford BD209 (0.55 g, 42%) as a yellowcrystalline solid.

LC/MS: Expected for C₂₁H₂₀FN₅O₆S₂: 521.08; found: 522.1 (M+H).

¹H NMR (400 MHz, CDCl₃) δ: 8.34 (s, 1H), 8.27 (br, s, 2H), 8.05 (d,J=9.2 Hz, 1H), 7.94 (d, J=2.4 Hz, 1H), 7.30 (dd, J=2.8, 9.2 Hz, 1H),6.96 (d, J=8.8 Hz, 2H), 6.64 (d, J=8.8 Hz, 2H), 5.21 (d, J=2.0 Hz, 2H),4.72-4.76 (m, 1H), 4.61-4.63 (m, 1H), 4.37-4.38 (m, 1H), 4.02-4.11 (m,1H), 3.81-3.85 (m, 2H), 3.15-3.17 (m, 2H).

Preparation of BD246:

Preparation of (S)-ethyl1-(2-azido-6-(tert-butoxycarbonylamino)hexanoyl)piperidine-4-carboxylate(126)

General experimental procedure for coupling reaction (C) was followed.Performed on 1.1 g scale. The residue was purified over silica gel usingEtOAc:Hexanes (1:1) as an eluent to afford 126 (1.13 g, 76%) as acolorless oil.

LC/MS: Expected for C₁₉H₃₃N₅O₅: 411.25; found: 434.2 (M+Na).

Preparation of(S)-4-(5-azido-6-(4-(ethoxycarbonyl)piperidin-1-yl)-6-oxohexylamino)-4-oxobutanoic acid (127)

To a 100 mL round bottom flask containing 126 (1.1 g, 2.68 mmol) at 0°C., was added 4M HCl in dioxane (54 mL). The temperature was raised toRT and stirred for 2.5 h. After the reaction is done, dioxane removed invacuo to get the colorless salt (0.928 g, 100%) and used for next step.To a 50 mL round bottom flask containing dihydrofuran-2,5-dione (6 mg,0.06 mmol), catalytic amount of DMAP, amine (20 mg, 0.0576 mmol) wasadded and stirred at RT for 5 h. After the completion of reaction,silica added concentrated and purified by flash column chromatographyusing MeOH:CHCl₃ (1:9) as an eluent to get 127 as a colorless solid (16mg, 73%).

LC/MS: Expected for C₁₈H₂₉N₅O₆: 411.21; found: 412.2 (M+H⁺).

Preparation of(S)-4-(6-(4-(ethoxycarbonyl)piperidin-1-yl)-6-oxo-5-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)hexylamino)-4-oxobutanoicacid (BD246)

To a 10 mL round bottomed flask equipped with a magnetic stir barcontaining t-BuOH:THF:H₂O (1:1:1, 1 mL) was placed azide (16 mg, 0.0389mmol) and alkyne (20 mg, 0.0389 mmol). To this solution CuSO₄ (2 mg,0.0097 mmol), sodium ascorbate (1.5 mg, 0.0078 mmol) were added andstirred for 12 h. Silica added concentrated to dryness and purified oversilica gel using MeOH:CH₂Cl₂ (1:4) as an eluent to afford BD246 (8.1 mg,31%) as a light yellow solid.

LC/MS: Expected for C₂₈H₃₇N₇O₉S₂: 679.21; found: 680.3 (M+H⁺).

Preparation of BD247:

Preparation of (S)-tert-butyl5-azido-6-oxo-6-(4-(trifluoromethyl)benzylamino)hexylcarbamate (128)

To a 200 mL round bottom flask containing acid (3.1 g, 11.55 mmol) inDMF (100 mL) was treated with HOBt (4.25 g, 31.5 mmol) and EDC (6.0 g,31.5 mmol) at room temperature. After stirring for 1 h, a solution ofamine (1.5 mL, 10.5 mmol) in DMF (2 mL) and NaHCO₃ (4.4 g, 52.5 mmol)was added to the reaction mixture and stirred for 12 h. The reaction wasthen poured into water (300 mL) and extracted with EtOAc (3×100 mL). Thecombined organic extracts were washed with water (100 mL), brine (100mL), dried over MgSO₄ and concentrated in vacuo. The residue waspurified over silica gel using EtOAc:Hexanes (1:2) as an eluent toafford 128 (3.9 g, 87%) as a colorless solid.

LC/MS: Expected for C₁₉H₂₆F₃N₅O₃: 429.2; found: 452.4 (M+Na⁺).

Preparation of(S)-4-(5-azido-6-oxo-6-(4-(trifluoromethyl)benzylamino)hexylamino)-4-oxobutanoicacid (129)

To a 500 mL round bottom flask containing 128 (3.9 g, 9.09 mmol) at 0°C., was added 4M HCl in dioxane (182 mL). The temperature was raised toRT and stirred for 2.5 h. After the reaction is done, dioxane removed invacuo to get the colorless salt (3.3 g, 100%) and used for next step. Toa 50 mL round bottom flask containing dihydrofuran-2,5-dione (5.4 mg,0.0546 mmol), catalytic amount of DMAP, amine (19 mg, 0.052 mmol) wasadded and stirred at RT for 5 h. After the completion of reaction,silica added concentrated and purified by flash column chromatographyusing MeOH/CHCl₃ (10%) as an eluent to get 129 as colorless solid (6.6mg, 31%).

LC/MS: Expected for C₁₈H₂₂F₃N₅O₄: 429.16; found: 430.2 (M+H).

Preparation of(S)-4-oxo-4-(6-oxo-5-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-6-(4-(trifluoromethyl)benzylamino)hexylamino)butanoicacid (BD-2-47)

To a 10 mL round bottomed flask equipped with a magnetic stir barcontaining t-BuOH:THF:H₂O (1:1:1, 1 mL) was placed 129 (6.6 mg, 0.0154mmol) and alkyne (8 mg, 0.0154 mmol). To this solution CuSO₄ (1 mg,0.0039 mmol), sodium ascorbate (0.6 mg, 0.0031 mmol) were added andstirred for 12 h. Silica added concentrated to dryness and purified oversilica gel using MeOH:CH₂Cl₂ (1:4) as an eluent to afford BD-2-47 (9.3mg, 93%) as a light yellow solid.

LC/MS: Expected for C₂₈H₃₀F₃N₇O₇S₂: 697.16; found: 698.3 (M+H).

Preparation of BD2120:

Preparation of 2-(3-(bromomethyl)phenoxy)tetrahydro-2H-pyran (130)

To a 250 mL round bottomed flask equipped with a magnetic stir bar,rubber septum and argon inlet containing DCM (133 mL) was placed bromide(5 g, 26.7 mmol). To this solution DHP (4.83 mL, 53.4 mmol) and PPTS(1.0 g, 4.0 mmol) were added and the reaction was allowed to stir at RTfor 12 h. The reaction was concentrated on silica and the residue waspurified over silica gel using EtOAc:Hexanes (1:9) as an eluent toafford 130 (5.7 g, 79%) as a colorless oil.

Preparation of (2S)-ethyl2-amino-3-(3-(tetrahydro-2H-pyran-2-yloxy)benzylthio)propanoate (131)

To a 500 mL round bottomed flask equipped with a magnetic stir bar,rubber septum and argon inlet containing DMF (200 mL) was placed 130(5.7 g, 21.0 mmol). To this solution Cs₂CO₃ (6.8 g, 21.0 mmol) and TBAI(7.75 g, 21.0 mmol) were added at 0° C. and the reaction was allowed tostir at RT for 2 h. The reaction was then cooled to 0° C. and thiol wasadded and the reaction was allowed to stir at RT for 12 h. The reactionwas poured into water (500 mL) and extracted into EtOAc (3×150 mL). Thecombined organic extracts were washed with water (150 mL), brine (150mL), dried over MgSO₄ and concentrated in vacuo. The residue waspurified over silica gel using EtOAc:Hexanes (9:1) as an eluent toafford 131 (5.9 g, 83%) as a colorless oil.

LC/MS: Expected for C₁₇H₂₅NO₄S: 339.15; found: 340.4 (M+H).

¹H NMR (400 MHz, CDCl₃) δ: 7.19 (t, J=7.6 Hz, 1H), 6.99-7.01 (m, 1H),6.91-6.94 (m, 2H), 5.40 (t, J=3.2 Hz, 1H), 4.17 (q, J=7.2, 14 Hz, 2H),3.85-3.92 (m, 1H), 3.7 (s, 2H), 3.56-3.66 (m, 2H), 2.84-2.88 (m, 1H),2.71 (2dd, J=1.6, 7.6 Hz, 1H), 1.93-2.01 (m, 1H), 1.81-1.84 (m, 2H),1.54-1.72 (m, 3H), 1.26 (t, J=7.2 Hz, 3H).

Preparation of (2S)-ethyl2-(2-azidoacetamido)-3-(3-(tetrahydro-2H-pyran-2-yloxy)benzylthio)propanoate(132)

To a 500 mL round bottom flask containing 131 (5.9 g, 17.38 mmol) andazido acid (2.13 g, 20.8 mmol) in THF (174 mL) was treated with EDC(5.33 g, 27.81 mmol), HOBt (3.75 g, 27.81 mmol) and TEA (12.2 mL, 86.9mmol) at room temperature and was stirred for 12 h. The reaction wasconcentrated on silica and was purified over silica gel usingEtOAc:Hexanes (1:1) as an eluent to afford 132 (6.5 g, 89%) as acolorless oil.

LC/MS: Expected for C₁₉H₂₆N₄O₅S: 422.16; found: 445.2 (M+Na).

Preparation of (S)-ethyl2-(2-azidoacetamido)-3-(3-hydroxybenzylthio)propanoate (133)

To a 250 mL round bottom flask containing 132 (6.5 g, 15.4 mmol) in MeOH(150 mL) at RT, was added Cone. HCl (1 mL) and stirred for 2.5 h. Thereaction was concentrated on silica and purified over silica gel usingEtOAc:Hexanes (1:1) as an eluent to afford 133 (4.8 g, 92%) as acolorless oil.

LC/MS: Expected for C₁₄H₁₈N₄O₄S: 338.1; found: 361.1 (M+Na).

Preparation of (S)-ethyl2-(2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)-3-(3-hydroxybenzylthio)propanoate(134)

To a 25 mL round bottomed flask equipped with a magnetic stir barcontaining THF (5 mL) was placed alkyne (149 mg, 0.44 mmol) and azide(251 mg, 0.44 mmol). To this solution CuI (8 mg, 0.044 mmol) and DIPEA(0.084 mL, 0.484 mmol) were added and stirred for 12 h. Silica wasadded, concentrated to dryness and purified over silica gel usingEtOAc:Hexanes (1:1) as an eluent to afford 134 (379 mg, 95%) as a lightyellow solid.

¹H NMR (400 MHz, CDCl₃) δ: 7.81-7.84 (m, 2H), 7.05-7.35 (m, 12H),6.68-6.77 (m, 3H), 6.52-6.55 (m, 4H), 5.19 (s, 2H), 5.07 (br, s, 2H),4.66-4.69 (m, 1H), 4.06-4.12 (m, 2H), 3.60 (s, 6H), 3.53 (d, J=4.0 Hz,2H), 2.83 (d, J=5.2 Hz, 2H), 1.16-1.25 (m, 3H).

Preparation of (S)-ethyl2-(2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)-3-(3-(prop-2-ynyloxy)benzylthio)propanoate(135)

To a 10 mL round bottomed flask equipped with a magnetic stir bar,rubber septum and argon inlet containing DMF (0.5 mL) was placed 134 (49mg, 0.054 mmol). To this solution K₂CO₃ (22 mg, 0.162 mmol) and3-bromoprop-1-yne (0.01 mL, 0.0702 mmol) were added and the reaction wasallowed to stir at 60° C. for 12 h. The reaction was then poured intowater (50 mL) and extracted into EtOAc (3×20 mL). The combined organicextracts were washed with water (20 mL), brine (20 mL), dried over MgSO₄and concentrated in vacuo used for next step without furtherpurification.

Preparation of (2S)-ethyl2-(2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)-3-(3-((1-(1-fluoro-3-hydroxypropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzylthio)propanoate(136)

To a 10 mL round bottomed flask equipped with a magnetic stir barcontaining THF (1 mL) was placed 135 (46 mg, 0.0486 mmol) and azide (6mg, 0.0486 mmol). To this solution CuI (1 mg, 0.00486 mmol) and DIPEA(0.09 mL, 0.0535 mmol) were added and stirred for 12 h. Silica added,concentrated to dryness and purified over silica gel using EtOAc:Hexanes(1:2) as an eluent to afford 136 (yield not determined) as a lightyellow solid.

LC/MS: Expected for C₅₁H₅₂FN₉O₁₀S₃: 1065.3; found: 764.1 (M-DMT).

Preparation of(2S)-3-(3-((1-(1-fluoro-3-hydroxypropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid (BD2120)

To a 10 mL round bottom flask containing 136 (51 mg, 0.0486 mmol) inMeOH (2 mL) at RT, was added 1M HCl (1 mL) and stirred for 2 h. Afterthe reaction is done, MeOH was removed and the residue was dissolved inTHF:H₂O (1:1, 0.5 mL). To this LiOH (3 mg, 0.0309 mmol) was added andreaction was stirred at RT for 2 h, sample dilute with water (5 mL) andpurified by HPLC using CH₃CN:H₂O (1:2) as an eluent to afford BD-2-120(5.9 mg, 27%) as colorless solid.

LC/MS: Expected for C₂₈H₃₀FN₉O₈S₃: 735.1; found: 736.0 (M+H).

Preparation of BD336:

Preparation of ethyl 2-(4-(trifluoromethyl)benzylamino)acetate (137)

To a 200 mL round bottom flask containing amine (3 g, 17.1 mmol) in DCE(60 mL) at RT, was added aldehyde (1.83 g, 18.0 mmol) and sodiumtriacetoxyborohydride (5.07 g, 23.94 mmol) stirred for 2 h. After thereaction is done, reaction is poured into sat. NaHCO₃ (200 mL) andextracted with DCM (3×50 mL). The combined organics were washed withbrine (50 mL), dried over MgSO₄ concentrated on silica and was purifiedover silica gel using EtOAc:Hexanes (1:2) as an eluent to afford 137(3.91 g, 88%) as a yellow oil. LC/MS: Expected for C₁₂H₁₄F₃NO₂: 261.10;found: 262.1 (M+H).

Preparation of ethyl2-(2-azido-N-(4-(trifluoromethyl)benzyl)acetamido)acetate (138)

To a 25 mL round bottom flask containing 137 (0.307 g, 1.18 mmol) andazido acid (0.89 g, 1.77 mmol) in THF mL) was treated with EDC (0.362 g,1.89 mmol), HOBt (0.255 g, 1.89 mmol) and TEA (0.83 mL, 5.9 mmol) atroom temperature and was stirred for 12 h. The reaction was concentratedon silica and was purified over silica gel using EtOAc:Hexanes (2:1) asan eluent to afford 138 (0.259 g, 64%) as a yellow oil.

LC/MS: Expected for C₁₄H₁₅F₃N₄O₃: 344.11; found: 367.1 (M+Na).

Preparation of ethyl2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)acetamido)acetate(139)

To a 10 mL round bottomed flask equipped with a magnetic stir barcontaining THF (4 mL) was placed 138 (0.259 mg, 0.75 mmol) and alkyne(0.201 mg, 0.75 mmol). To this solution CuI (0.014 g, 0.075 mmol) andDIPEA (0.2 mL, 1.125 mmol) were added and stirred for 4 h. Concentratedto dryness on silica and purified over silica gel using EtOAc:Hexanes(1:1) as an eluent to afford 139 (0.177 g, 38%) as a light yellow solid.

LC/MS: Expected for C₂₄H₂₃F₃N₆O₆S₂: 612.11; found: 613.1 (M+H).

Preparation of2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)acetamido)aceticacid (BD336)

To a 20 mL round bottomed flask equipped with a magnetic stir barcontaining THF:H₂O (1:1, 10 mL) was placed 139 (176 mg, 0.29 mmol). Tothis solution LiOH (61 mg, 1.45 mmol) was added and the reaction wasallowed to stir at RT for 3 h. After the reaction was done, THF wasremoved and the aqueous layer was acidified to pH=3 with 6 M HCl. Thereaction was then poured into brine (50 mL) and extracted into CHCl₃(3×20 mL). The combined organic extracts were washed with water (20 mL),brine (20 mL), dried over MgSO₄ and concentrated in vacuo to affordBD336 (yield not determined) as a colorless solid.

LC/MS: Expected for C₂₂H₁₉F₃N₆O₆S₂: 584.08; found: 585.1 (M+H).

Preparation of UG3150:

Preparation of (S)-methyl2-(2-azidoacetamido)-3-(4-(2-fluoroethoxy)phenyl)propanoate (140)

To a 500 mL round bottom flask containing 56 (2.16 g, 6.33 mmol) at 0°C., was added 4M HCl in dioxane (127 mL). The temperature was raised toRT and stirred for 2.5 h. After the reaction is done, dioxane removed invacuo to get the colorless salt (1.75 g, 100%) and used for next step.To a 100 mL round bottom flask containing azido acid (1.91 g, 18.9 mmol)in DMF (38 mL) was treated with EDC (3.61 g, 18.92 mmol) and HOBt (2.55g, 18.92 mmol) at room temperature. After stirring for 1 hr, HCl salt(1.52 g, 5.49 mmol) and NaHCO₃ (2.65 g, 31.54 mmol) were added to thereaction mixture and stirred for 12 h. The reaction was then poured intowater (150 mL) and extracted with EtOAc (3×50 mL). The combined organicextracts were washed with water (50 mL), brine (50 mL), dried over MgSO₄and concentrated in vacuo. The residue was purified over silica gelusing EtOAc:Hexanes (1:1) as an eluent to afford 140 (1.55 g, 87%) as acolorless oil. LC/MS: Expected for C₁₄H₁₇FN₄O₄: 324.12; found: 325.2(M+H).

Preparation of(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid (UG3150)

To a 25 mL round bottomed flask equipped with a magnetic stir barcontaining t-BuOH:THF:H₂O (1:1:1, 9 mL) was placed 140 (0.39 g, 1.194mmol) and alkyne (0.32 g, 1.194 mmol). To this solution CuSO₄ (0.015 g,0.056 mmol), sodium ascorbate (0.024 g, 0.119 mmol) were added andstirred for 12 h. Reaction was concentrated to dryness and used for nextstep. To this LiOH (0.012 g, 0.279 mmol) was added and reaction wasstirred at RT for 2 h, sample dilute with water (25 mL) and purified byHPLC using CH₃CN:H₂O (1:2) as an eluent to afford UG3150 (0.09 g, 84%)as a colorless solid.

LC/MS: Expected for C₂₃H₂₃FN₆O₇S₂: 578.11; found: 579.1 (M+H).

Fluorescent Tag:

Preparation of tert-Butyl1-azido-2-oxo-7,10,13-trioxa-3-azahexadecan-16-ylcarbamate (141)

To a 25 mL round bottomed flask equipped with a magnetic stir bar,rubber septum, and argon inlet containing tert-butyl3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propylcarbamate (amine, 160 mg,0.5 mmol), 2-azidoacetic acid (56 mg, 0.55 mmol, in 50% DCM solution),NaHCO₃ (168 mg, 2 mmol), and 1 mL DMF was added EDC (115 mg, 0.6 mmol).The mixture was stirred at rt for 3 h and concentrated in vacuo. Thecrude product was purified by silica chromatography (gradient 5% to 90%EtOAc in hexane) to afford compound 141 as a clear oil (130 mg, 65%). MS(ESI) m/z 426 (M+Na⁺).

Preparation of tert-Butyl2-oxo-1-(4-02-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-7,10,13-trioxa-3-azahexadecan-16-ylcarbamate(142)

To a 25 mL round bottomed flask equipped with a magnetic stir bar,rubber septum, and argon inlet containing tert-butyl1-azido-2-oxo-7,10,13-trioxa-3-azahexadecan-16-ylcarbamate (130 mg, 0.36mmol), 6-(prop-2-ynyloxy)benzo[d]thiazole-2-sulfonamide (Alkyne, 107 mg,0.4 mmol), CuI (6.9 mg, 0.036 mmol), and THF (3 mL) was added DIPEA (52mg, 0.4 mmol). The mixture was stirred at rt for 15 h and concentrated.The crude material was purified with silical chromatography (gradient10% to 90% EtOAc in hexane) to afford compound 142 as a clear wax (125mg, 52%). MS (ESI) m/z 694 (M+Na⁺).

Preparation of2-(6-Hydroxy-3-oxo-3H-xanthen-9-yl)-4-(2-oxo-1-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-7,10,13-trioxa-3-azahexadecan-16-ylcarbamoyl)benzoicacid) (144)

To a 25 mL round bottomed flask equipped with a magnetic stir bar,rubber septum, and argon inlet containing tert-Butyl2-oxo-1-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-7,10,13-trioxa-3-azahexadecan-16-ylcarbamate(142, 125 mg, 0.18 mmol) was added 4 M HCl in dioxane (2 mL). Themixture was stirred at rt for 1 h and concentrated in vacuo and furtherdried under high vacuum to afford hydrochloride salt 143 as a clear wax(140 mg, 100%). MS (ESI) m/z 572 (M+H⁺).

To this hydrochloride salt (30 mg, 0.049 mmol) in 1 mL DMF was addedNaHCO₃ (21 mg, 0.25 mmol) and the mixture was stirred for 3 min. To thissolution covered with alumina foil was added4-((2,5-dioxopyrrolidin-1-yloxy)carbonyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoicacid (fluorescine, 25 mg, 0.054 mmol). The reaction was stirred at rt indark for 2 h and concentrated, and diluted with 10 mL of MeOH and 10 mLof water. The solution was loaded on preparative RP-HPLC and eluted withTFA (0.05%) buffered MeCN and water (gradient 10% to 80% MeCN). Thefractions containing the desired product 144 was lyophilized to afford ayellow solid (20 mg, 40%). MS (ESI) m/z 930(M+H⁺).

Preparation of DHK33:

Preparation of (R)-methyl3-(benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate(141)

Acetylene (6.1 mg, 0.023 mmol, 1.05 equiv) was treated with azide (6.7mg, 0.022 mmol, 1 equiv) and CuSO₄.5H₂O (0.04 M aqueous solution in pH7.4 phosphate buffer, 0.2 equiv), sodium ascorbate (0.1 M aqueoussolution in pH 7.4 phosphate buffer, 0.4 equiv) in t-BuOH (0.5 mL) andH₂O (0.5 mL). The mixture was stirred at room temperature for 24 h.After the reaction was complete, the mixture was diluted with 1 mL ofwater and 1 mL of ether. The solid product was filtered, washed with anaqueous 0.1% NH₄OH solution (1 mL), water (1 mL) and ether (1 mL) anddried under vacuum. Yield: 0.011 g, 88%.

Preparation of(R)-3-(benzylthio)-2-(2-(4-02-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid (DHK33)

Compound 141 (5.0 mg, 0.0087 mmol, 1 equiv) in a THF/H₂O mixture (1:1, 1mL) was treated with LiOH (0.4 mg, 0.010 mmol, 1.2 equiv) and irradiatedin a Biotage Emrys Optimizer microwave reactor (250 W) at 100° C. for 10min. After cooling the contents of the tube to room temperature, thesolvent was removed and the crude product was purified by HPLC. Yield: 3mg, 63%.

Preparation of(S)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)propanamide(DHK251)

A 5 mL microwave tube was charged with acid (14 mg, 0.030 mmol, 1equiv), PS-Carbodiimide (49 mg, 0.061 mmol, 2 equiv),1-hydroxybenzotriazole (4.0 mg, 0.030 mmol, 1 equiv) and4-trifluoromethylbenzylamine (0.004 mL, 0.027 mmol, 0.9 equiv) indichloromethane (1 mL) and dimethylformamide (0.1 mL). The suspensionwas irradiated in a Biotage Emrys Optimizer microwave reactor (250 W) at100° C. for 10 min. After cooling to room temperature the reactionmixture was filtered through an SPE-cartridge (pre-packed with 500 mgsilica-bound carbonate and preconditioned with 2 mL of CH₂Cl₂) andwashed with dichloromethane (2 mL). The dichloromethane washes werediscarded. The cartridge was further washed with methanol (3×2 mL) andthe eluents were collected via gravity filtration in a scintillationvial. Evaporation of all volatile components in a centrifugal vacuumevaporator (Genevac HT-4) provided the desired product (0.078 g, 42%).

Preparation of (DHK2120 Precursor):

Preparation of Ethyl1-((2S)-2-(tert-Butoxycarbonylamino)-3-(4-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)phenyl)propanoyl)piperidine-4-carboxylate(143)

To a stirring slurry of commercially available amine (10 g, 35.5 mmol)in DMF (250 mL) was added, sequentially, EDC (13.6 g, 71.1 mmol), HOBt(9.6 g, 71.1 mmol), NaHCO₃ (10 g, 118.5 mmol), and ethylpiperidine-4-carboxylate (3.72 g, 23.7 mmol). The mixture was stirred at23° C. overnight. The reaction mixture was then poured into water,extracted 3×EtOAc, and the combined organic extracts were then washed1×H₂O, 1× brine, and dried over MgSO₄. Solvents were removed in vacuoand the crude residue purified by flash chromatography on silica gelusing hexanes/ethyl acetate on a Biotage purification system yieldingthe amide 142 as a colorless, viscous oil. The amide 142 (9.96 g, 23.7mmol) was then dissolved in DMF (80 mL) and K₂CO₃ (6.6 g, 47.4 mmol) wasadded followed by 2-(2-bromoethoxy)tetrahydro-2H-pyran (7.16 mL, 47.4mmol). The mixture was heated to 60° C. and left to stir overnight. Thereaction mixture was then poured into water, extracted 3×EtOAc, and thecombined organic extracts were washed 1×H₂O, 1× brine, and dried overMgSO₄. Solvents were removed in vacuo and the crude residue purified byflash chromatography on silica gel using hexanes/ethyl acetate on aBiotage purification system yielding the amide 143 as a colorless,viscous oil (8.8 g, 68%).

Preparation of (S)-Ethyl1-(2-azido-3-(4-(2-hydroxyethoxy)phenyl)propanoyl)piperidine-4-carboxylate(144)

To a stirring solution of the amide 143 (8.8 g, 16 mmol) in dioxane (20mL) at 23° C. was added a solution of 4 M HCl in dioxane (320 mL). Themixture was stirred for 9 h and concentrated in vacuo to afford a crude,clear, viscous pale-yellow oil. A slurry of NaN₃ (1.56 g, 24 mmol) inpyridine (25 mL) was then cooled to 0° C. and trifluoromethanesulfonicanhydride (4 mL, 24 mmol) was added dropwise before allowing the mixtureto warm to 23° C. and stir for 3 h. A solution of the aminehydrochloride (6.4 g, 16 mmol) in H₂O (11 mL) was then added followed byCuSO₄.5H₂O (600 mg, 2.4 mmol). The combined mixture was allowed to stirat 23° C. overnight. An aqueous saturated solution of NaHCO₃ was thenadded and the organic layer was extracted 3×EtOAc. The combined organicextracts were washed 1×10% CuSO₄, 2×1 M HCl, 1× brine, and dried overMgSO₄. Solvents were removed in vacuo and the crude residue purified byflash chromatography on silica gel using hexanes/ethyl acetate on aBiotage purification system yielding the azide 144 as a colorless,viscous oil (3.3 g, 53%).

Preparation of (S)-Ethyl1-(2-azido-3-(4-(2-(tosyloxy)ethoxy)phenyl)propanoyl)piperidine-4-carboxylate(145)

To a stirring solution of the alcohol 144 (650 mg, 1.67 mmol) in DCM (17mL) cooled to 0° C. was added triethylamine (0.7 mL, 5 mmol) followed byp-toluenesulfonic anhydride (1.09 g, 3.34 mmol). The mixture was stirredat 0° C. for 20 min and the solvents were removed in vacuo. The cruderesidue was purified by flash chromatography on silica gel usinghexanes/ethyl acetate on a Biotage purification system yielding thetosylate 145 as a colorless, viscous oil (807 mg, 89%).

Preparation of (S)-Ethyl1-(2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-3-(4-(2-(tosyloxy)ethoxy)phenyl)propanoyl)piperidine-4-carboxylate(DHK2-120 precursor)

To a stirring solution ofN-(bis(4-methoxyphenyl)(phenyl)methyl)-6-(prop-2-ynyloxy)benzo[d]thiazole-2-sulfonamide(91 mg, 0.159 mmol) and the tosylate 145 (87 mg, 0.159 mmol) in THF (1mL) was added copper(I) iodide (3 mg, 0.0159 mmol) thendiisopropylethylamine (30 μL, 0.175 mmol). The mixture was allowed tostir for 2 h at 23° C. then concentrated in vacuo and the crude residuepurified by flash chromatography on silica gel using hexanes/ethylacetate on a Biotage purification system yielding the desired product asa white, crystalline solid (145 mg, 82%).

Example 6 Preparation of (S)-Methyl2-((S)-2-(4-((2-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(tert-butoxycarbonyl)-3-(4-(2-(tosyloxy)ethoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(DHK2-134 precursor)

Preparation of (2S)-Methyl2-42S)-2-(tert-butoxycarbonylamino)-3-(4-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(147)

To a stirring slurry of commercially available 145 (5.9 g, 21.2 mmol) inDMF (140 mL) was added, sequentially, EDC (8.1 g, 42.3 mmol), HOBt (5.7g, 42.3 mmol), NaHCO₃ (5.92 g, 70.5 mmol), and (S)-methyl2-amino-3-(4-(trifluoromethyl)phenyl)propanoate (3.5 g, 14.1 mmol). Themixture was stirred at 23° C. overnight. The reaction mixture was thenpoured into water, extracted 3×EtOAc, and the combined organic extractswere then washed 1×H₂O, 1×brine, and dried over MgSO₄. Solvents wereremoved in vacuo and the crude residue purified by flash chromatographyon silica gel using hexanes/ethyl acetate on a Biotage purificationsystem yielding the amide 146 as a colorless, viscous oil. The amide 146(7.19 g, 21.2 mmol) was then dissolved in DMF (50 mL) and K₂CO₃ (3.89 g,28.2 mmol) was added followed by 2-(2-bromoethoxy)tetrahydro-2H-pyran(4.26 mL, 28.2 mmol). The mixture was heated to 60° C. and left to stirovernight. The reaction mixture was then poured into water, extracted3×EtOAc, and the combined organic extracts were washed 1×H₂O, 1× brine,and dried over MgSO₄. Solvents were removed in vacuo and the cruderesidue purified by flash chromatography on silica gel usinghexanes/ethyl acetate on a Biotage purification system yielding theamide 147 as a pale yellow, viscous oil (5.5 g, 61%).

Preparation of (S)-Methyl2-((S)-2-azido-3-(4-(2-hydroxyethoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(149)

To a stirring solution of the amide 147 (5.5 g, 8.6 mmol) in dioxane (20mL) at 23° C. was added a solution of 4 M HCl in dioxane (172 mL). Themixture was stirred for 4 h and concentrated in vacuo to afford crude,clear, viscous pale-yellow oil. A slurry of NaN₃ (839 mg, 12.9 mmol) inpyridine (13 mL) was then cooled to 0° C. and trifluoromethanesulfonicanhydride (2.17 mL, 12.9 mmol) was added dropwise before allowing themixture to warm to 23° C. and stir for 3 h. A solution of the aminehydrochloride 148 (4.22 g, 8.6 mmol) in H₂O (6 mL) was then addedfollowed by CuSO₄.5H₂O (321 mg, 1.29 mmol). The combined mixture wasallowed to stir at 23° C. overnight. An aqueous saturated solution ofNaHCO₃ was then added and the organic layer was extracted 3×EtOAc. Thecombined organic extracts were washed 1×10% CuSO₄, 2×1 M HCl, 1× brine,and dried over MgSO₄. Solvents were removed in vacuo and the cruderesidue purified by flash chromatography on silica gel usinghexanes/ethyl acetate on a Biotage purification system yielding theazide 149 as a pale yellow, viscous oil (800 mg, 20%).

Preparation of (S)-Methyl2-((S)-2-azido-3-(4-(2-(tosyloxy)ethoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(150)

To a stirring solution of the alcohol 149 (800 mg, 1.67 mmol) in DCM (17mL) cooled to 0° C. was added triethylamine (0.7 mL, 5 mmol) followed byp-toluenesulfonic anhydride (1.09 g, 3.34 mmol). The mixture was stirredat 0° C. for 20 min and the solvents were removed in vacuo. The cruderesidue was purified by flash chromatography on silica gel usinghexanes/ethyl acetate on a Biotage purification system yielding thetosylate 150 as a viscous amber oil (945 mg, 90%).

Preparation of (S)-Methyl2-((S)-2-azido-N-(tert-butoxycarbonyl)-3-(4-(2-(tosyloxy)ethoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(151)

To a stirring solution of the tosylate 150 (376 mg, 0.59 mmol) inacetonitrile (5 mL) was added di-tert-butyl dicarbonate (193 mg, 0.89mmol) followed by 4-dimethylaminopyridine (4 mg, 0.03 mmol). Thesolution was allowed to stir overnight at 23° C. Solvents were removedin vacuo and the crude residue purified by flash chromatography onsilica gel using hexanes/ethyl acetate on a Biotage purification systemyielding the Boc-protected amide 151 as a pale yellow, viscous oil (262mg, 60%).

Preparation of (S)-Methyl2-((S)-2-(4-((24N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)benzo[d]thiazol-6-yloxy)methyl)-11′-1,2,3-triazol-1-yl)-N-(tert-butoxycarbonyl)-3-(4-(2-(tosyloxy)ethoxy)phenyl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate(DHK2134 precursor)

To a stirring solution ofN-(bis(4-methoxyphenyl)(phenyl)methyl)-6-(prop-2-ynyloxy)benzo[d]thiazole-2-sulfonamide(83 mg, 0.145 mmol) and the Boc-protected amide 151 (107 mg, 0.145 mmol)in THF (0.7 mL) was added copper(I) iodide (3 mg, 0.0145 mmol) thendiisopropylethylamine (28 μL, 0.16 mmol). The mixture was allowed tostir for 2 h at 23° C. then concentrated in vacuo and the crude residuepurified by flash chromatography on silica gel using hexanes/ethylacetate on a Biotage purification system yielding the desired product asa yellow, crystalline solid (145 mg, 82%).

Preparation of(S)-2-(4-(4-(N-(bis(4-Ethoxyphenyl)(phenyl)methyl)sulfamoyl)phenyl)-1H-1,2,3-triazol-1-yl)-3-methylbutanoicacid (DHK2-97 precursor)

Aldehyde 152 (57 mg, 0.22 mmol, 1.0 equiv) in 1,2-dichlorethane (2 mL)was treated with dimethylamine (2 M solution in THF) (0.17 mL, 0.34mmol, 1.5 equiv) and the mixture was stirred at room temperature for 1h. Sodium triacetoxyborohydride (71 mg, 0.34 mmol, 1.5 equiv) and aceticacid (0.01 mL) were added and stirred for 1 h at room temperature. Thereaction mixture was diluted with 25 mL of dichloromethane, washed with2×10 mL of saturated aqueous sodium bicarbonate solution, 50 mL ofwater, dried over sodium sulphate and evaporated under vacuo to yieldthe amine 153 (60 mg, 95%). Amine 153 (0.86 g, 3.0 mmol, I equiv) inethanol (50 mL) was treated with hydrazine hydrate (0.40 mL, 3.6 mmol,1.2 equiv) and the mixture was heated to reflux overnight. White solidprecipitated by cooling the reaction mixture to room temperature,filtered and the solid was discarded. The filtrate was concentratedunder vacuo and purified by column chromatography over SiO₂ using agradient of 100% EtOAc to 10% MeOH/90% EtOAc mixture to give1-(5-(aminomethyl)furan-2-yl)-N,N-dimethylmethanamine 154 (0.17 g, 37%).

A 5 mL microwave tube was charged with acid 6 (62 mg, 0.099 mmol, 1equiv), PS-Carbodiimide (0.16 g, 0.20 mmol, 2 equiv),1-hydroxybenzotriazole (13 mg, 0.098 mmol, 0.99 equiv) and1-(5-(aminomethyl)furan-2-yl)-N,N-dimethylmethanamine 154 (15 mg, 0.097mmol, 0.98 equiv) in dichloromethane (3 mL). The suspension wasirradiated in an Emrys Optimizer microwave reactor (250 W) at 60° C. for5 min. After cooling to room temperature the reaction mixture wasfiltered through an SPE-cartridge (prepacked with 500 mg silica-boundcarbonate and preconditioned with 2 mL of CH₂Cl₂) and washed withdichloromethane (2 mL). The dichloromethane washes were discarded. Thecartridge was again washed with methanol (3×2 mL) and the eluants werecollected via gravity filtration in a scintillation vial. Evaporation ofall volatile components in a centrifugal vacuum evaporator (GenevacHT-4) provided the desired product(S)-2-(4-(4-(N-(bis(4-methoxyphenyl)(phenyl)methyl)sulfamoyl)phenyl)-1H-1,2,3-triazol-1-yl)-3-methylbutanoicacid, DHK297 precursor (60 mg, 80%).

Preparation of(S)-2-Fluoro-N,N-dimethyl-N-((5-((3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamido)methyl)furan-2-yl)methyl)ethanaminium4-methylbenzenesulfonate (DHK2-97)

DHK297 precursor (25 mg, 0.033 mmol, 1 equiv) in THF (5 mL) was treatedwith 2-fluoroethyl 4-methylbenzenesulfonate (7.3 mg, 0.033 mmol, 1.02equiv) and stirred overnight at 75° C. Solvents were removed undervacuum and the resulting residue was washed with diethyl ether (5 mL)and dried under vacuum to yield the tosylate salt protected DHK2-97 (28mg, 88%).

Protected DHK2-97 (10 mg, 0.001 mmol, 1 equiv) in THF (2 mL) was treatedwith TFA (1 mL) and stirred at room temperature for 1 h. Solvents wereevaporated under vacuum and the resulting residue was purified by HPLCto yield(S)-2-fluoro-N,N-dimethyl-N-((5-((3-methyl-2-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)butanamido)methyl)furan-2-yl)methyl)ethanaminium 4-methylbenzenesulfonate, DHK297 (5 mg,72%).

General Procedure for Radiolabeling of Compound:

Preparation of Dry, Activated [F-18]Fluoride using K222/K1CO3

Oxygen-18 water was irradiated using 11 MeV protons (RDS-111 Eclipse,Siemens Molecular Imaging) to generate [¹⁸F]fluoride ion in the usualway. At the end of the bombardment, the [¹⁸O] water containing[¹⁸F]fluoride ion was transferred from the tantalum target to anautomated nucleophilic fluorination module (explora RN, SiemensBiomarker Solutions). Under computer control, the[¹⁸O]water/[¹⁸F]fluoride ion solution was transferred to a small anionexchange resin column (Chromafix 45-PS-HCO₃, Machery-Nagel) which hadpreviously been rinsed with water (10 mL). The [¹⁸O]water (1.8 mL) wasrecovered for subsequent purification and reuse. The trapped[¹⁸F]fluoride ion was eluted into the reaction vessel with a solution ofpotassium carbonate (3.0 mg) in water (0.4 mL). A solution of Kryptofix222 (20 mg) in acetonitrile (1.0 mL) was added, and the mixture washeated (70 to 95° C.) under vacuum and a stream of argon to evaporatethe acetonitrile and water.

Preparation of Dry, Activated [F-18]Fluoride Using Tetra-N-ButylAmmonium Bicarbonate:

Oxygen-18 water was irradiated using 11 MeV protons (RDS-111 Eclipse,Siemens Molecular Imaging) to generate [¹⁸F]fluoride ion in the usualway. At the end of the bombardment, the [¹⁸O] water containing[¹⁸F]fluoride ion was transferred from the tantalum target to anautomated nucleophilic fluorination module (explora RN, SiemensBiomarker Solutions). Under computer control, the[¹⁸O]water/[¹⁸F]fluoride ion solution was transferred to a small anionexchange resin column (Chromafix 45-PS-HCO₃, Machery-Nagel) which hadpreviously been rinsed with water (5 mL). The [¹⁸O]water (1.8 mL) wasrecovered for subsequent purification and reuse. The trapped[¹⁸F]fluoride ion was eluted into the reaction vessel with a solution oftetra-N-butyl ammonium bicarbonate (14 mg) in water (0.4 mL). A solutionof acetonitrile (1.0 mL) was added, and the mixture was heated (70 to95° C.) under vacuum and a stream of argon to evaporate the acetonitrileand water.

General Two-Pot Procedure for Radiolabelling of CA-IX Compounds:

After cooling, to the residue of “dry” reactive [¹⁸F]-fluoride ion wasadded a solution of the appropriate precursor (15±5 mg) in anhydrousMeCN (1 mL) was then added to the reaction vessel of the Explora RNsynthesis module and the reaction was heated at 95±5° C. for 5 min. Thereaction was then cooled to 35° C. and diluted with HPLC solvent (1.5mL). The mixture was passed through an alumina-light sep-pak and thenpurified directly by semi-preparative HPLC (column: 10.0 mm×250.0 mmPhenomenex Gemini, mobile phase: 60% MeCN (+0.05% v/v TFA): 40% water(+0.05% v/v TFA), flow rate=5 mL/min) and the fraction corresponding tothe protected intermediate was collected. Collection began when the peakreached 10 counts on the γ-detector chart recorder and stopped when thesignal dropped below 10 counts.

To the collected HPLC fraction was then added LiOH (2M, 0.25 mL) and thereaction was allowed was maintained at rt for 30 min. After this time,HCl (6M-12M, 1.0±0.1 mL) was added and the reaction was heated to 100°C. for 10 min. The reaction was then cooled and subsequently purified bysemi-preparative HPLC (Column: 10.0 mm×250.0 mm Phenomenex Gemini, Flowrate=5 mL/min)

Preparation of ¹⁸F-VM2133:

Mobile phase: Gradient 5% MeCN (+0.05% v/v TFA): 95% water (+0.05% v/vTFA)-95% MeCN (+0.05% v/v TFA): 5% water (+0.05% v/v TFA) over 30 min;Yield: 4.0-112 mCi (n=9); Radiochemical Purity: >99%; Specific Activity:20-36 Ci/μmol.

Preparation of ¹⁸F-VM391:

Mobile phase: Gradient 5% MeCN (+0.05% v/v TFA): 95% water (+0.05% v/vTFA)-95% MeCN (+0.05% v/v TFA): 5% water (+0.05% v/v TFA) over 30 min;Yield: 4.0-10.4 mCi (n=9); Radiochemical Purity: >99%; SpecificActivity: Not determined.

Preparation of ¹⁸F-VM4037:

Mobile phase: 38% MeCN (+0.05% v/v TFA): 62% water (+0.05% v/v TFA);Yield: 1.3-193 mCi (n=16); Radiochemical Purity: >99%; SpecificActivity: 1.8-8.2 Ci/μmol

Preparation of ¹⁸F-VM4047:

Mobile phase: 30% MeCN (+0.05% v/v TFA): 70% water (+0.05% v/v TFA);Yield: 1.0-14.7 mCi (n=9); Radiochemical Purity: >99%; SpecificActivity: 1.8-2.8 Ci/μmol.

Preparation of ¹⁸F-DHK-2134:

Mobile phase: 45% MeCN (+0.05% v/v TFA): 55% water (+0.05% v/v TFA);Yield: 2.75 mCi (n=1); Radiochemical Purity: >99%; Specific Activity:Not determined.

General Procedure for Reformulation of Radiolabelled Compounds into 10%ethanol: 90% Sterile Water Formulations Suitable for Injection:

The HPLC fraction corresponding to the radiolabelled compound wascollected, diluted into sterile water (40 mL) and this was passedthrough a C-18 sep-pak. Compound remained bound to the sep-pak whilstresidual HPLC solvent was washed away and the sep-pak was then washedwith further sterile water (10 mL). The radiolabelled compound was theneluted with USP ethanol (1.0 mL) and diluted with sterile water (9 mL).Alternatively, the product is eluted with 60% EtOH:Water (1.0 mL) anddiluted with sterile water (5 mL). This provided radiolabelled compoundformulated in either 5 or 10 mL of 10% ethanol.

Activity was recorded using the hot-cell dose calibrator and then QCanalysis was performed immediately (Chemical and radiochemical puritywere determined by analytical HPLC: Column: 4.6 mm×150.0 mm PhenomenexGemini; Mobile phase: Gradient 5% MeCN (+0.05% v/v TFA): 95% water(+0.05% v/v TFA)-95% MeCN (+0.05% v/v TFA): 5% water (+0.05% v/v TFA)over 30 min; Flow rate=1 mL/min).

Procedures for Preparation of Other Radiolabelled CA-IX Biomarkers:

Typical One-Pot Labelling Procedure

Preparation of VM3147 and VM241

[18F]Fluoride was prepared using TBAB according to the typical proceduredescribed above. After cooling, a solution of the appropriate precursor(15±5 mg) in anhydrous MeCN (1 mL) was added to the residue of “dry”reactive [¹⁸F]-fluoride ion in the reaction vessel of the Explora RNsynthesis module and the reaction was heated at 95±5° C. for 5 min. Thereaction was then cooled to room temperature, LiOH (2M, 0.25 mL) wasadded and the reaction was maintained at rt for 30 min. After this time,HCl (6M, 0.3±0.01 mL) was added and the reaction was heated to 100° C.for 10 min. The reaction was then cooled and subsequently purified bysemi-preparative HPLC (Column: 10.0 mm×250.0 mm Phenomenex Gemini,Mobile phase: Gradient 5% MeCN (+0.05% v/v TFA): 95% water (+0.05% v/vTFA)-95% MeCN (+0.05% v/v TFA): 5% water (+0.05% v/v TFA) over 30 min,Flow rate=5 mL/min). The collected HPLC fraction was then reformulatedinto a 10% EtOH formulation suitable for injection using the generalprocedure described above.

Preparation of ¹⁸F-VM3147:

Yield: 58 mCi from 933 mCi fluoride; Radiochemical Purity: >99%;Specific Activity: Not determined.

Preparation of ¹⁸F-VM241:

Yield: 33 mCi from 1000 mCi fluoride; Radiochemical Purity: >90%;Specific Activity: Not determined.

Radiolabelling via “Click” Chemistry

General Procedure for Preparation of [18F]Fluoropentyne

[18F]Fluoride was prepared using K₂CO₃ and Kryptofix-2.2.2 according tothe typical procedure described above. After cooling, a solution oftosyl pentyne (20±2.5 mg) in anhydrous MeCN (0.8 mL) was then added tothe residue of “dry” reactive [¹⁸F]-fluoride ion in the reaction vesselof the Explora RN synthesis module and the reaction was heated at 110±5°C. for 3 min. After this time, the crude material was purified bydistillation and pure [18F]fluoropentyne was isolated in a solution ofMeCN and collected in a cold-trap at −78° C. (dry-ice/acetone).

VM3135 by “Click” Chemistry

The solution of [18F]fluoropentyne was warmed up to room temperature andto this was added a mixture of sodium ascorbate (40 mg),tris-(benzyltriazolylmethyl)amine (TBTA ligand, 25 mg), copper(II)sulfate (1M aqueous solution, 0.25 mL) and VM3135 precursor (3 mg) inDMF (0.35 mL): H₂O (0.2 mL): MeCN (0.1 mL): and the mixture was left atrt for 45 min with occasional agitation. After this the reaction wasdiluted with water (2 mL) and purified by semi-preparative HPLC (column:10.0 mm×250.0 mm Phenomenex Luna C18, mobile phase: Gradient 5% MeCN(+0.05% v/v TFA): 95% water (+0.05% v/v TFA)-95% MeCN (+0.05% v/v TFA):5% water (+0.05% v/v TFA) over 30 min; Flow rate=1 mL/min) and thefraction corresponding to the protected intermediate was collected.Collection began when the peak reached 10 counts on the γ-detector chartrecorder and stopped when the signal dropped below 10 counts. Thecollected HPLC fraction was then reformulated into a 10% EtOHformulation suitable for injection using the general procedure describedabove.

Yield 73 mCi from 560 mCi fluoride; Radiochemical Purity: >95%; SpecificActivity: Not determined.

BW2-13 by “Click” Chemistry

The solution of [18F]fluoropentyne was warmed up to room temperature andto this was added a mixture of sodium ascorbate (29 mg), ammonia (0.7 Min MeOH, 0.1 mL), copper(1) acetate (1.5 mg) and BW2-13 precursor (2 mg)in DMF (0.2 mL): H₂O (0.25 mL): MeCN (0.25 mL). and the mixture was leftat rt for 30 min with occasional agitation. After this the reaction wasdiluted with water (2 mL) and purified by semi-preparative HPLC (column:10.0 mm×250.0 mm Phenomenex Luna-C18, mobile phase: Gradient 5% MeCN(+0.05% v/v TFA): 95% water (+0.05% v/v TFA)-95% MeCN (+0.05% v/v TFA):5% water (+0.05% v/v TFA) over 30 min; Flow rate=1 mL/min) and thefraction corresponding to the protected intermediate was collected.Collection began when the peak reached 10 counts on the γ-detector chartrecorder and stopped when the signal dropped below 10 counts. Thecollected HPLC fraction was then reformulated into a 10% EtOHformulation suitable for injection using the general procedure describedabove.

Yield 18.4 mCi; Radiochemical Purity: Not determined; Specific Activity:Not determined.

Typical [18F]-Fluoroethyltosylate Labelling Procedure

[18F]Fluoride was prepared using K₂CO₃ and Kryptofix-2.2.2 according tothe typical procedure described above. After cooling, a solution ofethylene ditosylate (9±1 mg) in anhydrous MeCN (0.9 mL) was added to theresidue of “dry” reactive [¹⁸F]-fluoride ion in the reaction vessel ofthe Explora RN synthesis module and the reaction was heated at 115±5° C.for 10 min. The reaction was then cooled to room temperature, andpurified by semi-preparative HPLC (column: 10.0 mm×250.0 mm PhenomenexACE-C18, mobile phase: 50% MeCN: 50% aqueous ammonium formate; Flowrate=5 mL/min).

The HPLC fraction corresponding to [18F]fluoroethyl tosylate wascollected, diluted into sterile water (15 mL) and this was passedthrough a Phenomonex Strata-X 33 μm polymeric reverse-phase sep-pak.Compound remained bound to the sep-pak whilst residual HPLC solvent waswashed away and the sep-pak was then washed with further sterile water(10 mL). [18F]fluoroethyl tosylate was then eluted off the sep-pak withDMSO (0.5 mL).

Preparation of DHK97

[18F]fluoroethyl tosylate was prepared as described above and eluted offwith DMSO (0.5 mL) into a vial charged with DHK97 precursor (8±2 mg) inMeCN (0.8 mL). The reaction was heated at 100° C. for 10 min. After thistime, HCl (1M, 0.9±0.1 mL) was added and the reaction was heated to 100°C. for 10 min. The reaction was then cooled, neutralized with sodiumacetate (2M, 0.45±0.05 mL) and subsequently purified by semi-preparativeHPLC (Column: 10.0 mm×250.0 mm Phenomenex Luna-C18, Mobile phase:Gradient 5% MeCN (+0.05% v/v TFA): 95% water (+0.05% v/v TFA)-95% MeCN(+0.05% v/v TFA): 5% water (+0.05% v/v TFA) over 30 min, Flow rate=5mL/min). The collected HPLC fraction was then reformulated into a 10%EtOH formulation suitable for injection using the general proceduredescribed above.

Yield: 0.2-2.2 mCi (n=3); Radiochemical Purity: >99%; Specific Activity:Not determined.

TABLE 1 In Vitro Binding Assay Code Mol. (Library Entry Name ChemicalStructure Wt. Screening) Library 1

1 DHK3

443.48 x^(a) 2 DHK4

489.57 x 3 DHK5

337.40 x 4 DHK7

462.52 √ 5 DHK8

427.43 x 6 DHK11

449.47 x 7 DHK12

427.52 x 8 DHK14

323.41 x 9 DHK15

405.51 x 10 DHK18

393.26 x 11 DHK19

403.50 √ 12 DHK20

445.51 x 13 DHK22

386.42 x 14 DHK23

413.49 x 15 DHK24

523.01 x 16 DHK25

403.46 √ √ 17 DHK26

375.41 x 18 DHK27

354.39 x 19 DHK29

355.37 √ 20 DHK63

412.42 x 21 DHK65

382.40 x 22 DHK66

324.36 x 23 DHK67

430.43 x 24 DHK70

458.57 x 25 DHK71

385.83 x 26 DHK72

530.64 x 27 DHK73

324.40 x 28 DHK76

433.55 x 39 DHK78

412.42 x 30 DHK82

437.51 x 31 DHK101

364.40 x 32 DHK102

371.41 x 33 DHK104

428.46 x 34 DHK106

419.42 x 35 DHK107

495.38 x 36 DHK108

281.33 x 37 DHK109

473.57 x 38 DHK111

386.38 x Library 2

39 DHK33

546.62 x 40 DHK34

394.45 x 41 DHK36

519.58 x 42 DHK39

485.52 x 43 DHK40

506.53 x 44 DHK41

484.57 x 45 DHK43

380.47 x 46 DHK44

462.57 x 47 DHK45

546.64 x 48 DHK47

450.31 x 49 DHK48

460.55 x 50 DHK49

502.56 x 51 DHK50

462.57 x 52 DHK51

443.48 x 53 DHK52

470.54 x 54 DHK54

460.51 x 55 DHK55

412.43 x 56 DHK56

487.49 x 57 DHK57

500.53 x 58 DHK58

507.61 x 59 DHK59

527.64 x 60 DHK60

381.41 x 61 DHK61

532.61 x 62 DHK85

515.63 x 63 DHK86

442.88 x 64 DHK87

587.69 x 65 DHK88

381.45 x 66 DHK90

593.70 x 67 DHK91

490.60 x 68 DHK92

476.47 x 69 DHK93

469.47 x 70 DHK94

552.43 x 71 DHK95

338.39 x 72 DHK96

530.62 x 73 DHK97

494.57 x 74 DHK100

381.41 x 75 DHK110

479.59 x 76 DHK112

443.43 x Library 3

77 DHK113

576.67 √ √ 78 DHK114

424.50 x^(b) 79 DHK115

549.62 x 80 DHK116

515.57 x 81 DHK117

536.57 √ 82 DIIK118

514.62 x 83 DHK119

492.61 x 84 DHK120

576.69 x 85 DHK121

480.36 √ 86 DHK123

532.61 √ 87 DHK124

492.61 x 88 DHK125

473.53 √ 89 DHK126

500.59 x 90 DHK127

490.56 √ 91 DHK128

442.47 √ 92 DHK129

517.53 x 93 DHK130

530.58 x 94 DHK132

557.68 x 95 DHK134

562.66 x 96 DHK135

545.67 x 97 DHK136

472.93 x 98 DHK137

411.50 x 99 DHK138

623.74 x 100 DHK139

520.65 x 101 DHK140

499.52 x 102 DHK141

582.48 x 103 DHK143

560.67 x 104 DHK144

524.62 x ^(a)Inhibition% is less than 40%.

TABLE 2 In Vitro Binding Assay Code Mol. (Library Entry Name ChemicalStructure Wt. (Screening) Library 4

1 DHK165

431.48 x^(a) 2 DHK166

427.52 x 3 DHK168

481.49 x 4 DHK174

469.56 x 5 DHK175

499.58 x 6 DHK176

451.54 x 7 DHK177

409.46 x 8 DHK178

414.48 x 9 DHK179

405.51 x 10 DHK180

377.46 x 11 DHK181

381.45 x 12 DHK182

494.57 x 13 DHK183

503.57 x 14 DHK184

463.55 x 15 DHK185

436.53 x 16 DHK186

455.53 x 17 DHK187

471.53 x 18 DHK188

460.59 x 19 DHK189

467.54 x 20 DHK190

470.55 x 21 DHK191

525.67 x Library 5

22 DHK-2-1

479.53 x 23 DHK-2-2

475.56 x 24 DHK-2-3

568.71 x 25 DHK-2-4

518.59 x 26 DHK-2-5

544.65 x 27 DHK-2-6

455.53 x 28 DHK-2-7

517.60 x 29 DHK-2-8

547.63 x 30 DHK-2-9

499.58 x 31 DHK-2-10

457.50 x 32 DHK-2-11

462.52 x 33 DHK-2-12

453.56 x 34 DHK-2-13

425.50 x 35 DHK-2-14

429.49 x 36 DHK-2-15

542.61 x 37 DHK-2-16

551.61 x 38 DHK-2-17

511.59 x 39 DHK-2-18

484.57 x 40 DHK-2-19

503.57 x 41 DHK-2-20

519.57 x 42 DHK-2-21

508.64 x 43 DHK-2-22

515.59 x 44 DHK-2-23

573.71 x Library 6

45 DHK-2-24

568.59 √ √ 46 DHK-2-25

518.58 x 47 DHK-2-26

514.62 x 48 DHK-2-27

607.77 x 49 DHK-2-28

557.65 x 50 DHK-2-29

583.71 x 51 DHK-2-30

494.59 x 52 DHK-2-31

556.66 x 53 DHK-2-32

586.68 x 54 DHK-2-33

538.64 x 55 DHK-2-34

496.56 x 56 DHK-2-35

501.58 x 57 DHK-2-36

492.61 x 58 DHK-2-37

464.56 x 59 DHK-2-38

468.55 x 60 DHK-2-39

581.67 x 61 DHK-2-41

550.65 √ 62 DHK-2-42

523.63 x 63 DHK-2-43

542.63 x 64 DHK-2-44

558.63 √ 65 DHK-2-45

547.69 x 66 DHK-2-47

612.77 x 67 DHK-2-48

625.72 x Library 7

68 DHK-2-51

616.63 √ 69 DHK-2-52

566.63 x 70 DHK-2-53

562.66 x 71 DHK-2-54

655.81 x 72 DHK-2-55

605.69 x 73 DHK-2-56

631.75 x 74 DHK-2-57

542.63 x 75 DHK-2-58

604.70 x 76 DHK-2-59

634.73 x 77 DHK-2-60

586.68 x 78 DHK-2-61

544.60 √ 79 DHK-2-62

549.62 x 80 DHK-2-63

540.66 x 81 DHK-2-64

512.60 x 82 DHK-2-65

516.59 x 83 DHK-2-66

629.71 √ √ 84 DHK-2-67

638.71 x 85 DHK-2-68

598.69 √ 86 DHK-2-69

571.67 x 87 DHK-2-70

590.67 x 88 DHK-2-71

606.67 √ 89 DHK-2-72

595.74 x 90 DHK-2-73

602.69 x 91 DHK-2-74

660.81 x 92 DHK-2-75

673.76 x ^(a)Inhibition % is less than 40%.

TABLE 3 Kd (nM) Name Chemical Structure CA-IX DHK7

17 DHK19

14 DHK25

5 CLogP: 1.3936 DHK29

20 DHK113

10 DHK117

14.1 DHK121

25 DHK123

12.5 DHK125

16.7 DHK127

25 DHK128

12.5 DHK159

14.1 DHK160

20 DHK161

10 DHK2-24

1 CLogP: 3.85914 DHK2-44

5 CLogP: 3.22094 DHK2-51

2.5 DHK2-66

2 CLogP: 3.69214 DHK2-71

2.5 CLogP: 3.71094 DHK2-68

3.4 CLogP: 1.78814 DHK2-41

5 CLogP: 1.29814 VM2-36

10 VM2-41

5 CLogP: 2.74794 DHK2-84

10 DHK2-94

10 DHK2-95

25 DHK2-97

34 DHK2-118

5 CLogP: 1.95914 DHK2-120

5 CLogP: 1.58314 DHK2-127

2 DHK2-134

0.5 DHK2-130

5 DHK2-133

1.7 DHK2-119

3.4 BD2-09

17 DHK2-129

1.2 DHK2-132

0.5 DHK2-128

10 DHK2-135

5 BD2-46

34 BD2-47

20 DHK2-148

34 DHK2-147

11 DHK2-157

25 DHK2-141

34 DHK2-160- F1

10 DHK2-160- F2

5 DHK2-161

5 DHK2-173

2 DHK2-176

5 DHK2-180

14 DHK2-181

2 DHK2-187

17 BW-96

1.7 VM2-106

5 VM2-107a

10 BW-139-1A

1.7 BW-369-1B

2.5 BW-139-2C

1.2 BW-139-2D

2.5 VM2-93

10 VM2-107b

5 BW-141-1

5 BW-141-2

3.4 BD2-120

5 VM2-126

10 VM2-128B

2.5 VM2-128C

5 VM2-131

11 VM2-133

5 BW2-23

10 BW2-27

10 BW2-41

5 BW2-45

5 DHK3-48

10 VM3-91

5 CLogP: 0.99834 DHK3-158

14 (QPlogPo/w): −3.83 DHK3-155

11 (QPlogPo/w): −5.14 DHK3-154

25 (QPlogPo/w): −0.47 DHK3-156

10 CLogP: −3.36606 DHK3-149

10 (QPlogPo/w): −2.35 VM3-163

10 (QPlogPo/w): −4.13 VM3-165A/B

5/11 (QPlogPo/w): 0.95 VM3-167A/B

5/10 (QPlogPo/w): 1.69 BD3-36

14 CLogP: 3.16314 VM4009

5 CLogP: 0.80194 VM4021

3.3 CLogP: 2.03894 VM4047a

5 CLogP: 2.22094 VM4047b

11 CLogP: 2.22094 VM4037a

1.3 CLogP: 3.16394 VM4037b

5 CLogP: 3.16394 UG3150

3.3 CLogP: 1.92694 VM4041

5 CLogP: 0.983939 WZ01101

14 CLogP: 3.16394 GGC121A

11 CLogP: 1.92694 GGC121B

13 CLogP: 0.983939

1. A compound consisting of the Formula Ia or Ib:

wherein for Ia and Ib: each G is independently a bond or isindependently selected from the group consisting of cycloalkyl,aryl-CH(Y)—, heterocyclyl, aryl and heteroaryl, wherein said cycloalkyl,aryl-CH(Y)—, heterocyclyl, aryl and heteroaryl are substituted orunsubstituted; n is 0, 1, 2 or 3; X is a bond, or is selected from thegroup consisting of —O—, —S—, —S(O)—, —S(O)₂—, —NR^(o)— where R^(o) isH, C₁₋₅alkyl or CH₂CO₂R″ wherein R″═H or C₁-C₃-alkyl;—NR^(o)—C(O)—CH(R)— where R^(o) is H or C₁₋₅alkyl; heterocyclyl, aryl,heteroaryl, C₁₋₆alkyl and C₁₋₆alkyl wherein 1 or 2 carbon atoms of theC₁₋₆alkyl is replaced by a —O—, —C(O)—, —S—, —S(O)—, —S(O)₂— or —NR′″—where R′″ is H or C₁₋₅alkyl, and where the C₁₋₆alkyl is optionallysubstituted with 1 or 2 substituents selected from the group consistingof —OH, —SH, NH₂, heterocyclyl, aryl and heteroaryl; X′ is selected fromthe group consisting of a quaternary ammonium salt, imidate salt,thiolate salt, oxonium cation, boron-amine salt, pyridinium salt, —SO₂H,—SO₃H, —PO₃H, —OPO₃H, N-oxide, —B(OH)₂, —OH, amino, halo, —CF₃, —CH₂F,—CHF₂, —COOH, —COOC₁₋₅alkyl, —COC₁₋₅alkyl, —CO-aryl, —CO-heteroaryl,C₁₋₆alkyl, amino-C₁₋₅alkyl-, optionally substituted aryl, optionallysubstituted heteroaryl, halo-C₁₋₅alkyl, halo-C₁₋₅alkoxy; Z′—C₁₋₆alkyl,Z′—C₂₋₆alkyl-O—, Z′-C₂₋₆alkyl-O-C₁₋₃alkyl-, Z′—C₂₋₆alkyl-S—,Z′—C₂₋₆alkyl-NH—, Z′—C₂₋₆alkyl-NH—C₁₋₃alkyl-,Z′—C₂₋₆alkyl-N(C₁₋₃alkyl)-C₁₋₃alkyl-, Z′—(CH₂CH₂—O)₁₋₅—, wherein Z′ isselected from the group consisting of halo, —CF₃, —CH₂F, —CHF₂, aryl,substituted aryl, heteroaryl, and substituted heteroaryl; Y is H or isselected from the group consisting of a quaternary ammonium salt,imidate salt, thiolate salt, oxonium cation, boron-amine salt,pyridinium salt, —SO₂H, N-oxide, —B(OH)₂, —COOR″, —SO₃R″, —P(O)₂OR″ and—OP(O)₂OR″ wherein R″ is H or C₁₋₃alkyl; R is H or a side chain of anencoded amino acid, halobenzyl, —C₁₋₅alkyl-OR″-C₁₋₅alkyl-N(R″)₂,—C₁₋₅alkyl-NR″C(O)—(CH₂CH₂O)_(m)—C₁-C₅-alkyl-CO₂R″ wherein m is 0-8,—C₁₋₅alkyl-NR″C(O)—C₁-C₅-alkyl-X′ wherein said —C₁₋₅alkyl is optionallysubstituted with OR″ or CH₂OR″, —C₁₋₅alkyl-o, m, orp-aryl-(O—CH₂CH₂)₁₋₅-halo wherein said —(O—CH₂CH₂)₁₋₅-halo is optionallysubstituted with one or more OR″, or —C₁₋₅alkyl-o, m, orp-aryl-(CH₂CH₂)₁₋₅-halo, wherein R″═H or C₁-C₃-alkyl; and Z is —CH₂O—;wherein at least one of the group X, X′, G, X and Y optionally comprisesa radionuclide; or a pharmaceutically acceptable salt thereof,optionally in the form of a single stereoisomer or mixtures ofstereoisomers thereof.
 2. The compound of claim 1, wherein the compoundis of the Formula Ia, or a pharmaceutically acceptable salt thereof,optionally in the form of a single stereoisomer or mixtures ofstereoisomers thereof.
 3. The compound of claim 1, wherein the compoundis of the Formula Ib, or a pharmaceutically acceptable salt thereof,optionally in the form of a single stereoisomer or mixtures ofstereoisomers thereof.
 4. The compound of claim 1, wherein theradionuclide is selected from the group consisting of ¹¹C, ¹⁸F, ¹³N and¹⁵O.
 5. The compound of claim 1, wherein X′ is selected from the groupconsisting of carboxylic acids, sulfonic acids, phosphonic acid andammonium ion and their respective salts.
 6. The compound of claim 1,wherein the X′ comprises a group selected from —COOH, —SO₃H, —PO₃H,—N(C₁₋₆alkyl)₃ ⁺X⁻ wherein X⁻ is a counter anion.
 7. The compound ofclaim 1, wherein: X is a bond, or is selected from the group consistingof heterocyclyl, aryl, heteroaryl, C₁₋₆alkyl, C₁₋₆alkyl wherein 1 or 2carbon atoms of the C₁₋₆alkyl is replaced by a —O—, —C(O)—, —S—, —S(O)—,—S(O)₂— or —NR′″— where R′″ is H or C₁₋₅alkyl, —NR^(o)—C(O)—CH(R)— whereR^(o) is H or C₁₋₅alkyl, and where the C₁₋₆alkyl is optionallysubstituted with 1 or 2 substituents selected from the group consistingof —OH, —SH, NH₂, heterocyclyl, aryl and heteroaryl.
 8. The compound ofclaim 1, wherein: each G is independently a bond or is independentlyselected from the group consisting of substituted or unsubstitutedheterocyclyl, substituted or unsubstituted aryl and substituted orunsubstituted heteroaryl.
 9. The compound of claim 1, wherein: each G isindependently a bond or is independently selected from the groupconsisting of substituted or unsubstituted heterocyclyl, aryl andheteroaryl; and X′ is selected from the group consisting of a quaternaryammonium salt, imidate salt, thiolate salt, oxonium cation, boron-aminesalt, pyridinium salt, —SO₂H, —SO₃H, —PO₃H, —OPO₃H, N-oxides, —B(OH)₂,halo, —CF₃, —CH₂F, —CHF₂, —COOH, halo-C₁₋₅alkyl, halo-C₁₋₅alkoxy-;Z′—C₂₋₆alkyl, Z′—C₂₋₆alkyl-O—, Z′—C₂₋₆alkyl-S—, Z′—C₂₋₆alkyl-NH—,Z′—C₂₋₆alkyl-NH—C₁₋₃alkyl-, Z′—(CH₂₋₆alkyl-N(C₁₋₃alkyl)-C₁₋₃alkyl-,Z′(CH₂CH₂—O)₁₋₅—, wherein Z′ is selected from the group consisting ofhalo, —CF₃, —CH₂F, —CHF₂, aryl and heteroaryl.
 10. The compound of claim1, wherein: Y is H or is selected from the group consisting of aquaternary ammonium salt, imidate salt, thiolate salt, oxonium cation,boron-amine salt, pyridinium salt, —SO₂H, N-oxide, —B(OH)₂, —COOR″,—SO₃R″, —P(O)₂OR″ and —OP(O)₂OR″ wherein R″ is H or C₁₋₃alkyl; and R isH or a side chain of an encoded amino acid, —C₁₋₅alkyl-o, m, orp-aryl-(O—CH₂CH₂)₁₋₅-halo or —C₁₋₅alkyl-o, m, orp-aryl-(CH₂CH₂)₁₋₅-halo.
 11. The compound of claim 1, wherein: X′ isselected from the group consisting of a quaternary ammonium salt,imidate salt, thiolate salt, oxonium cation, boron-amine salt,pyridinium salt, —SO₂H, N-oxide, —B(OH)₂, halo, —CF₃, —CH₂F, —CHF₂,halo-C₁₋₅alkyl, halo-C₁₋₅alkoxy-; Z′—C₂₋₆alkyl, Z′—C₂₋₆alkyl-O—,Z′—C₂₋₆alkyl-S—, Z′—C₂₋₆alkyl-NH—, Z′—C₂₋₆alkyl-N(C₁₋₃alkyl)-C₁₋₃alkyl-,Z′—(CH₂CH₂—O)₁₋₅—, wherein Z′ is selected from the group consisting ofhalo, —CF₃, —CH₂F, —CHF₂, aryl and heteroaryl.
 12. The compound of claim1 of the Formula Ia:

each G is independently a bond or is independently selected from thegroup consisting of substituted or unsubstituted heterocyclyl, aryl andheteroaryl; n is 1 or 2; X is a bond, or is selected from the groupconsisting of —O—, —S—, —S(O)—, —S(O)₂—, —NR^(o)— where R^(o) is H,C₁₋₅alkyl or CH₂CO₂R″ wherein R″ H or C₁-C₃-alkyl; —NR^(o)—C(O)—CH(R)—where R^(o) is H or C₁₋₅alkyl; C₁₋₆alkyl, C₁₋₆alkyl wherein 1 or 2carbon atoms of the C₁₋₆alkyl is replaced by a —O—, —C(O)—, —S—, —S(O)—,—S(O)₂— or —NR′″— where R′″ is H or C₁₋₅alkyl, and where the C₁₋₆alkylis optionally substituted with 1 or 2 substituents selected from thegroup consisting of —OH, —SH, NH₂, heterocyclyl, aryl and heteroaryl; X′is selected from the group consisting of a quaternary ammonium salt,imidate salt thiolate salt, oxonium cation, boron-amine salt, pyridiniumsalt, —SO H, N-oxide, —B(OH)₇, —OH, amino, halo, —CF₃, —CH₂F, —CHF₂,—COOH, —COOC₁₋₅alkyl, —COC₁₋₅alkyl, —CO-aryl, —CO-heteroaryl, C₁₋₆alkyl,amino-C₁₋₅alkyl-, optionally substituted aryl, optionally substitutedheteroaryl, halo-C₁₋₅alkyl, halo-C₁₋₅alkoxy; Z′—C₁₋₆alkyl,Z′—C₂₋₆alkyl-O—, Z′—C₂₋₆alkyl-S—, Z′—C₂₋₆alkyl-NH—C₁₋₃alkyl-,Z′—C₂₋₆alkyl-N(C₁₋₃alkyl)-C₁₋₃alkyl-, Z′—(CH₂CH₂—O)₁₋₅—, wherein Z′ isselected from the group consisting of halo, —CF₃, —CH₂F, —CHF₂, aryl,substituted aryl, heteroaryl, and substituted heteroaryl; Y is H or isselected from the group consisting of a quaternary ammonium salt,imidate salt, thiolate salt, oxonium cation, boron-amine salt,pyridinium salt, —SO₂H, N-oxide, —B(OH)₂, —COOR″, —SO₃R″, —P(O)₂OR″ and—OP(O)₂OR″ wherein R″ is H or C₁₋₃alkyl; and R is H or a side chain ofan encoded amino acid, halobenzyl, —C₁₋₅alkyl-OR″, —C₁₋₅alkyl-N(R″)₂,—C₁₋₅alkyl-NR″C(O)—(CH₂CH₂O)_(m)—C₁-C₅-alkyl-CO₂R″ wherein in is 0-8,—C₁₋₅alkyl-, NR″C(O)—C₁-C₅-alkyl-X′ wherein said —C₁₋₅alkyl isoptionally substituted with OR″ or CH₂OR″, —C₁₋₅alkyl-o, m, orp-aryl-(O—CH₂CH₂)₁₋₅-halo wherein said —(O—CH₂CH₂)₁₋₅-halo is optionallysubstituted with one or more OR″, or —C₁₋₅alkyl-o, m, orp-aryl-(CH₂CH₂)₁₋₅-halo, wherein R″═H or C₁-C₃-alkyl.
 13. The compoundof claim 1 of the Formula Ia:

wherein: G is selected from the group consisting of heterocyclyl, aryland heteroaryl; n is 1 or 2; X′ is selected from the group consisting ofa quaternary ammonium salt, imidate salt, thiolate salt, oxonium cation,boron-amine salt, pyridinium salt, —SO₂H, N-oxide, —B(OH)₂, —OH, amino,halo, —CF₃, —CH₂F, —CHF₂, —COOH, —COOC₁₋₅alkyl, —COC₁₋₅alkyl, —CO-aryl,—CO-heteroaryl, C₁₋₆alkyl, amino-C₁₋₅alkyl-, optionally substitutedaryl, optionally substituted heteroaryl, halo-C₁₋₅alkyl,halo-C₁₋₅alkoxy-; Z′—C₁₋₆alkyl, Z′—C₂₋₆alkyl-O—, Z′—C₂₋₆alkyl-S—,Z′—C₂₋₆alkyl-NH—, Z′—C₂₋₆alkyl-NH—C₁₋₃alkyl-,Z′—C₂₋₆alkyl-N(C₁₋₃alkyl)-C₁₋₃alkyl, Z′—(CH₂CH₂—O)₁₋₅—, wherein Z′ isselected from the group consisting of halo, —CF₃, —CH₂F, —CHF₂, aryl,substituted aryl, heteroaryl, and substituted heteroaryl; Y is H or isselected from the group consisting of a quaternary ammonium salt,imidate salt, thiolate salt, oxonium cation, boron-amine salt,pyridinium salt, —SO₂H, N-oxide, —B(OH)₂, —COOR″, —SO₃R″, —P(O)₂OR″ and—OP(O)₂OR″ wherein R″ is H or C₁₋₃alkyl; and R is H or a side chain ofan encoded amino acid, halobenzyl, —C₁₋₅alkyl-OR″, —C₁₋₅alkyl-N(R″)₂,—C₁₋₅alkyl-NR″C(O)—(CH₂CH₂O)_(m)—C₁-C₅-alkyl-CO₂R″ wherein m is 0-8,—C₁₋₅alkyl-NR″C(O)—C₁-C₅-alkyl-X′ wherein said —C₁₋₅alkyl is optionallysubstituted with OR″ or CH₂OR″, —C₁₋₅alkyl-o, m, orp-aryl-(O—CH₂CH₂)₁₋₅-halo wherein said —(O—CH₂CH₂)₁₋₅-halo is optionallysubstituted with one or more OR″, or —C₁₋₅alkyl-o, m, orp-aryl-(CH₂CH₂)₁₋₅-halo, wherein R″═H or C₁-C₃-alkyl.
 14. The compoundof claim 13, wherein: G is selected from the group consisting of aheterocyclyl, aryl and heteroaryl; n is 1 or 2; X′ is selected from thegroup consisting of a quaternary ammonium salt, imidate salt thiolatesalt oxonium cation boron-amine salt, pyridinium salt, —SO₂H, N-oxide,—B(OH)₂, —OH, amino, halo, —COOH, amino-C₁₋₅alkyl-, halo-C₁₋₅alkyl,halo-C₁₋₅alkoxy-; Z′—C₁₋₆alkyl, Z′—C₂₋₆alkyl-O—, Z′—C₂₋₆alkyl-NH—,Z′—C₂₋₆alkyl-NH—C₁₋₃alkyl-, Z′—C₂₋₆alkyl-N(C₁₋₃alkyl)-C₁₋₃alkyl-,Z′—(CH₂CH₂—O)₁₋₅—, wherein Z′ is selected from the group consisting ofhalo, —CF₃, —CH₂F, —CHF₂; Y is selected from the group consisting of aquaternary ammonium salt, imidate salt, thiolate salt, oxonium cation,boron-amine salt, pyridinium salt, —SO₂H, N-oxide, —B(OH)₂, —COOR″,—SO₃R″, —P(O)₂OR″ and —OP(O)₂OR″ wherein R″ is H or C₁₋₃alkyl; and R isH or a side chain of an encoded amino acid.
 15. The compound of claim 1,wherein the compound is:(R)-2-((S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid;(2S)-2-((2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid;(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethoxy)benzyl)propanamide;(S)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(1H-indol-3-yl)propanoicacid;(S)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(3-(trifluoromethyl)phenyl)propanoicacid;(S)-3-(4-cyanophenyl)-2-(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)propanoicacid; (S)-methyl3-(3-(2-fluoroethoxy)benzylthio)-2-(S)-4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;(R)-3-(3-(2-fluoroethoxy)benzylthio)-2-(R)-4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid;(R)-3-(3-(2-fluoroethoxy)benzylthio)-2-(S)-4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid;(S)-2-(S)-3-(4-(((4S,5R)-5-(fluoromethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid;(S)-2-((R)-3-(4-(((4S,5R)-5-(fluoromethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid;3-(3-(2-fluoroethoxy)benzylthio)-2-(4-hydroxy-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid;(S)-2-(S)-3-(4-((2S,3R)-4-fluoro-2,3-dihydroxybutoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid;(S)-2-((R)-3-(4-((2S,3R)-4-fluoro-2,3-dihydroxybutoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid;(2R)-3-(3-((1-(1-fluoro-3-hydroxypropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid;(2R)-3-(3-(2-fluoroethoxy)benzylsulfinyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid;(S)-3-(3-(2-fluoroethoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)meth1-1H-1,2,3-triazol-1-yl)acetamido)propanoic acid;(2S)-3-(3-(3-fluoro-2-hydroxypropoxy)benzyloxy)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid;(2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid;(2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid;(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid;(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid;(S)-3-(4-(2-fluoroethoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid;(2S)-3-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoicacid;(2S)-3-(4-(1-fluoro-3-hydroxypropan-2-yloxy)phenyl)-2-(S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid; and(2S)-3-(4-(1-fluoro-3-hydroxypropan-2-yloxy)phenyl)-2-(R)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoicacid.
 16. The compound of claim 1, wherein the compound is: (R)-Methyl3-(benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoate;(R)-3-(3-(2-Fluoroethoxy)benzylthio)-2-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)propanoic(2S)—N-((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)-Methyl2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-(4-(trifluoromethyl)phenyl)propanoate;(S)-Methyl3-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-(4-(trifluoromethyl)phenyl)propanoate;(S)-3-(S)-3-Methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid;(S)-3-Phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)propanamide;(S)—N-((5-Methyl-3-phenylisoxazol-4-yl)methyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)-Ethyl1-(3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoyl)piperidine-4-carboxylate;(2S)—N((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)-Ethyl1-(3-(4-(2-Fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoyl)piperidine-4-carboxylate;(S)-3-(4-(2-Fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)propanamide;(S)-1-(3-(4-(2-Fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanoyl)piperidine-4-carboxylicacid; (S)-Methyl2-((S)-3-(4-(2-fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoate;(S)-2-(S)-3-Methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid; and(S)-2-(S)-3-(4-(2-Fluoroethoxy)phenyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)-3-(4-(trifluoromethyl)phenyl)propanoicacid.
 17. A compound that is:6-((1-(2-Morpholinoethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)—N-(4-Methylpridin-2-yl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;N-Morpholino-3-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)benzamide;(S)—N-Benzyl-4-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)pentanamide;6-((1-((2R)-3-Methyl-1-(3-methylpiperidin-1-yl)-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)—N-(2,5-Dimethylbenzyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)—N-Cyclohexyl-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)—N-Benzyl-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-11′-1,2,3-triazol-1-yl)butanamide;4-(3-Methoxy-3-oxo-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)benzoicacid; Propyl4-(2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)acetamido)benzoate;6-((1-(2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(R)—N-(Biphenyl-4-yl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;6-((1-(4-((1S,2R)-1,2-Dihydroxyoctyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;6-((1-(7-Chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;6-((1-(6-Hydroxyhexyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;6-((1-((1S,2S)-2-(Cinnamyloxy)-1,2-diphenylethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)-3-Methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(thiophen-3-yl)ethyl)butanamide;6-((1-(2-(2,4-Dioxo-1,2-dihydroquinazolin-3(4H)-yl)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;6-((1-(2-(4-(3,5-Dichlorophenyl)piperazin-1-yl)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(E)-6-((1-(1-(Styrylsulfonyl)piperidin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(E)-6-(1-(1-Cinnamoylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)—N-(4-Fluorobenzyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)—N-Benzyl-N,3-dimethyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)—N-(2-((5-((Dimethylamino)methyl)furan-2-yl)methylthio)ethyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)-6-((1-(3-Methyl-1-oxo-1-(4-(pyrimidin-2-yl)piperazin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)-3-Methyl-N-((5-(pyridin-2-yl)thiophen-2-yl)methyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;6-((1-((S)-1-((R)-2-(Hydroxymethyl)pyrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)-6-((1-(3-Methyl-1-oxo-1-(4-(pyridin-2-yl)piperazin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)-Ethyl2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)-3-phenylpropanoate;(S)-Ethyl3-methyl-2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)butanoate;(S)-Methyl2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;(S)-3-Methyl-N-(pyridin-2-ylmethyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)—N-Cyclohexyl-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)—N-(Cyclopropylmethyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)—N-(3-Hydroxypropyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)-3-Methyl-N-((5-methyl-3-phenylisoxazol-4-yl)methyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)-6-((1(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-3-methyl-1-oxobutan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)-6-((1-(3-Methyl-1-oxo-1-(4-(pyrrolidin-1-yl)piperidin-1-yl)butan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)—N-(2-(4-Benzylpiperazin-1-yl)ethyl)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamide;(S)-Ethyl3-(1H-indol-3-yl)-2-((S)-3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoate;(S)—N-(4-Fluorobenzyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)—N-Benzyl-N-methyl-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide:(S)—N-(245-((Dimethylamino)methyl)furan-2-yl)methylthio)ethyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)-6-((1-(1-Oxo-3-phenyl-1-(4-(pyrimidin-2-yl)piperazin-1-yl)propan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)-3-Phenyl-N-((5-(pyridin-2-yl)thiophen-2-yl)methyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;6-((1-((S)-1-(R)-2-(Hydroxymethyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)-6-((1-(1-Oxo-3-phenyl-1-(4-(pyridin-2-yl)piperazin-1-yl)propan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(R)-ethyl3-Phenyl-2-((S)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)propanoate;(S)-Ethyl3-methyl-2-((S)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamido)butanoate;(S)-3-Phenyl-N-(pyridin-2-ylmethyl)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)1H-1,2,3-triazol-1-yl)propanamide;(S)—N-Cyclohexyl-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)—N-(Cyclopropylmethyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)—N-(3-Hydroxypropyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)-6-((1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(2S)—N((2,3-Dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)-6-((1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)-6-((1-(1-(4-(2-Hydroxyethyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzo[d]thiazole-2-sulfonamide;(S)—N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-3-phenyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propanamide;(S)—N,N,N-Trimethyl-2-oxo-2-(6-oxo-5-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-6-(4-(trifluoromethyl)benzylamino)hexylamino)ethanaminium;(S)-3,10-Dioxo-4-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-1-(4-(trifluoromethyl)phenyl)-13,16,19,22,25-pentaoxa-2,9-diazaoctacosan-28-oicacid;(S)-4-Oxo-4-(6-oxo-5-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-6-(4-(trifluoromethyl)benzylamino)hexylamino)butanoicacid;(S)-4-(6-(4-(Ethoxycarbonyl)cyclohexyl)-6-oxo-5-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)hexylamino)-4-oxobutanoicacid; and(S)-6-(S)-2-Amino-3-hydroxypropanamido)-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-(trifluoromethyl)benzyl)hexanamidehydrochloride.
 18. A compound of Formula:

wherein G is aryl; n is 1; X′ is Z′—C₂₋₆alkyl-O, wherein Z′ is halo; Yis —COOH; R is isopropyl; Z is —CH₂O—; and wherein X′ optionallycomprises a radionuclide; or a pharmaceutically acceptable salt thereof;optionally in the form of a single stereoisomer or mixtures ofstereoisomers thereof.
 19. A compound of claim 18, wherein: wherein G isphenyl; n is 1; X′ is FCH₂CH₂O— or ¹⁸FCH₂CH₂O—; Y is —COOH; R isisopropyl; and Z is —CH₂O—; or a pharmaceutically acceptable saltthereof, optionally in the form of a single stereoisomer or mixtures ofstereoisomers thereof.